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SUMMARY 
The traditional quality culture in the pharmaceutical industry is 
driven by the regulatory process of marketing authorisation and 
manufacturing authorisation. These components of the South African 
regulatory control system are exclusively technically-orientated, 
with no managerial focus. 
This study identifies several quality management principles which 
could find general application in the pharmaceutical industry. The 
research compares the current regulatory control system with the 
total quality concept, and highlights the positive contribution 
which the total quality approach is able to make in terms of its 
field of reference; the strategic business value of quality; quality 
policy formulation; the quality organisational structure; enhanced 
operations management; and management's control over quality costs, 
in particular. 
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CHAPTER ONE: INTRODUCTION 
1.1 GENERAL 
Due to the nature of pharmaceutical products, and the 
consequent risk of serious unwanted reactions or 
therapeutic failure which may result from products 
that are substandard in quality, there is universal 
acceptance within the pharmaceutical industry of the 
need to assure the quality of these products. For the 
same 
part 
should 
reason, there is also universal insistence on the 
of consumers that such assurance of quality 
be verified wherever possible by independent 
regulatory authorities who have statutory powers. The 
assumprtion which underlies the creation of a system of 
regulatory control is that these controls will lead to 
better, safer and perhaps more ec6nomical medical 
treatment (Dukes, 1985, pp. 1 - 2). 
The statutory controls imposed in terms of the 
Medicines and Related Substances Control Act (South 
Africa, 1965) by the South African Medicines Control 
Council (MCC) are consistent with similar systems 
established in the major industrial countries of 
Western Europe and North America. The statutory powers 
of the MCC include the authority to grant or refuse 
permission for a medicine to be marketed in the 
Republic of South Africa (hereafter referred to as 
South Africa), to determine such preconditions as it 
may deem necessary to control the manufacture and sale 
-2-
of each product, and to punish offenders by for 
instance cancelling the marketing authorisation 
(registration)of a product, or by having specific 
batches of product recalled from the market. The MCC 
is also empowered to approve or prohibit the trial use 
of all investigatory new drugs during clinical investi-
gations conducted in this country. Moreover, the MCC 
has established a national system for collating and 
monitoring adverse drug reactions (ADRs) related to 
any drug marketed in this country, whether such a 
reaction occurred within the country or was reported 
from elsewhere (Folb, et al., 1988, pp. 772-778, and 
Pillans & O'Connor, 1992, pp. 492-493). 
Before being granted marketing authorisation by the 
MCC, the prospective manufacturer (applicant) is 
required to submit a Medicines Registration dossier 
(the so-called MBR 1 dossier) in which details are 
given concerning the proposed formulation, pharma-
ceutical development, therapeutic efficacy, safety, 
stability, controls over incoming materials, the 
intermediate product, the final product, and the 
manufacturing process (see Section 3.6). This 
information is then evaluated by the various 
specialist sub-committees of the MCC, after which the 
Council makes known its decision regarding the 
registration status of the proposed product (see 
Section 3.4). If registration is granted, the MCC will 
also determine the conditions of sale (scheduling 
status) and the conditions of manufacture of that 
-3-
product. With regard to the conditions of sale or 
scheduling status of a medicine, it may briefly be 
stated that the provisions of the Medicines and 
Related Substances control Act determines who may sell 
a medicine, 
take place, 
and under what conditions such a sale may 
or such a product may be advertised. The 
exact requirements differ according to the scheduling 
status allocated to each individual product by the MCC 
(see Section 3.7). 
With reference to the determination of the conditions 
of manufacture of a product, the MCC has adopted the 
policy of granting marketing authorisation for a 
particular product on condition that an acceptable 
standard of "good manufacturing practice" (GMP) be 
maintained in the place of manufacture, thereby 
conferring a quasi-legal status upon GMP guidelines 
(see Chapter 4). Various GMP guidelines have been 
published internationally, all of which are aimed at 
providing insight into generally-accepted principles 
of quality assurance within the pharmaceutical 
industry, and these guidelines may be said to 
represent the collective wisdom of the industry and 
the relevant regulatory authorities. These guidelines 
cover aspects such as the qualifications and 
experience of the responsible personnel; the layout 
and amenities of production and storage areas; 
sanitation; maintenance of equipment; verification of 
raw materials; supervision of manufacture; in-process 
quality controls; documentation; and control over 
labelling and packaging (see section 4.6). 
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It should however be noted that GMP guidelines were 
never intended to be a blueprint for a total quality 
system, 
most GMP 
that as 
to GMP 
quality 
industry 
dictated 
situation 
and this limitation is clearly acknowledged in 
publications. There is a danger, however, 
a result of the quasi-legal status accorded 
guidelines in south Africa, the scope of 
control within the local pharmaceutical 
may be limited to the field of reference 
by regulatory requirements only. Such a 
would be unsatisfactory not only from a 
regulatory point of view, but industry itself may thus 
be prevented from benefiting from the positive 
contribution to business profitability which a 
well-designed total quality system is able to make. 
When seen from a quality management perspective, it is 
clear from the aforementioned background that the 
South African regulatory control system dovetails into 
many~ but not all, of the activities that are 
routinely performed by an enterprise which operates an 
effective total quality system. In the course of this 
research the existing system of regulatory control (in 
its broadest sense) will be "superimposed" upon the 
structure of a total quality system in order to 
identify areas of common purpose and, more 
importantly, to highlight those areas where the 
present approach to quality control in the 
pharmaceutical industry may be enhanced by a total 
quality system. 
-5-
1.2 A DESCRIPTION OF THE SOUTH AFRICAN PHARMACEUTICAL 
INDUSTRY AND ITS PRODUCTS 
For the purposes of this dissertation the South 
African pharmaceutical .industry will be defined as 
being that part of the chemical industry which is 
engaged in the manufacture of final dosage forms that 
are suitable for human and animal medicinal use. 
Activities related to the bulk manufacture of raw 
materials, i.e. fine chemical manufacture, · and the 
manufacture of any remedy not manufactured in terms of 
the provisions of the Medicines and Related Substances 
Control Act, are not considered to be part of the 
pharmaceutical manufacturing process. However, the 
packaging process as well as that part of the distri-
bution process which falls under the direct control of 
the manufacturer will, for the purposes of this 
research, be considered to be part of the 
pharmaceutical manufacturing process. 
Five distinguishing characteristics according to which 
pharmaceutical products may be classified are pre-
sented in Table 1.1, which was adapted from a study by 
the National Productivity Institute (1989, p. 7). 
These characteristics relate to the product dosage 
form; therapeutic category; product differentiation 
status; point of sale; and scheduling status. The 
therapeutic category into which a particular product 
may be classified is determined by the pharmacological 
-6-
TABLE 1.1 : A CLASSIFICATION OF PHARMACEUTICAL PRODUCTS 
A 
PRODUCT DOSAGE FORM 
Capsules (Hard Gelatin) 
Capsules (Soft Gelatin) 
Tablets (Uncoated) 
Tablets (Coated) 
Liquids (Non-sterile) 
Liquids (Sterile, Non-
parenteral) 
Powders (Sterile) 
Powders (Non-sterile) 
Aerosols 
Large and Small Volume 
Parenterals 
Ointments/Creams 
(sterile) 
Ointments/Creams (Non-
sterile) 
Suppositories 
Pessaries 
Lozenges 
.-------- - ------- - ----- ,----------- I I 
I B I c I D I E 
I I _I ____________ I 
---r-- I 
I THERAPEUTIC CATEGORY STATUS !PRODUCT DIFFEREN- !POINT OF SALE !SCHEDULING 
I I TIATION I I 
I I I I 
----,- -r 
I 1 I Alimentary Tract I I I 
I I and Metabolism I I I 
I 2 I Central Nervous I l I 
I I System I I I 
I 3 I Respiratory system !Branded medicines i.e lover the counter !Unscheduled 
I I !medicines identified l(O.T.C) medicines1--~~~~~~~ 
I lby trade name. li.e available I 
4 I Cardiovascular I !without prescrip-1 
I System I I tion. I 
5 j Systematic Anti- I I I 
I Infectives I I I 
6 I Musculo-Skeletal I I I 
I System I I I 
7 I Dermatologicals I I I 
8 I Genito-Urinary I I I Schedule 1 to 2 
I System and Sex Hormones1--~~~~~~~~~-1-~~~~~~~--t 
9 I Other I I I 
10 I Sensory Organs !Generic Medicines i.e !Prescription I 
I !medicines identified !medicines i.e I 
11 I Blood and Blood- lby a descriptive or !available only !schedule 3 to 7 
I forming Organs lformulary name. Ion prescription. I 
12 I Systematic I I I 
I Hormones I I I 
13 I Parisitology I I I 
14 I Cytostatics I I I 
I I I I I 
I I I I I 
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action{s) of the active ingredient{s) of that product. 
This particular method of classification may therefore 
be used to define the market segment in which a 
particular product will compete. Fourteen such 
therapeutic categories .are listed under column B of 
Table 1.1; these categories have been arranged in 
order of descending market share in South Africa 
during 1988 (ibid., p. 14). 
Products marketed in the same therapeutic market 
segment may compete with one another on the basis of 
therapeutic value despite the fact that opposing 
products may not necessarily be generically 
equivalent. This may explain why, according to the 
Steenkamp Commission of Inquiry {South Africa, 1978, 
pp. 8 9), market concentration within therapeutic 
submarkets is appreciably smaller in the pharma-
ceutical industry than in a considerable number of 
other manufacturing industries in this country. This, 
however, does not mean that oligopolistic or even 
monopolistic structures may not be present in sub-
markets that are for instance highly specialised or 
technologically very complex, but which represent a 
very small proportion of the overall market for 
pharmaceutical products. 
One such 
systemic 
share was 
example is to be found in the category for 
hormones where, in 1978, the largest market 
49,76 per cent of the total sales; however, 
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this market segment at that stage represented only 1,2 
per cent of the total market for pharmaceutical 
products (ibid., p. 12). 
An important feature .of the industrialisation of 
pharmaceutical production has been the introduction of 
branded medicines which are identified by means of 
trade names, as opposed to generic medicines which are 
not patented products and are identified by means of 
chemical names or pharmacopoeial references. The 
degree to which one product may be differentiated from 
a competing product has a direct influence on the 
marketing strategy that will be adopted for that 
product. 
methods 
based on 
Consequently, one of the most commonly-used 
of classifying pharmaceutical products is 
the distinction between "branded" medicines 
and "generic" medicines (see column C of Table 1.1) 
Product differentiation is of particular significance 
to the pharmaceutical industry, due mainly to the 
unique characteristics of the market in which it 
operates. In particular, the market for prescription 
medicines (see column D of Table 1.1) is unique 
because of the fact that the final consumer does not 
himself select the product which he is about to use; 
instead, a physician makes this decision on behalf of 
the consumer. Moreover, the final consumer often does 
not foot the bill for a prescription medicine because 
of the subsidies that are provided by medical aid 
societies or state-operated medical services. 
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The abovementioned characteristics result in the 
so-called "isolation effect", which tends to isolate 
the decision to purchase a medicine from sensitivity 
to the price of the product concerned. In addition, 
the very nature of a. patient's clinical condition 
gives rise to the so-called "necessity usually 
effect", thereby further contributing to the low 
elasticity of demand which has traditionally been 
associated with the market for prescription medicines 
(ibid., p. 19). Fiscal constraints in particular, 
however, necessitate careful revue of this traditional 
viewpoint regarding the demand characteristics of 
prescription medicines (see Section 2.2.2). 
Health service strategists are increasingly 
emphasising the need for the individual to assume 
greater responsibility for his personal state of 
health. In keeping with this philosophy, there is a 
strong trend towards self-medication, i.e. the use of 
proprietary medicines without professional super-
vision, for the treatment of minor illnesses (National 
Productivity Institute, loc Cit. I p. 22). Self-
medication is seen as playing an important role in 
future cost containment within the healthcare system 
(Sutherland, 1985, p. 120). Products that are 
classified as "over the counter" (OTC) medicines (see 
column D of Table 1.1) would be available to this 
particular market sector. Unscheduled medicines would 
typically be available to the consumer via general 
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dealers, supermarkets and pharmacies, whereas schedule 
1 and 2 medicines are available without prescription 
from 
the 
(South 
pharmacies 
Medicines 
Africa, 
3 to schedule 
only, in terms of the provisions of 
and Related substances Control Act 
1965,. Section 22A). The sale of 
7 medicines may in terms of the same 
statutory 
tion (see 
status of 
provisions, be initiated only upon prescrip-
column E of Table 1.1). The scheduling 
a medicine is in practice probably the most 
frequently used method for classifying pharmaceutical 
products, because of its legal implications regarding 
the sale and advertising of a medicine. This aspect, 
as it relates to the statutory controls over the 
advertising and sale of medicines, is discussed in 
greater detail in Section 3.7 of this dissertation. 
1.3 NEW DESIGN CONTROL IN THE PHARMACEUTICAL INDUSTRY 
The -possible consequences of design failure in a 
pharmaceutical product are much more acute than would 
be the case with a product which does not put lives at 
risk. Probably the most chilling example of this 
truism is the thalidomide disaster which occurred in 
the early 1960's, and which lead to the birth of 
grossly deformed infants to some of the mothers who 
had used a supposedly safe sleeping pill containing 
the drug (see Section 2.4.2.1). One of the lessons 
learned from the thalidomide tragedy is that even 
investigatory drugs need to be carefully controlled; 
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although thalidomide was never commercially available 
in the United States of America, the drug had been 
distributed to over 1 000 doctors in that country on 
an investigatory basis. Seventeen cases of birth 
defects were subsequently reported in the United 
States, although ten of these were traced to purchases 
of the drug in other countries (Janssen, 1981, p.437). 
New design control in the pharmaceutical industry is 
indeed a moving target, with some problems being 
identified after having eluded even the most 
exhaustive clinical investigations, and in some cases 
defying explanation altogether. Conlan (1990, p.32) 
notes that, of the 198 drugs granted marketing authori-
sation in the United States of America between 1976 
and 1985, 
necessitated 
102 had "serious postapproval risks" which 
labelling changes or withdrawal from the 
Andel (1985, pp. 234 - 239) observes that 
safe drugs do not, and probably never will 
market. van 
absolutely 
exist; the 
fore be 
derived 
degree of risk to the consumer must there-
counterbalanced by the level of benefit 
from the use of a particular medicine. Certain 
elements of the risk involved in the use of a medicine 
may be self-induced by the final consumer. Non-
compliance with the prescribed dosage regimen, inter-
actions with other medicines used to self-medicate, 
and the non-medicinal use of a medicine in order to 
satisfy a craving or habit, are but a few examples of 
such self-induced risk elements. 
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Similarly, the irrational use 
scribers of these products may 
consumer at risk. This would 
rationale behind regulatory 
of medicines by pre-
also put the final 
serve to explain the 
controls over the 
information which is communicated to prescribers and 
consumers in advertisements, package inserts and 
labels, and the preconditions that are applied to the 
sale of medicines (see Section 3.7). 
In order to reduce the risk associated with the use of 
a medicine, it is incumbent upon the manufacturer to 
take all steps possible to assure the safety and thera-
peutic efficacy of the product concerned. To this end, 
the manufacturer is required by the Medicines and 
Related Substances Control Act (South Africa, 1965, 
Section 14) to submit an application for registration 
(i.e. an application for marketing authorisation) to 
the MCC. This application for registration must be 
submitted in the form of the so-called MBR 1 registra-
tion dossier (see Section 3.6) in which the applicant 
furnishes scientifically-based proof concerning the 
safety and therapeutic efficacy of the proposed 
product. In effect, the MBR 1 dossier is a summary of 
the new design control routine performed by the 
applicant; the MCC functions as the external auditor 
of that routine (see Chapter 3). 
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1.4 A DESCRIPTION OF THE PHARMACEUTICAL MANUFACTURING 
PROCESS WITH REFERENCE TO CRITICAL AREAS OF CONTROL 
The classification of pharmaceutical products which is 
presented in Table 1.1 includes a large variety of 
dosage forms listed under column A of the table. The 
diversity of dosage forms (product types) thus listed 
is an indication of the fact that the individual 
manufacturing processes involved are equally diversi-
fied. For instance, the production line which is used 
to produce a tablet will differ considerably from that 
used to produce a liquid dosage form, both in terms of 
the equipment used as well as the nature of the 
processes involved. Moreover, the nature of the 
in-process controls and the manufacturing environment 
are both directly related to the type of product being 
manufactured. The production of a sterile product, for 
instance, is possible only in an environment that will 
ensure a specific air quality in terms of the limits 
set for micro-organisms and particulate matter, and 
the in-process controls that are used are consequently 
designed to verify compliance with those environmental 
limits in particular. The production of radio-pharma-
ceuticals, be they liquid or solid dosage forms, 
similarly requires a very specialised manufacturing 
environment and unique in-process controls. 
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Schroeder (1985, pp. 134 155) states that the 
manufacturing process in general may be classified 
under two main categories: Firstly a classification 
which is based on the type of product flow and, 
secondly, a classification which is based on the type 
of customer order (i.e. make-to-stock, or make-to-
order). In the experience of the present author, the 
pharmaceutical manufacturing process can best be 
described as being an intermittent-flow process, which 
Schroeder (ibid., pp. 136 - 138) describes as being 
characterised by production in batches at intermittent 
intervals; equipment and labour are organised into 
work centres requiring similar types of skill or 
equipment, and the product will flow only through the 
work centres necessary for its manufacture. Due to the 
unpredictable demand for pharmaceutical products, 
these products are usually made-to-stock rather than 
made-to-order. 
Despite the diversity of manufacturing processes 
encountered within the pharmaceutical industry, it is 
possible to present a process flow diagram which is 
representative of the pharmaceutical manufacturing 
process in general. such a flow diagram is presented 
in Figure 1.1, and is based upon the author's personal 
observations within the industry. Figure 1.1 high-
lights in particular the critical areas of control in 
the pharmaceutical manufacturing process. A brief 
description of each of these areas of control is given 
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in the paragraphs which follow. This summary contains 
references to documents and procedures that are either 
unique to the pharmaceutical industry, or that are of 
particular significance in the pharmaceutical indus-
trial context. Later chapters of this dissertation 
describe these documents and procedures in greater 
detail. The nature, content, and purpose of the MBR 1 
registration dossier is for instance described in 
Chapter 3. It is also important to note that the 
critical areas of control which are identified in 
Figure 1.1 generally correspond to those that are 
focused upon by the so-called good manufacturing 
principles to which both the pharmaceutical industry 
and the regulatory authorities subscribe; the nature 
and importance of GMP principles are highlighted in 
Chapter 4 of this dissertation, which also includes a 
detailed description of the various control documents 
used. 
Incoming material receipt and quarantine 
Figure 1.1 shows that the pharmaceutical manufacturing 
commences with the receipt of incoming process 
materials. Materials are visually screened by goods 
receiving personnel for any obvious signs of contami-
nation, cross-contamination or damage, in accordance 
with written standard operating procedures. 
1.4.2 
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The delivery note is matched to the relevant purch-
asing order originally issued by the purchasing 
department, in order to verify the receipt of 
materials from approved vendors only. The consignment 
is then placed into quarantine by physically isolating 
the material in a demarcated storage area and/or by 
means of a status labelling system. Quality control 
personnel sample the material in accordance with 
written sampling procedures, whereafter the analytical 
and other test controls are carried out as specified 
under Annexures 6 (raw materials) and 9B (packaging 
materials) of the product's MBR 1 registration dossier 
(see Sections 3.6.9 and 3.6.15). Depending on the 
results of these control procedures, the batch of 
incoming material is either accepted or rejected. 
Approved and rejected materials are identified as such 
by means of a status labelling or other suitable 
control system, and moved to an approved or rejected 
materials storage area as the case may be. 
Dispensing 
A picklist of raw materials is provided by the 
production planning department. The materials required 
are drawn from the approved raw materials warehouse on 
a "First In First Out"-basis. The appropriate quan-
tities of materials are then weighed or measured in a 
dispensary under the supervision of a pharmacist, and 
all details regarding the dispensing process are 
recorded on the relevant batch manufacturing document. 
1.4.3 
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Dispensed 
staging 
materials are labelled and then staged in a 
area to await collection by the relevant 
production department. Much emphasis is placed during 
this process upon the accuracy of measurements, the 
prevention of mix-ups, and the avoidance of 
contamination and cross-contamination. The signatures 
of both the technician and the supervising pharmacist 
are recorded on the relevant batch manufacturing 
document in respect of every action for which they are 
responsible. Unused raw materials are returned to the 
approved raw materials warehouse, and the relevant 
inventory records are updated accordingly. 
Production 
The relevant production department collects the 
staged, dispensed raw materials which are then 
identified and, in some cases, re-weighed or 
re-measured on the production floor under the 
supervision of a pharmacist, who also supervises and 
records the addition of each material to the mix. 
In-process 
intervals 
controls are 
by production 
undertaken at the prescribed 
personnel, while independent 
checks are done by personnel from the quality control 
department. Step-by-step processing instructions 
appear on the batch manufacturing document as they 
appear in Annexure 11 of the product's MBR 1 dossier 
(see Section 3.6.17). All in-process controls and 
1.4 .4 
1.4. 5 
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activities are recorded on the batch manufacturing 
document. Machine maintenance and cleaning records are 
checked according to written standard operating 
procedures before production commences. 
In-process quarantine 
In-process bulk product may in some cases be 
transferred directly onto a packaging line, but in 
most production lines the bulk product is placed into 
quarantine to await sampling and analysis by the 
quality control laboratory. Bulk product which is 
found to comply with the relevant specifications is 
then transferred 
rejected material 
to the packaging department, whereas 
may be reworked or destroyed at the 
discretion of the quality control manager. The results 
of all tests, including the above-mentioned tests, are 
recorded. These records will also contain the signed 
release or rejection decision by the quality control 
department. 
Packaging 
A Packaging Instruction specifies the nature and 
quantities of bulk product and packaging components 
that are required at the designated packaging line. A 
pharmacist certifies that all materials and components 
brought onto the line are of the correct identity and 
quantity. A pharmacist also certifies in writing that 
1.4.6 
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the line is clear of any foreign packaging components 
or bulk product. In-process checks relating to fill 
volume or mass for instance, are made at prescribed 
intervals by operators and line supervisors, while 
independent checks are. made by personnel from the 
quality control function during the entire packaging 
run. Upon completion of the run, a pharmacist again 
certifies the line to be clear of all bulk product and 
packaging materials. All the above-mentioned checks 
and controls are recorded on batch manufacturing 
documents. The packaged final product is then trans-
ferred to the finished product quarantine area to 
await sampling and analysis by the quality control 
laboratory, prior to final release or rejection. 
Off-line overprinting 
Particular attention is paid to the control of all 
printed packaging components during the pharmaceutical 
manufacturing process. The accuracy of the printed 
information, which for instance relates to aspects 
such as product identity, potency and dosage 
instructions, are considered to be of critical 
importance to product safety. Printed components are 
typically sourced in one of three ways: (i) From third 
party suppliers; (ii) by means of on-line overprinting 
during the production process, or; (iii) by way of 
in-house off-line overprinting. The overprinting 
process usually involves the addition of batch-
specific information such as an expiry date and lot 
1.4.7 
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number on a preprinted label and/or carton. A 
pharmacist will proofread the overprinting before 
allowing the process to continue. If the overprinting 
is done on-line, this check will form part of the 
particular manufacturing procedure. A facsimile of the 
overprinted component thus approved is attached to the 
relevant batch manufacturing record, together with the 
signature of the pharmacist who verified the accuracy 
thereof. In some cases the product itself is 
overprinted, as in the case of a logo or statement 
regarding product potency, which may appear on a 
tablet, capsule, or other dosage form. This process is 
controlled in the same manner as that which is 
described above. 
Finished product quarantine 
At the end of the packaging run, the packaged product 
will' await sampling and analysis by the quality 
control laboratory prior to final approval or 
rejection. As in the case of incoming materials 
discussed under Section 1.4.1, sampling is done 
according to a prescribed sampling plan and written 
standard operating procedures. Laboratory analysis is 
done in accordance with the methods specified in the 
relevant MBR 1 dossier (see Section 3.6). The finished 
product will remain in quarantine until the relevant 
analytical results are known, and a document audit has 
been carried out on the batch manufacturing records. 
1.4.8 
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The approved product is thereafter transferred to the 
approved product warehouse to await despatch, whereas 
rejected product 
await disposal 
control manager. 
is transferred to a reject store to 
under the control of the quality 
Samples of every batch of product 
are kept in a retention.sample store under the control 
of the quality control department until one year after 
the date of expiry of that particular batch (in 
practice this usually relates to a total storage 
period of four years). Regular samples are taken from 
retained stock; these samples are then analysed to 
verify product stability during the product's entire 
shelf life (see Section 3.6.16). 
Final product despatch 
The following activities of the final product despatch 
process represent important measures of control: (i) 
In accordance with the requirements of Section 22A of 
the - Medicines and Related Substances Control Act 
(South Africa, 1965), scheduled medicines may be sold 
only to authorised customers, and the control of 
customer validity therefore forms an important part of 
the despatch process (see Section 3.7). (ii) Batch 
distribution records must be kept in respect of every 
product despatched because any product recall proce-
dure which may be necessary, will be based on these 
data (see MCC, 1988, Circular to applicants ref. 
7/88). (iii) Measures must be taken to assure the 
protection of the product against environmental or 
mechanical damage whilst in transit. 
1.5 
1.5.1 
1.5.2 
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THE RESEARCH APPROACH AND METHODOLOGY 
General 
The nature of this research is that of an overview of 
domain phenomena which are of universal importance, 
mainly by means of exploratory research but also 
including descriptive surveys. 
Miniature investigation 
A preliminary study regarding the application of a 
system of total quality control to the pharmaceutical 
industry in south Africa was submitted by the author 
to the Department of Business Economics (Honours 
Studies) of the University of south Africa (Mader, 
1989). This study highlighted certain shortcomings in 
the guidelines for Good Manufacturing Practice which 
at present is considered to be the linchpin of quality 
control in the pharmaceutical industry. This study 
also touched briefly on the broader role played in 
quality control by the registration process in terms 
of which pharmaceutical products are screened by the 
South African Medicines Control Council. The present 
research is aimed at expanding on these findings. 
1.5.3 
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Hypothesis development 
From the literature, and from personal observation, 
the following hypotheses were developed concerning the 
use of a quality management approach to the evaluation 
of the regulatory control system used to assure the 
quality of medicines manufactured in South Africa: 
(i) The existing system of regulatory control may be 
enhanced by a quality management approach to the 
problem of assuring the quality of medicines 
This hypothesis is based upon the perception that, 
generally speaking, 
the total quality 
a commitment by top management to 
management philosophy, and the 
resultant strategic business decisions that are based 
on quality considerations, does not appear to be the 
primary motivational force behind the quality control 
activities routinely performed by the industry. 
Instead, with a few notable exceptions, the quality 
control programmes operated by the industry appear to 
be driven firstly by a preoccupation with defect 
detection (as opposed to defect prevention) in order 
to limit product liability risks and, secondly, by 
what is perceived within the industry to be a 
trade-off situation between regulatory demands 
regarding quality control and the cost of implementing 
those demands (i.e. without regard for any positive 
contribution to cash flow or profitability). 
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(ii) The establishment of a system of total quality will 
(iii) 
result in a superior operations management system as 
compared to the good manufacturing practice principles 
presently used 
The so-called good manufacturing practice guidelines 
currently used by industry are characterised by a 
number of inherent limitations with regard to their 
scope, approach, and financial, managerial, and 
strategic considerations. These limitations can be 
overcome by means of a total quality system, which 
also forms an integral part of modern operations 
management systems such as just-in-time management. 
Quality management principles may be used to develop 
a structured approach to the problem of delegating 
quality authorities and responsibilities within the 
pharmaceutical industry 
In terms of the provisions of the Pharmacy Act (South 
Africa, 1974, Section 22), the managing director of a 
} 
body corporate which is engaged in the manufacture of 
medicines must be a pharmacist who in fact manages the 
business of that body corporate. There are sound 
reasons for this requirement, related mainly to 
ethical and disciplinary considerations. This 
statutory requirement is however based upon the 
assumption that a person who received training in the 
natural sciences only will have the necessary 
managerial skills to effectively delegate his quality 
responsibilities 
enterprise. The 
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within 
managerial 
the modern business 
hierarchy dictated by 
statute may therefore in practice be distorted by the 
realities faced by industry. The strong link that is 
established by a total quality system between the 
managerial decision making process and the technical 
activities related to quality control, is seen to be 
of particular value in this situation. 
(iv) There is a need for more accurate quality cost data 
in the pharmaceutical industry 
1.5.4 
There appears to be a growing concern within the 
pharmaceutical industry about what is perceived to be 
a possible over-capitalisation in the present system 
of statutory quality control, particularly in view of 
the pressures being experienced in what has up to now 
been a relatively price inelastic market. Empirical 
evaluation of this viewpoint will largely depend on 
the availability of accurate and reliable quality cost 
data: It is however anticipated that the research will 
identify a need for more accurate quality cost data 
within the industry. 
The research methodology 
The hypotheses 
interviews with 
were researched by means of personal 
randomly selected pharmaceutical 
companies. A structured questionnaire was used during 
these interviews (see Annexure 1). A detailed descrip-
tion of the methodology employed is given in Chapter 
6. 
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1.6 THE LIMITATIONS OF THE RESEARCH 
The research is limited to a business economic 
problem of quality control in the approach to the 
South African pharmaceutical industry. More specifi-
cally, a 
principle 
ment of 
microeconomic approach based on the economic 
is adopted in order to research the achieve-
the highest possible quality output through 
the most efficient use of company resources, as seen 
from the point of view of the individual enterprise. 
No attempt is made to evaluate the South African 
regulatory 
ref er to 
particular, 
not attempt 
manner, to 
control system per se, other than to 
its quality management implications. In 
it must be stressed that the research does 
to contribute, other than in an indirect 
what Dukes (lac.cit., pp. 21 - 30) refers 
to as the "regulatory controversy" regarding the 
relaxation or intensification of the regulatory 
controls presently applied to medicines, or the much 
broader controversy surrounding social regulation in 
general. Due to the dynamic nature of the regulatory 
control environment the research should moreover not 
be considered to be an up to date source of reference 
regarding current regulatory requirements. 
1.7 THE EXPECTED CONTRIBUTION TO KNOWLEDGE BY THE RESEARCH 
It is anticipated that this research will demonstrate 
the relevance of a total . quality system to pharma-
ceutical production in South Africa. Moreover, it will 
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be shown that quality control is much more than a mere 
grouping of production-oriented technical projects and 
motivational activities without any clearly articu-
lated managerial focus. 
A degree 
definition 
currently 
of 
of 
used 
confusion appears to surround the 
the various quality-related concepts 
by the pharmaceutical industry. In 
particular, the inter-relationship between concepts 
such as "quality assurance", "good manufacturing 
practice", and "quality control" is not made clear in 
the technical literature. It is anticipated that the 
company-wide scope of the total quality concept, and 
its application to the entire industrial cycle, will 
provide greater clarity concerning the concepts 
currently used within the industry. 
It is anticipated that this research will be of value 
to the pharmaceutical industry particularly with 
regard to the emphasis which is placed upon the 
strategic business value of quality. Moreover, the 
approach adopted in this research is expected to be of 
value to regulatory authorities in their role as 
external auditors of the industrial quality control 
system, as well as with regard to the formulation of 
regulatory control policies. 
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CHAPTER TWO: MACROENVIRONMENTAL DEMANDS ON THE QUALITY OF 
PHARMACEUTICAL PRODUCTS 
2.1 GENERAL 
This chapter reviews those economic, technological and 
political macroenvironmental factors which impact upon 
quality in general, and the quality of pharmaceutical 
products in particular. The potential of the total 
quality management philosophy to contribute positively 
to the formulation of a response by management to 
these microenvironmental factors, will be highlighted 
in Chapter 5 of this dissertation. The present chapter 
is also intended to provide a philosophical background 
to the regulatory controls currently applied to 
medicines; the actual mechanism according to which the 
South African regulatory control system operates is 
discussed in Chapters 3 and 4 of this dissertation. 
2.2 THE ECONOMIC ENVIRONMENT 
Markets require not only people, but purchasing power 
as well. Total purchasing power is a function of 
current income, prices, savings and credit 
availability (Kotler, 1980, p. 108). The main economic 
trends that have quality implications for the 
pharmaceutical industry in particular are described in 
the paragraphs which follow. 
2.2.1 
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Slowdown in real-income growth, and continued 
inflationary pressure 
According to Feigenbaum (1986, pp. 29 - 30), one of 
the least understood effects of inflation, when it has 
occurred in world markets, has been the corresponding 
growth of buyer and consumer insistence upon basic 
quality; buyers are likely to view a higher price as 
payment for what they expect to be higher quality. In 
the 1960's the annual rate of inflation in South 
Africa averaged 2,7 per cent, with a growth in real 
Gross Domestic Product of 5,7 per cent. In the 1970's 
inflation averaged 10,8 per cent and the growth in 
Gross Domestic Product had declined to 3,4 per cent, 
while in the 1980's this situation had worsened to an 
average rate of inflation of 14,7 per cent, with 
growth down to a mere 1,5 per cent (Barnard & du Toit 
1989, pp. 1 - 4). During 1992, inflation averaged 
13,9- per cent with Gross Domestic Product declining to 
minus 2,1 per cent; during 1993 inflation decreased to 
9,7 per cent whilst Gross Domestic Product had 
increased to 1,2 per cent (ABSA Bank, 1994, p. 1). 
The cost of materials has been identified as the cost 
item which exerts most influence on the cost of sales 
ratio of a pharmaceutical product, and has been 
calculated to vary between 23,82 per cent and 53,39 
per cent (National Productivity Institute, 1989, p. 
57). The elimination of waste, which is fundamental to 
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the just-in-time/total quality control concept should 
therefore be of strategic importance to the South 
African pharmaceutical industry. Imported raw 
materials on average account for approximately 80 per 
cent of the total materials requirements of the 
pharmaceutical industry (ibid., p. 101), and a high 
domestic rate of inflation relative to the country's 
major trading partners, coupled to a deteriorating 
rate of exchange, must therefore reduce the ability of 
the local pharmaceutical industry to compete on 
international markets, and serve to inflate domestic 
prices of medicines. The real effective rate of 
exchange of the rand has weakened by 6,4 per cent over 
the 15 months to March 1994 (ABSA Bank, loc. cit., 
p. 2). 
Domestic prices of medicines have indeed increased 
significantly in recent years. According to a survey 
started in 1988, the domestic prices of certain 
medicines have for instance been found to be 20 per 
cent higher than in Great Britain, and 70 per cent 
higher than in Australia (Die Burger, 30 April 1990, 
p. 3). This same survey found that, compared to the 
prices 
South 
those 
report 
index 
in twelve Western countries, medicine prices in 
Africa were higher than in all but three of 
countries. Boyce & Bartlett (1990, p. 147) 
that, during 1984 to 1989, ·the medicines price 
in South Africa increased by 152 per cent (20,3 
per cent per annum), while the consumer price index 
2.2.2 
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increased by 108,4 per cent (15,8 per cent per annum) 
over the same period. They conclude that the annual 
increase in the domestic price of pharmaceutical 
products has exceeded . the annual increase in the 
consumer price index by an average of 4,5 per cent per 
annum during the period 1984 to 1989. According to 
Feigenbaum (loc. cit., pp. 29 - 32),consumer insis-
tence upon basic quality may be expected to grow under 
the circumstances described above. However, other 
pressures are being unleashed as a direct result of 
the spiralling cost of medicines, which also have a 
direct bearing on product quality; these aspects are 
discussed below. 
Fiscal constraints on the use of medicines 
The market for prescription medicines is unique in the 
sense that the choice of product is not made by the 
consumer but by a third party (the physician, or 
prescriber), and in many cases is paid for by a fourth 
party (the patient's medical aid fund). Moreover, 
this market is characterised by the so-called 
"necessity effect" which results from the fact that 
the price of the product has little influence on the 
willingness of the consumer to use the product 
prescribed by the physician; he buys what the 
physician prescribes, regardless of the price. 
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According to the Steenkamp Commission of Inquiry 
(South Africa, 1978, p. 19), these factors have 
traditionally combined to give this market low 
elasticity of demand. New developments are placing 
these traditional concepts under increasing pressure, 
however, and the cost of medicine has for some time 
now been of prime concern not only to Government but 
also to the man in the street (Retief, 1984, p. 590). 
According to figures released by the Registrar of 
Medical Schemes for the year ended December 1989 
(South Africa, 1990), only 5,5 per cent of the Black 
population group in South Africa, 30,2 per cent of 
Coloureds, 33,8 per cent Asians, and 68,8 per cent 
Whites are members of medical aid schemes. This means 
that only 19,5 per cent of the total South African 
population are members of medical aid schemes, and 
that the State and private individuals who are not 
members of medical aid schemes accept direct liability 
for the medical expenses of 80,5 per cent of the 
population. 
Boyce & Bartlett (loc. Cit. I pp. 147 - 148) stat~ 
that expenditure on medicines by medical schemes in 
the private sector in South Africa accounted for 26,1 
per cent of total expenditure on medical services 
during 1988. Because of the fact that this figure 
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contributions of patients in the form of 
as well as the cost of medicines 
excludes the 
co-payments, 
administered 
consider a 
to hospitalised patients, these authors 
estimate of aggregate 
expenditure on 
30 per cent 
services. This 
more accurate 
medicines in the private sector to be 
of the total expenditure on medical 
figure for the relative expenditure on 
medicines in South Africa is considerably higher than 
the corresponding figure in other Western countries, 
notably the United States of America (nine per cent), 
the United Kingdom (twelve per cent), and the average 
for all European Economic Community countries (sixteen 
per cent). Boyce & Bartlett (ibid.) are of the opinion 
that differences in the patterns of utilization of 
medicines are of key importance in explaining this 
disparity in expenditure, but note that higher price 
levels in South Africa also play a role in this 
regard. The Association of Medical Schemes cite the 
continued rise in medicine prices as constituting a 
"major factor" in pushing up medical aid subscriptions 
(Eastern Province Herald, 18 April 1990, p. 2). 
South Africa currently spends between 5,5 and 5,9 per 
cent of Gross National Product on health, and there is 
little prospect of this being substantially increased 
in the forseeable future (Folb, 1990, p. 120). Under 
these circumstances it is therefore easy to understand 
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why methods are being sought to reduce overall 
expenditure on medicines, or at least to reduce the 
rate at which these costs are increasing, in both the 
public and private sectors. Central to the various 
options available for .achieving this goal is the use 
of generic medicines. 
"Generic substitution" is said to have taken place 
when a medicine containing the same active 
ingredient(s), in the same dosage, and in the same 
dosage form, is dispensed instead of the branded 
product originally prescribed. Savings from the use of 
generic medicines can be significant, as price 
differences between generic products and their branded 
equivalents vary between 15 per cent and 85 per cent 
(Boyce & Bartlett, loc. cit., p. 148). The issue of 
generic substitution 
controversy. 
is, however, shrouded in 
Early in November 1984 the South African Pharmacy 
Council resolved to request the Minister of Health to 
approve the amendment of the council's Ethical Rules 
in such a manner as to allow pharmacists to supply 
cheaper, generically equivalent medicines to the 
public in the place of branded products prescribed by 
physicians, subject to a number of conditions (South 
Africa Pharmacy Council, 1984, pp. 2 - 3). The concept 
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of "generic substitution" became a reality on 16 
November 1984 with the gazetting of the above-
entioned amendment to the Ethical Rules governing the 
pharmacy profession. On 26 April 1985, in his address 
to the 18th Annual General Meeting of the then 
Pharmaceutical and Chemical Manufacturers Association 
(PCMA) the chairman, Dr Hugo Snyckers, announced that 
individual members of the PCMA were to apply to court 
to have the S.A. Pharmacy Council's amended Ethical 
Rule set aside (Anon., 1985, p. 274). The Pharmacy 
Council did not oppose this application by members of 
the PCMA upon the advice of the then Minister of 
Health, and the amended Ethical Rule was withdrawn 
(Van Zyl, 1990). 
Generic 
practice 
substitution 
in South 
has, however, been common 
African State and Provincial 
hospitals for several decades. Basic to the logistical 
system employed in the supply of medicines by the 
public sector, is the so-called open bid or tender 
system of purchasing whereby bids are called for the 
supply of medicines on the basis of generic (not brand 
name) specification. Although no studies have been 
reported of the savings achieved by means of generic 
substitution in the public sector in south Africa, 
expenditure on medicines by the State constitutes less 
than ten per cent of total public health expenditure. 
The extent of these savings is dramatic when compared 
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with current expenditure on medicines in the private 
sector, which amounts to 30 per cent of total expenditure 
on health services in that sector (Boyce & Bartlett, loc. 
cit., p. 148). 
In an attempt to generate similar savings in the private 
sector, the Pharmaceutical Society of South Africa (PSSA) 
devised the so-called "maximum medical aid price" (MMAP) 
system for the supply of cheaper medicines to the patient 
within the legal constraints that apply at present. The 
MMAP system described by Sutherland (1985, pp. 89 - 119), 
is based upon a limited list of widely prescribed medicines 
for which generic alternatives are available. In terms of· 
the MMAP system, the financial liability of members of 
participating medical aid schemes will be restricted to the 
price level set out in the MMAP list of medicines. Should a 
patient or the prescriber prefer to receive the original 
(more expensive) brand prescribed, the patient will have to 
pay -the difference in price. This aspect of freedom of 
choice is important, particularly in the light of 
objections from within the medical profession to what is 
perceived to be a limitation on the clinical discretion of 
the prescriber. 
Bloom & 
of the 
Goldston (1989, pp. 199 - 201) describe the impact 
MMAP system on a private sector medical aid scheme 
for municipal 
first twelve 
employees in the Cape Province, which in the 
months of operation generated savings of 9,3 
-38-
per cent on medicines. Boyce & Bartlett (1989, pp. 142 
146) report on a MMAP programme that was conducted 
on a voluntary basis in the Orange Free State during 
1985. They state that savings on the cost of medicines 
to 6,2 per cent during the first six months amounted 
of its 
could 
operation, and are of the opinion that savings 
have been greater had participation in the 
scheme by physicians and 
mandatory. Price (1990, pp. 
study comparing prescribing 
public sector health care 
pharmacists been made 
158 - 160) describes a 
patterns and costs at a 
centre with that of the 
private 
concludes 
per item 
should be 
in-house 
treatment 
fee-for-service medical aid sector, and 
that the substantial difference in the cost 
(25 per cent of that in the private sector) 
ascribed mainly to generic substitution, 
repacking of medicines, and the use of 
protocols in the public sector. Repacking of 
medicines in advance of their sale is illegal in terms 
of -section 14(4) of the Medicines and Related 
Substances Control Act (South Africa, 1965); it is 
however common practice in most State-operated 
institutions. 
The Pharmaceutical Manufacturers Association (PMA) in 
particular has been consistent in its opposition to 
the implementation of generic substitution of 
prescribed medicines. The PMA believes that this 
concept ''cannot be associated with the principles of a 
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free market economy", and describes it as being a form 
of "interference" rather than a legitimate attempt to 
introduce a measure of competition in the market 
(Pharmaceutical Manufacturers Association, 1989, p. 
13). The PMA also contends that" ... the savings to be 
achieved (by means of generic substitution) would be 
minimal compared to the risk to the patient and 
compared to the resultant distortion of the free 
market concept (sic)". In support of this viewpoint, 
the PMA quotes a study by Scott & Reekie who conclude 
that if for every possible product available in South 
Africa in June 1984 a generic prescription was 
written, the savings would amount to only 4,6 per cent 
to 6,6 per cent of the total private sector market. 
This same study concluded that" ... price increases 
(of medicines) have been below the rate of inflation 
11 (ibid• I P • 14) • 
Boyce & 
out that 
Reekie 
developed 
Bartlett (loc. cit., p. 146) however point 
the theoretical projections made by Scott & 
are based upon the so-called HEW-formula 
by the Department of Education and Welfare 
in the United States of America, and that this formula 
does not take into account practices in respect of 
quantities prescribed, or the dispensing tariff of 
pharmacists. However, despite their reservations about 
its validity, Boyce & Bartlett (ibid.) applied this 
formula to the Orange Free State sample ref erred to 
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above. Whereas Scott & Reekie postulated maximum 
overall savings in the region of six per cent, the 
Orange Free State sample yielded a figure of 11,5 per 
cent. Moreover, the claim that increases in the 
domestic price of medicines prior to 1984 have 
remained below the rate of inf lat ion cannot today be 
reconciled with the figures presented by Boyce & 
Bartlett (1990, p. 147). 
The opinions of the PMA are also not shared by the 
National Association of Pharmaceutical Manufacturers 
(NAPM). The latter association was formed in the 
mid-eighties inter alia as a result of differences 
within the local pharmaceutical industry concerning 
the issue of generic substitution. The NAPM is mindful 
of the value of product differentiation strategies 
(based on brand names), but is willing to accept the 
implementation of the generic substitution concept in 
the public interest (Midlane, 1990). 
It does not fall within the scope of this research to 
expand upon all the issues surrounding the concept of 
generic substitution, nor is it intended to present 
generic substitution as being the only issue which is 
relevant to the problem of reducing the financial 
burden on the financiers of medicine consumption. 
However, both Price (loc. cit.) as well as Boyce & 
Bartlett (loc. cit.) conclude from their studies 
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that a rationalisation in the prescribing habits of 
physicians is of crucial importance in this regard, 
and these authors also agree that generic substitution 
is an important component of this rationalisation 
process. Moreover, the. use of generic medicines is a 
basic tenet of the Essential Drugs Programme which was 
formulated by the World Health Organisation (WHO) with 
the objective of extending the accessibility 
(including the financial accessibility) of the most 
necessary medicines to populations whose basic health 
needs cannot be met by the existing systems of supply 
(World Health Organisation, 1990, pp. 7 - 23). 
Suffice it to state that there is compelling evidence 
to support the viewpoint that generic (and 
therapeutic) equivalency will be an essential 
component of any future response to the macroeconomic 
environment of the market for medicines. From a 
quality management point of view, this scenario would 
serve to accentuate the strategic business importance 
of quality which is inherent in the generic concept: 
Considerations related to patient safety demand that 
products be equivalent in all respects. Such 
equivalency can, however, be established only on the 
basis of comparable quality. 
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2.3 The technological environment 
2.3.1 
Spectacular technological advances have been made 
during the relatively short history of the pharma-
ceutical industry. ·The increased production of 
medicines from synthetic as opposed to natural 
materials, the shift from so-called symptomatic to 
curative medicines, and the evolution from back-shop 
dispensaries to factory production and ultimately to 
research-based speciality manufacturing, have 
characterised this process of technological advance-
ment (Steenkamp Commission of Inquiry, loc. cit., 
pp. 4 6). This rapid change in the technological 
environment has by no means been restricted to the 
pharmaceutical industry alone, and the changes in the 
technological environment described in the paragraphs 
which follow, can be said to have been shared by 
industry in general. It should be noted, however, 
that- technological advances in the pharmaceutical 
industry have been characterised by a concomitant 
increase in the risks (to patients) associated with 
the use of modern medicines. 
The accelerating pace of technological change 
It is a sobering thought that most of the 
technologically complex products which we take for 
granted today were not available even one hundred 
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years ago. In the wake of such rapid technological 
change, the management of those factors which affect 
product quality has assumed major strategic business 
importance. Materials are worked to closer limits than 
ever before. The diversity of materials has expanded. 
Visual inspection methods have been replaced by 
precise chemical and physical measurements using 
highly specialised laboratory equipment that match the 
need for rapid and accurate information demanded by 
the modern production process. Manufacturing equipment 
has become more complex and much more dependent upon 
the quality of materials fed into it. The manu-
f acturing environment itself of ten has to be 
controlled as part of the modern production process; 
dust in an electronic assembly area, floor vibration 
transmitted to a numerically controlled machine tool, 
or room temperature variation during adjustments to 
aerospace guidance systems, are but a few examples of 
such- controls from outside of the pharmaceutical 
industry (see Feigenbaum, loc. cit., pp. 59 - 61). 
The lesson has been sharply taught that major 
technological changes cannot simply be overlaid upon 
old manufacturing; logistical; or managerial 
foundations (ibid., p. 49). This would explain why 
quality management has assumed such 
strategic importance in modern industry. 
universal 
2.3.2 
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Pressures on research and development programmes 
Modern technological development is generally charac-
by huge expenditure on research and terised 
development. 
(1985, pp. 
According ·to Cromie, quoted in Dukes 
81 82), the return on investment in 
research by pharmaceutical companies in the United 
Kingdom averaged 3 per cent during the period 1975 to 
1976, while the average for the industry as a whole 
during the same period was 10 per cent. Careful 
management of the investment in research and 
development is therefore necessary in order to 
maximise the rate of return on that investment. The 
concept of new design control, which is an integral 
part of a total quality control system, is therefore 
particularly relevant to achieving this goal. 
Compared to the research-based industries of the West, 
the - South African pharmaceutical industry is still at 
an early stage of development. An analysis of the cost 
structure of 51 pharmaceutical firms in 1974 and 1975 
showed an average expenditure on research and develop-
ment of 2,3 per cent of sales (Steenkamp Commission of 
Inquiry, loc. cit., p. 28). Due to the high percen-
tage of raw materials imported from overseas it would, 
however, be fair to conclude that expenditure by local 
companies on research and development may in reality 
2.3.3 
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be higher than this figure, since elements of the 
costs of research and development are build into the 
transfer pricing policies and licensing agreements 
prescribed by overseas principals. 
Increased regulation of technological change 
According to Kotler 
logical change is 
(loc. cit., 
encountering 
p. 
more 
114), techno-
regulation and 
opposition than ever before; as products in general 
become more complex, public demands for the assurance 
of product safety in particular can be expected to 
increase. By the middle of the twentieth century, the 
rapid expansion in the number of synthetic drugs had 
greatly increased the chances not only of achieving 
therapeutic advances, but also of creating new risks 
(Dukes, loc. cit., p. 8). Evans & Cunliffe (1987, p. 
11) note that present day controls on the manufacture 
and ·marketing of medicines were brought in to protect 
the public because of the growing power, for good and 
ill, of modern medicines. Government agencies have 
thus responded to public demands regarding the safety 
of medicines, by expanding their powers to investigate 
and ban products that might be directly harmful or 
have questionable side effects. 
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Legislation aimed at protecting the public against 
adulterated and misbranded medicines in particular, 
soon became outmoded as a result of the onrush of 
technological change in the international pharma-
ceutical industry. The. major system of current drug 
legislation in the United States of America can for 
instance be traced back to an incident in 1938 when 
more than one hundred people died after using the 
product "Elixir Sulfanilamide", which contained a 
poisonous solvent. According to Dukes (loc. cit., p. 
8), this tragedy was the result of the untested use of 
diethylene glycol as a solvent for sulfanilamide. The 
Federal 
in the 
Food, 
United 
Drug, and Cosmetic Act which became law 
States of America on June 30, 1938 
contained, amongst others, the following provisions: 
(i) Proof of intent to defraud was no longer required 
in order to stop false claims for medicines, thereby 
closing a loophole which had existed in that country's 
legislation since 1912. (ii) Federal court injunctions 
against violations were added to the previous legal 
remedies of product seizures and criminal 
prosecutions. (iii) Specific authority was provided to 
enable inspection of factories. (iv) Pharmaceutical 
manufacturers were required to provide specific proof 
that new products could be safely used before putting 
those products on the market (Janssen, 1981, pp. 428 -
429). 
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It also became apparent that many modern medicines, 
which were of great value if used under the direction 
of a physician, were too dangerous for uncontrolled 
use by lay persons. Different approaches to 
controlling the sale and distribution of medicines 
were adopted in different countries. In the United 
States of America, for instance, the Food and Drug 
Administration published a series of "Trade Corres-
pondence Letters" in which it gave notice that it 
would in future be illegal to distribute particular 
substances "for indiscriminate use by the general 
public in a manner which constitutes a serious danger 
to public health". The first such notice was drafted 
in 
In 
Act, 
in 
1938, and dealt with the substance sulfanilamide. 
terms of the so-called Humphrey-Durham Amenment 
which became law in the United States of America 
1951, the first statutory definition was given of 
kinds of medicines that could be sold only upon 
prescription of a physician (ibid., pp. 430 -
the 
the 
435). 
In South Africa, statutory controls over the sale and 
distribution of medicines during the period 
immediately preceding current legislation, were 
embodied in the provisions of the Medical, Dental and 
Pharmacy Act, No. 13 of 1928, as amended; medicines 
were classified either as so-called "Division One 
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Poisons", "Division Two Poisons", "Potentially Harmful 
Drugs", or "Habit Forming Drugs", in order to pre-
scribe the conditions under which each category of 
medicine could be acquired, imported, sold, or 
supplied. The category under which a particular 
substance was classified was determined after 
agreement between the Medical and Dental Council and 
the (then) Pharmacy Board in the form of a resolution 
approved by the Minister of Health and published in 
the Government Gazette under the signature of the 
State President (Pannall, 1967, pp. 32 - 65). The 
Medical, Dental and Pharmacy Act was superceded by the 
Medicines and Related Substances Control Act (South 
Africa, 1965), which may be described as being part of 
the international wave of drug legislation which 
followed 
the early 
in the 
Sixties 
wake of the thalidomide disaster in 
(see Dukes, loc. cit., pp. 8 - 9). 
The thalidomide disaster, which lead to an outbreak of 
phocomelia (gross foetal deformities) in a number of 
countries, is described under Section 2.4.2.1 of this 
dissertation. 
The system of marketing authorisation, which is 
currently applied by regulatory authorities worldwide, 
ensures that all medicinal products are assessed by a 
competent authority and also that contemporary 
standards of safety, quality and efficacy are adhered 
-49-
to (see EEC draft GMP guide, 1989, p. 7). Some 
countries impose additional criteria, for instance, 
"medical need" and "therapeutic value" standards have 
been applied in Norway since 1928 (Wardell, 1983, pp. 
6 - 7). In terms of the provisions of Section 1(3) of 
the Medicines and Related Substances Control Act 
(South Africa, 1965), however, standards of safety, 
quality and therapeutic efficacy are the sole criteria 
used by the south African Medicines Control Council 
(MCC) to determine whether or not the availability of 
a particular medicine is in the public interest. A 
description of the South African regulatory control 
system is given in Chapter 3 of this dissertation. 
2.3.3.1 Self-regulation by the pharmaceutical industry 
From the few examples given in Section 2.3.3, it would 
appear that regulatory controls over medicines were 
often introduced in response to mishaps and disasters 
connected with their use. The pharmaceutical industry 
has tended to oppose these developments, while arguing 
the case for self-regulation (Dukes, loc. cit., pp. 
9 11). It is suggested for instance that responsi-
bility for proper procedures during experimental 
trials on humans should be shared by the investigator, 
his peers, and the industrial sponsor concerned 
(Lasagna, 1983, pp. 177 182). However, the like-
lihood of this particular suggestion being accepted by 
any regulatory authority is considerably reduced by 
-so-
reports such as that of a French scientist who 
allegedly ignored rules for human-subject research by 
injecting ten children in Zaire with a trial AIDS 
vaccine (Cape Times, 11 March 1991, p. 4 ). Herxheimer 
& Collier (1990, pp. 307 - 311) review the results of 
an attempt by the Association of the British Pharma-
ceutical Industry to regulate the promotion of 
prescription medicines by means of its own code of 
practice during the period 1983 to 1988. These authors 
describe the 
Association, 
dealing with 
nature of the complaints referred to the 
the method used by the Association for 
these complaints, and the results of the 
(which were undertaken with the full investigations 
support of the British Department of Health). They 
conclude that the Association's code of practice has 
failed to deter promotional excesses, and that the 
Association's attempt at self-regulation " ... seems to 
be a service to itself rather than the public", mainly 
because the Code of Practice Committee is not publicly 
accountable and also because it lacks the necessary 
authority. 
Folb & Schlebusch (1989, pp. 643 - 645) counter the 
argument that self-regulation may be achieved with the 
assistance of a court of law if necessary, by 
ref erring to the legal battle in South Africa between 
Colgate-Palmolive and Elida-Ponds concerning their 
respective claims for the anti-tartar activity of 
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toothpaste (not a medicine), and the fact that legal 
fees alone amounted to six million Rands. These 
authors contrast this costly settlement with the fact 
that, notwithstanding the legal right of a party who 
is aggrieved by a decision of the Medicines Control 
Council to take that decision on appeal to a court of 
law, the industry had since 1967 without exception 
pref erred to settle such differences directly by 
negotiation (the first such appeal was subsequently 
lodged in 1993). 
A feature of the introduction of legislation requiring 
marketing authorisation as part of the modern regula-
tory control process has been the sharp decrease in 
the number of products marketed. Dukes, loc. cit., 
p. 10) for instance draws attention to the fact that 
39 000 pharmaceutical product licences existed in the 
United Kingdom in 1971 when the Medicines Act of 1968 
was - implemented in that country; by 1983 some 22 000 
of these had been withdrawn from the market. A similar 
trend was observed in Spain (Dukes, ibid.), In South 
Africa, an estimated 780 new products would have 
appeared on the local market immediately before the 
Medicines Control Act came into force in July 1968; 
this figure had declined to 70 products by the end of 
1968 (Snyman, 1971, pp. 297 299). A number of 
authors ascribe this phenomenon 
part to the inadequacy of the 
regulation by the pharmaceutical 
loc. cit., 9 - 11). 
as being related in 
doctrine of self-
industry (Dukes, 
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2.4 The political / legal environment 
Regulatory authorities have a certain margin for 
discretion when making decisions concerning the safety 
of a medicine in that administrative law allows for 
differing cultural, philosophical, religious, and 
ethical convictions. In other words, decisions 
concerning the risk/benefit ratio of a medicine are 
not based solely on scientific criteria but must also 
reflect a societal point of view. Consequently, 
regulatory authorities all over the world may take 
different decisions regarding product safety (and 
other attributes), even in cases where the facts of 
the matter are the same. Such risk/benefit evaluations 
are, in theory, undertaken by statutory bodies on the 
assumption that members of society are prepared to pay 
for accepted risks either as taxpayers or as buyers. 
In view of the fact that any decision by a regulatory 
authority has an effect on society-at-large, such 
decisions must have a political dimension. It 
the ref ore follows that regulatory authorities are 
subject to political pressures (Van Andel, 1985, pp. 
231 - 239). 
Kotler (loc. cit., p. 115) describes the political 
system as being a broad term for the interacting set 
of laws, government agencies, and pressure groups that 
influence and constrain the conduct of various 
organisations and individuals in a particular society. 
2.4.1 
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He states that legislation affecting business in the 
United States of America has three purposes: (i) To 
protect companies from each other by preventing unfair 
competition, such as in the case of selective 
predatory pricing policies for instance. (ii) To 
protect consumers from unfair business practices; it 
is felt that, if left alone, some firms would for 
instance adulterate their products, mislead through 
advertising, deceive through their packaging, and bait 
through their prices. (iii) To protect the larger 
interests of society against unbridled business 
behaviour; a characteristic of recent legislation has 
for instance been that the social costs created by 
certain production processes or products are shifted 
back to the industries concerned (Kotler, ibid., pp. 
116 117). Certain of the features of the political 
environment described by Kotler (ibid., pp. 115 -
121), are considered to be of particular relevance to 
this-research, and are referred to below. 
More vigorous government agency involvement 
Kotler (ibid. I p. 120) is of the opinion that 
government agencies are driven by self-interest, which 
requires them to demonstrate their usefulness in order 
to justify their need for larger budgets. Moreover, he 
describes the relationship between such agencies and 
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business in general as being of an adversarial nature, 
and states that these agencies attract personnel with 
an anti-business attitude. Approximately twenty years 
before these viewpoints of Kotler were published, this 
same situation was viewed in an entirely different 
light by fellow-American Vance Packard (1960, pp. 234 
235), who accused government agencies of being 
preoccupied with the promotion of industrial interests 
to the virtual exclusion of consumer interests. 
Packard alleged that government officials were deeply 
involved 
supposed 
statement 
Committee 
Food and 
in fraternizing with the industries they were 
to regulate, and specifically referred to a 
allegedly made to a Senate Investigational 
to the effect that a senior official of the 
Drug Administration was more concerned with 
maintaining cordial relations with the pharmaceutical 
industry than he was with a proposed warning against 
drug addiction on the label of a certain product. 
These contrasting viewpoints of Kotler and Packard are 
possibly a reflection of the changes that have 
occurred in the political environment of the United 
States 
which 
tendency 
agencies 
industry 
of America, and elsewhere, during the timespan 
separates their respective viewpoints. The 
of a more vigorous involvement by government 
in the regulation of the pharmaceutical 
in particular was most certainly accelerated 
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by disasters such as the thalidomide affair (see 
Section 2.4.2.1), but should also be seen in the light 
of the growth of public interest groups and the 
resultant political pressures which were brought to 
bear on regulatory authorities world-wide (see Section 
2.4.2). 
The protection of the public interest with regard to 
medical matters is not a new concept. The first Act of 
Parliament dealing with the regulation of medical 
affairs in England, for instance, was passed in the 
year 1511, during the reign of King Henry Vlll. This 
act, which prescribed the qualifications necessary for 
persons to practise as physicians or surgeons, was not 
repealed until 1948. Apothecaries gained their own 
Royal Charter from James 1 in 1617. Again the accent 
was on the protection of the public interest, and the 
Charter reads in part: "(whereas) ... unskillful and 
ignorant men do abide in the City of London ... do make 
and compound many unwholesome, hurtful, dangerous and 
corrupt medicines ... to the great peril and daily 
hazard of the lives of the King's subjects ... " 
(Wolstenholme, 1983, pp. 13 14). Human nature, 
whether typified by indomitable inventiveness, 
shameless greed, or sheer ignorance, has not changed 
over the years; man's ability to inflict harm has, 
however, increased apace with his technological 
ability to do good. Serious concern is therefore today 
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still being expressed about the extent to which 
standards of health care may be compromised by 
pharmaceutical products that are poorly formulated, 
degraded, or criminally inspired (World Health 
Organisation, 19a9, p. 19). 
I 
A recent reminder that such concern is not misplaced, 
was provided by a report concerning substandard and 
counterfeit pharmaceuticals which are being marketed 
worldwide (Masland & Marshall, 1990, pp. 18 - 23). The 
report refers to large quantities of counterfeit burn 
remedies, confiscated in Mexico, which were found to 
contain sawdust, coffee, or dirt, and which caused 
raging skin infections. In Europe, millions of doses 
of a counterfeit cardiac medicine were used by 
unsuspecting patients, luckily without any known 
casualties. American pharmaceutical manufacturers are 
said to be losing 16,2 million dollars per year as a 
result of trade in counterfeit medicines in the United 
States of America. More than a quarter of all 
medicines marketed in Nigeria are estimated to be 
counterfeit, and 109 children died in that country 
during September 1990 due to a poisonous raw material 
having been incorporated into a paediatric medicine as 
the result of the raw material having been mislabelled 
(Masland & Marshall, ibid.). 
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Feigenbaum (loc. cit., pp. 56 - 57) draws attention 
to yet another dimension of regulatory control which 
is of direct concern to government policymakers; 
namely the impact of the internationalisation of 
quality on world trade.·He states that the maintenance 
of world trade patterns that are as free as possible, 
and yet are consistent with restrictions on inequit-
able practices such as dumping or the unfair pricing 
of comparable products, are important aspects of 
governmental economic policy. He notes that products 
are comparable only if their quality is comparable, 
and that this requires clear and measurable quality 
and quality practices which in turn places increasing 
emphasis upon the quality control programmes necessary 
to maintain these (international) requirements. The 
World Health Organisation Certification Scheme on the 
Quality of Pharmaceutical Products moving in Inter-
national Commerce (World Health Organisation, 1989, p. 
109)" is an example of international collaboration in 
the field of transnational commerce in pharmaceutical 
products. It is an administrative instrument through 
which each particular Member State can provide another 
Member 
product 
whether 
State with attestation on whether a particular 
has been granted marketing authorisation, or 
a particular manufacturing plant has been 
granted manufacturing 
internally recognised 
authorisation, based upon 
standards of quality assurance 
or, as it is termed in the industry, standards of 
2.4.2 
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good manufacturing practice (good manufacturing 
practice principles applied in the pharmaceutical 
industry are discussed in Chapter 4 of this 
dissertation). This scheme is seen as offering a 
mechanism not only for controlling legitimate trade in 
pharmaceutical products, but also for combating 
illicit trade in falsely labelled, counterfeited, or 
substandard goods (World Health Organisation, loc. 
cit., p. 110). James E. Wavle Jnr (1986, p. 5), 
speaking in his capacity as president of the Parke-
Davis division of the multinational pharmaceutical 
manufacturer warner-Lambert,is of the opinion that the 
pharmaceutical industry in the United States of 
America owes a large share of its success in world 
markets to the activities of the Federal Food and Drug 
Administration. He considers regulators and the 
regulations which they enforce to be among the 
nation's prized national resources because they add a 
dimension to the national health care system that 
makes it the standard for the world to follow. 
The growth of public interest groups 
The rapid growth of public interest groups that are 
dedicated to lobbying for increased consumer protec-
tion and business regulation has been one of the main 
features of the international political environment in 
recent times. According to Kotler (loc. cit., p. 
121) the eight major public interest groups in the 
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United States of America had, in the mid-Seventies, 
collectively attracted more members and funds than the 
two national political parties of that country. The 
main principles of consumer protection in nearly all 
developed countries are: (i) That products should be 
safe and not of inferior quality. (ii) That business 
practices which negatively affect the economic 
interests of consumers should be regulated. (iii) That 
consumers should have the information necessary to 
make rational choices. (iv) That procedures should be 
provided for the speedy redress of complaints (Price, 
1986, p. 30). 
The gullibility of the lay public, especially with 
regard to the treatment or alleviation of disease, has 
provided a fertile market for the unscrupulous entre-
preneur throughout the history of mankind. Before the 
introduction of modern regulatory controls, the market 
abounded with products that were labelled with false 
or misleading claims regarding their therapeutic 
efficacy; labels commonly did not declare ingredients 
nor did they contain warnings regarding misuse; adulte-
ration was widespread, and many products contained 
dangerous narcotics. One of the most infamous examples 
of the latter state of affairs is the addiction of 
infants to so-called "soothing syrups" marketed in 
the United States of America at the turn of this 
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century, and which contained varying amounts of 
morphine, opium, or heroin. This was the era of "Dr 
Johnson's· Mild Combination Treatment for Cancer", 
"Warner's Safe Cure for Diabetes", and "Kick-a-poo 
Indian Sagwa" 
Following the 
large urban 
(Janssen, loc. cit., pp. 420 - 441). 
industrial revolution and the rise of a 
working class, the patent medicine 
industry in Europe blossomed, and intensive 
advertising was conducted by means of the new printed 
media to promote a variety of relatively innocuous 
herbal laxatives, sedatives, expectorants, and 
antacids, but also for the promotion of medicines that 
were claimed to offer cures for tuberculosis, cancer, 
and syphilis (Dukes, loc. cit., pp. 5 - 9). 
South African history, too, abounds with tales of 
quacks and quack remedies which serve to illustrate 
the limited medical knowledge of the period, 
especially amongst the lay public. The State Gazette 
dated 14 August 1866, for instance, carried an adver-
tisement by a Dr Jacobus Otto of Potchefstroom in 
which he introduces himself to the public as the 
"Wonder Doctor who cured cancer without cutting; stone 
(sic) without stabbing; water (sic) without 
tapping; consumption; piles; and indeed any other 
trouble" (Laidler & Gelfand, 1971, p. 317). A cure for 
lung disease in cattle was advertised in "The Friend" 
dated 19 April 1856 as consisting of a teaspoonful of 
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blue stone (copper sulphate), a tablespoonful of 
salpetre, and two tablespoonsful of soot, mixed in a 
bottle of water (ibid., p. 323). An advertisement 
which appeared in the "Cape Times" in 1901 advised the 
public to smoke Taddy·' s Myrtle Grove cigarettes "as 
protection from the plague" (Joyce, 1981, p. 54). 
Most of the drug legislation passed in Europe during 
the nineteenth century dealt with the regulation of 
the pharmacy profession, i.e. with training and 
licensing requirements as well as the assurance of 
adequate standards of quality for drugs. However, 
pressures for further change were starting to emerge, 
and these pressures came largely from independent 
investigators and protest movements. The Bruinsma 
brothers, for instance, published a book in the 
Netherlands in 1878 in which they presented an 
analysis of many of the useless remedies on sale at 
the time, the methods used to sell them, and the true 
cost of their ingredients (Dukes, loc. cit., p. 7). 
In the United States of America, national magazines in 
1904 began to crusade against what was perceived to be 
flagrant social injustice and exploitation of the ill 
by patent medicine promoters. The Pure Food Movement, 
which was started in the 1870's, is considered to be 
the original and principal source of the political 
support for the Food and Drug Act of 1906; it was 
-62-
primarily a trade movement, but a number of concerned 
journalists assisted in arousing public opinion with 
their cartoons, articles and editorials, despite 
strenuous opposition from whiskey distillers and 
patent medicine manufacturers in particular, who were 
at the time the largest advertisers in that country. 
The "Chicago Tribune" was at the forefront of the 
fight against paediatric medicines containing narcotic 
substances; support came from the "Ladies Home 
Journal", the medical and pharmacy professions, and 
the lay public. 
Public indignation 
issue was finally 
reached a boiling point, and the 
addressed by the passing of the 
Harrison Narcotic Act 
hardships of the 1930 
F.J. Schlink published 
worth", which signalled 
movement world wide. 
in 1914. During the economic 
depression, Stuart Chase and 
a book entitled "Your money's 
the start of a new consumer 
Various mishaps involving 
medicines, such as the "Elixir Sulfanilamide"-incident 
of 1938 (see Section 2.3.3) attracted public interest, 
but the one disaster which is generally considered to 
have resulted in the modern regulatory control systems 
that are applied world wide to this day, is the 
so-called thalidomide incident (see Section 2.4.2.1). 
According to one author, this incident can be 
summarised in one sentence: "The headlines screamed, 
the public was aroused, the drug manufacturers ran 
scared, and the opponents of a tough bill jumped for 
cover" (Janssen, loc. cit., pp. 420 - 441). 
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Shuster (1983, pp. 81 88) is of the opinion that 
pressure groups in the field of medicine are a 
concomitant of social evolution and the spread of 
education, opportunity, and the diffusion of power 
which goes with what he terms the "democratic mode". 
In particular, he believes that pressure groups are 
and are consequently exposed to media-sustained 
"irresponsible" media pressure in the form of 
"eccentric" and "inflammatory" reporting; that they 
are used to the professional advantage of politicians; 
that consumerism coupled with what he refers to as "a 
primitive view of democracy", has lead to the 
enunciation of the "right to more" as a social 
principle (particularly in the field of medicine) and 
that, because of the emphasis that is placed upon 
freedom of speech by Western Democracy, equality of 
expression is often confused with equality of ideas. 
Lay pressure groups are consequently not concerned or 
constrained by their own lack of expertise. Moreover, 
he cites a fundamental distrust of science and 
scientists (to which he refers as the "anti-science 
movement"), as well as a fear of the market ethic and 
its perceived lack of concern for the needs of 
society, as further encouragement for the activities 
of pressure groups. He states that the problem being 
faced by the pharmaceutical industry (and medicine in 
general) is the widespread impression that technology 
is the servant of finance and state, rather than of 
mankind. 
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Van Andel (loc. cit., pp. 234 239) notes that 
drugs with side-effects that can be perceived and 
related to by lay people, are more likely to become 
public targets than those which are not. He states 
that absolutely safe drugs do not, and probably never 
will exist; consumers therefore have to accept a 
certain degree of risk, particularly in cases where 
the level of benefit counterbalances the level of 
risk. Regulatory authorities, apparently under 
pressure from the media or pressure groups, however, 
seem to be prepared to accept only "zero risk", as he 
puts it. 
Whatever its aetiology, consumerism should be 
recognised as being a permanent and powerful force 
with which business management in general must deal on 
a routine basis. In the early sixties however, an 
event occurred which had such an emotional impact on 
society worldwide that it has had a permanent effect 
on . public demands for the regulation of the pharma-
ceutical industry in particular. That event was the 
thalidomide disaster, which involved the birth of 
thousands of badly deformed inf ants to mothers who had 
used this drug during pregnancy. 
The story behind the thalidomide disaster borders on 
the fictional, and is characterised by examples of 
Machiavellian cunning and dishonesty which resulted in 
a human tragedy, the effects of which are still 
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evident more than thirty years after the event. A 
review of the international impact which these events 
had, and still has, on the pharmaceutical industry is 
deemed relevant to an understanding of the regulatory 
controls presently applied to that industry. The 
following section is devoted to a summary of the 
events surrounding the thalidomide incident, based on 
that given by Falb (1977). 
2.4.2.1 The thalidomide tragedy 
According to Folb (loc. cit.), the firm of Chemie 
Gruenenthal was formed after the Second World War by 
the Maurer family of Stolberg, near the German-Belgian 
border. Their original interests were in soap and 
cosmetics, and they began their career in synthetic 
drugs by clearing a section of their packing plant and 
hiring a small research staff of scientists and 
technicians. The average age of the members of the 
team was thirty; they were inexperienced, and none of 
the scientists involved was a pharmacologist, 
competent to predict the effects that a new compound 
might produce in humans. 
The 
from 
be 
Gruenenthal team developed a new sedative, derived 
glutamic acid, which they labelled K-17, soon to 
notorious as 
presented K-17 as 
thalidomide. Gruenenthal executives 
a wonder sleeping pill. One of the 
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mysteries of 
experimental 
the affair is that these men reported 
results which no one else has been able 
They claimed high potency as a sleeping 
absence of side-effects, and a drug 
safe that it was impossible to take an 
experimental data on which these claims 
to reproduce. 
pill, complete 
that was so 
overdose. The 
were based were subsequently destroyed by the firm and 
were never seen by others. 
Intensive marketing of the new "wonder drug" commenced 
amidst great interest from the European medical 
profession. The drug was available without prescrip-
tion, due to its claimed safety and lack of side-
effects; tens 
new product. 
of thousands of West Germans used the 
Despite its claims to the contrary, 
had, between 1957 to early 1961, Chemie Gruenenthal 
been informed of 
associated with 
1 600 cases of serious side-effects 
the use of thalidomide, including 400 
cases of peripheral neuritis (painful damage to the 
nerves of the extremities, producing paralysis), which 
several eminent German neurologists regarded as 
irreversible. The reaction of Chemie Gruenenthal to 
these reports was less than honest; they lied when 
doctors wrote to enquire whether side-effects of such 
a nature had been encountered before, and brushed 
aside highly relevant questions from worried doctors; 
they tried to suppress publication of unfavourable 
reports; 
reports 
opposed 
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they sought publication of favourable medical 
by means of bribery and influence; and they 
suggestions that thalidomide should be 
available on prescription only. 
Thalidomide was also sold to the Distillers Group of 
companies in Britain for marketing on the domestic 
market. The Biochemicals Division of the group had 
been commissioned in 1942 by the Ministry of Supply to 
produce penicillin for the war effort, but after the 
war it was never very profitable. The company was 
impressed by the Chemie Gruenenthal personnel and 
their product; they perceived the new product as 
representing an opportunity to gain a foothold in the 
British market for sedatives, which at that stage was 
worth several million pounds per annum. The most 
important competing product, the barbiturate group of 
products, had the serious disadvantage of being fatal 
in large doses. Gruenenthal's research work, their 
supposedly massive clinical experience, and their 
scientific claims were all taken at face value, and 
the large-scale distribution of thalidomide in the 
United Kingdom commenced. 
Despite the fact that they had no scientific basis for 
believing that thalidomide did not cross the placenta, 
the manufacturers later extended the claims made for 
this drug to include its recommended use in pregnant 
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women and nursing mothers. In fact, from elementary 
principles concerning the chemistry of thalidomide, 
it could with certainty have been predicted that the 
drug would gain access to the foetus; this was later 
confirmed by means of.a simple experimental investi-
gation involving the use of the radioactively-labelled 
drug. 
In June 1961, a leading Australian obstetrician, Dr 
William McBride, reported that there appeared to be a 
connection between thalidomide and the birth of 
deformed infants at the Woman's Hospital in Sydney. Dr 
McBride reported this information to the Australian 
branch of the Distillers Group, but it was never 
passed on to the parent company. Meanwhile, Professor 
w. Lenz, head of the University Clinic for Children in 
Hamburg, had brought to the notice of both Chemie 
Gruenenthal and the State Ministry of the Interior his 
susp-icions that the birth of approximately fifty to 
one hundred deformed inf ants per month in West Germany 
was linked to the use of thalidomide. Gruenenthal 
responded aggressively, but was compelled to withdraw 
its product from the market by the Ministry. At this 
stage Dr McBride's views were published in "The 
Lancet" and, in the wake of the ensuing publicity, 
Distillers Corporation withdrew thalidomide from the 
market in the United Kingdom in December 1961. 
Having 
mutilated 
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suffered the trauma of being delivered 
children, the grief of parents was 
by the ineptitude of the legal system of 
to adequately compensate them and their 
British Comm0nwealth law at the time held 
foetus injured by a drug taken by its mother 
compounded 
the day 
children. 
that a 
could not be viewed as the purchaser of that drug, and 
therefore had no privy of contract with the drug 
manufacturer or retailer. Moreover, it was regarded as 
being unlikely that the culpability of the drug manu-
facturers could be established in a court of law, 
because they had not broken any statute or regulation 
in their production and distribution of the drug. A 
British judge furthermore ignored actuarial advice to 
the contrary and determined in 1967 that financial 
compensation of the handicapped children should not 
take into account inflation, and the consequent 
depreciation of the amount awarded. The courts also 
could not find any formula for compensating 
intangibles such as the nervous shock suffered by 
mothers, and the effects on the families involved. 
Under these circumstances it is easy to understand how 
public dismay and resentment were mobilised by the 
news media, notably the London "Sunday Times", in 
support of a worldwide boycott of Distillers products. 
Eventually, in the mid-seventies, the Distillers 
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Group, with annual profits after tax of 40 million 
Pounds Sterling, established a trust of 25 million 
Pounds Sterling for the affected children. 
Despite 
largely 
the fact that the United States of America was 
unaffected by the thalidomide disaster, the 
Federal Food and Drug Act of 1906 was amended in 1962 
by the so-called Kefauver-Harris Amendment which dealt 
inter alia with requirements relating to the 
pretesting of drugs for safety and effectiveness, and 
which gave the Food and Drug Administration control 
over the production, distribution, and advertising of 
prescription medicines~ including quality control and 
periodic inspection of manufacturing plants. 
In the 
regulating 
United 
the 
Kingdom, a 
introduction 
voluntary 
of new 
system of 
drugs was 
introduced in 1963 under the aegis of the Committee on 
Safety of Drugs, and this was superceded by the 
promulgation of the Medicines Act in 1968, which 
provided for more elaborate statutory control of 
medicines (Weatherall, 1983, p. 47). Control bodies 
were similarly established worldwide, and the 
establishment of the South African Medicines Control 
council in 1965 was part of this international trend 
(see Chapter 3). Pressure by public interest groups 
had thus culminated in the increased international 
involvement of government agencies in the regulation 
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of the pharmaceutical industry. The macroenvironmental 
impact of the thalidomide affair on the pharmaceutical 
industry was indeed of a cataclysmic nature. 
2.5 SUMMARY 
The modern marketing environment places a strong 
emphasis on product quality. Certain economic, 
technological, and political macroenvironmental 
factors may be singled out as being fundamental to the 
demands made on the quality of pharmaceutical products 
in particular. 
With reference to the economic environment of the 
pharmaceutical industry it should be noted that, in 
any market which is characterised by increasing costs 
to the consumer, a concomitant increase in consumer 
demands for product quality may be anticipated. 
Whereas the market for pharmaceutical products has 
traditionally been considered to be relatively price 
inelastic, fiscal constraints on the use of medicines 
are now causing this market to become increasingly 
price elastic in the private as well as the public 
market sectors. A basic tenet of the international 
response to the problem of making essential medicines 
financially more accessible to all market sectors is 
the use of generic (as opposed to branded) medicines. 
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Generic equivalence between products can however be 
established only on the basis of comparable quality. 
The accelerating pace of change in the technological 
environment and the -resultant strategic business 
importance of those factors that affect product 
quality, together with the need for effective manage-
ment of what amounts to a substantial investment in 
research and development, are factors common to all 
industrial sectors. Technological advances in the 
pharmaceutical industry have, however, been charac-
terised by an increase in the risks associated with 
the use of modern medicines; legislation originally 
aimed at protecting the public against adulterated and 
mislabelled 
of the 
medicines soon became outmoded as a result 
onrush of technological change. current 
statutory controls focus instead on aspects such as 
the advertising, sale, and distribution of medicines, 
as well as the maintenance of contemporary standards 
of safety, quality, and therapeutic efficacy. The 
pharmaceutical industry has tended to oppose many of 
these statutory controls, but the ability of the 
industry to regulate itself is disputed by numerous 
informed observers. 
With reference to the political environment of the 
pharmaceutical industry, the extensive involvement of 
government agencies and the growth of public interest 
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groups are seen as being of particular importance. The 
involvement of government agencies in the protection 
of the public interest with regard to medical matters 
is not a new concept. Serious concern is however still 
being expressed about the extent to which standards of 
healthcare may be compromised by pharmaceutical 
products that are poorly formulated, degraded, or 
criminally inspired. Government agencies furthermore 
play an important role in the Certification Scheme of 
the World Health Organisation regarding the quality of 
pharmaceutical products traded between countries. 
One of the main features of the international 
political environment during recent years has been the 
rapid growth of public interest groups dedicated to 
lobbying for increased consumer protection and 
business regulation. The market for pharmaceutical 
products has been characterised by some early examples 
of consumer exploitation which resulted in public 
protest and political pressure. Pressure groups are 
however themselves prone to misuse, and are sometimes 
at a disadvantage due to a lack of technical 
knowledge. Absolutely safe medicines do not, and 
probably never will, exist; pressure by public 
interest groups and the mass media has, however, 
resulted in regulatory authorities adopting a very 
conservative approach to evaluating the degree of risk 
to which a consumer is necessarily exposed. The events 
surrounding the 
in the early 
system of the 
interest, is 
profound effect 
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thalidomide disaster, which occurred 
sixties, and the inability of the legal 
day to properly protect the public 
generally accepted as having had a 
on shaping the regulatory controls 
presently 
worldwide. 
imposed on the pharmaceutical industry 
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CHAPTER THREE: A DESCRIPTION OF THE SOUTH AFRICAN REGULATORY 
CONTROL SYSTEM 
3.1 GENERAL 
The South African Medicines and Related Substances 
control Act (South Africa, 1965) which came into 
effect on 1st April 1966, is the statutory foundation 
of the south African pharmaceutical regulatory control 
system (the macroenvironmental background of this 
control system is discussed in Chapter 2). This Act 
provides for the establishment of a Medicines Control 
council (MCC) which functions independently of 
government and industry. The MCC is mandated to serve 
the public interest with regard to the granting or 
refusal of marketing authorisation for medicines, as 
well as the determination of the conditions under 
which such products may be manufactured, sold and 
advertised. The statutory powers of the MCC include 
authority to carry out its decisions, and the power to 
punish parties who seriously off end the terms of the 
Act; marketing authorisation may for instance be 
withdrawn, or specific batches of a product may be 
removed from the market, if the MCC deems such action 
to be in the public interest (Folb, et al., 1988, 
pp. 772-778). 
Reference is made in Chapter 2 to the fact that the 
regulatory controls which are applied to pharma-
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ceutical products internationally are subject to a 
degree of controversy (see Sections 2.4.2 and 2.3.3.1 
for instance). A number of different issues underlie 
what Dukes (1985, pp. 21-30) refers to as the 
"regulatory controversy"• 
Arguments in favour of a relaxation of regulatory 
controls include the danger that excessive regulation 
will delay 
hinder the 
products; 
the marketing of useful new medicines and 
research process leading to useful new 
the possibility that the return on 
investment of the pharmaceutical industry will decline 
to a point where that industry will no longer attract 
sufficient capital to survive; and the danger that 
adverse effects on the pharmaceutical industry will 
cause unemployment and decrease export earnings, 
thereby harming the national interests of individual 
countries. Conversely, arguments which favour the 
intensification of regulatory controls include the 
need to avert drug disasters, of which the thalidomide 
tragedy (see Section 2.4.2.1) is the classic example; 
the alleged high incidence of serious adverse effects 
which were not recognised prior to the release of a 
medicine onto the market; and the notion that society 
should in principle exert more rigid control on a 
large and multinational industry such as the 
pharmaceutical industry (Dukes, ibid, pp. 24-28). 
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With reference to the south African regulatory control 
system in particular, it may be noted that this system 
was designed to cater predominantly for the country's 
First World needs. In order to make this system more 
relevant to the country's needs, demographic issues 
such as the fact that 17 languages are spoken in South 
Africa and that two thirds of the population cannot 
read or write need to be considered alongside the 
cultural issues (e.g. the use of traditional 
medicines) and economic issues peculiar to this 
country (Folb, et al., loc. cit.). 
The international and domestic debate concerning 
regulatory issues falls beyond the scope of this 
dissertation (see section 1.6 ). However, it is felt 
that the application of the total quality concept (see 
Section 5.5) to regulatory issues will be of value in 
making the necessary adjustments to the current system 
of regulatory control in South Africa. 
This chapter of the dissertation is devoted to a 
concise overview of the relevant sections of the 
Medicines and Related Substances Control Act in terms 
of its practical implications to the control of 
product quality in the pharmaceutical industry. In 
particular, the mechanism 
manufacturing authorisation 
tion is screened by the 
whereby an application for 
and marketing authorisa-
MCC will be reviewed with 
reference to the external quality auditing function 
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of the MCC and the Directorate of Medicines Control 
and Registration of the Department of Health. The 
relationship between much of the information which by 
law must be submitted. to the MCC in support of an 
application for marketing authorisation (see Section 
3.6) and the new design control; incoming material 
control; product control; and post marketing 
surveillance activities routinely performed as part of 
a total quality control system, will be highlighted. 
3.2 A HISTORICAL PERSPECTIVE 
Before the advent of the Medicines and Related 
Substances Control Act, there was no independent 
control over toxicological, teratogenic, or 
carcinogenic factors relating to the safety of 
medicines intended for human use. With reference to 
the · therapeutic efficacy of medicines that were 
marketed in South Africa prior to 1966, little or no 
control existed; clinical trials were often conducted 
only after a product had already been introduced to 
the market, while no effective controls existed to 
counter false or misleading claims made with regard to 
these medicines. Quality was judged according to the 
standards published in official compendia such as the 
British Pharmacopoeia 
Codex, which related 
and the British Pharmaceutical 
to a limited range of pharma-
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ceutical preparations; all other preparations were 
manufactured without any reference to specifications 
being necessary. Many products were marketed with no 
in-process or final release controls having been 
carried out (Van der Merwe, 1979). 
It is ironic that in the period up to 1966, when 
modern regulatory controls came into force, animals in 
South Africa enjoyed greater statutory protection than 
humans with regard to the safety and efficacy of the 
medicines intended for their use. In terms of the 
provisions of the Fertilizers, Farm Feeds and Remedies 
Act, No 36 of 1947, which still applies to a limited 
range of stock remedies to this day, an application 
for the registration of an agricultural or stock 
remedy has to be submitted to the Registering Officer 
of the Department of Agricultural Technical Services 
before it can be sold. Such an application has to be 
accompanied by details concerning every label, 
advertisement and other literature relating to the 
product; two samples of the product; experimental data 
relating to biological tests conducted in South 
Africa; full details regarding product composition; 
details concerning toxicity (including precautionary 
measures, symptoms of poisoning, and the use of an 
antidote); as well as a formal statement describing 
the properties claimed (Pannall, 1967, pp. 71 - 76). 
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To the extent that this research was able to reveal, 
consumers of medicines intended for human use at that 
time enjoyed statutory protection from dangerous and 
useless medicines only insofar as the provisions of 
the Food, Drug and Disinfectants Act, No 13 of 1929 
and the Medical, Dental and Pharmacy Act, No 13 of 
1928 allowed. According to Pannall (ibid., p. 92), 
the objective of the Food, Drug and Disinfectants Act 
was stated to be: " ... the prevention of the importing 
and sale of food, drugs and disinfectants which are 
unwholesome, adulterated or incorrectly described". 
According to Cluver (1960, p. 379), much evidence had 
been collected by South African health authorities 
prior to the introduction of this Act showing both the 
frequency of product adulteration and the extent to 
which· the public was being defrauded. This particular 
statute was in many respects similar to legislation 
passed in the United States of America at the turn of 
this- century in that foods and medicines were placed 
under the purview of the same statute, and that the 
primary focus of these controls was directed at 
adulteration and misbranding (see Janssen, 1981, pp. 
420 - 429). 
The Medical, Dental and Pharmacy Act is of interest in 
two respects. Firstly, it provided the statutory basis 
for control over the sale and distribution of 
medicines (see Section 2.3.3). Secondly, the so-called 
"Therapeutic Substance Regulations" were promulgated 
under this Act; these regulations may be regarded as 
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the forerunner of the statutory 
applied to pharmaceutical products 
controls that are 
in South Africa 
today. Therapeutic substances were defined to include 
vaccines, toxins, antigens, sera, antitoxins, insulin-
preparations, pituatry ·extract, antibiotics, intra-
vascular injections, enzymes, heparin preparations, 
corticotrophin, and human blood products only. The 
controls embodied in the regulations related inter 
alia to the issuing of licences to conduct research, 
manufacture or import therapeutic substances; 
container requirements; labelling requirements; 
potency; quality; toxicity; and expiry dating. The 
scope of this particular statute was by definition 
very limited, and the discretionary powers of the 
regulatory authority {the Secretary for Health) were 
basically restricted to the granting or refusal of 
licences, and the inspection of product storage 
conditions (Pannall, loc. cit., pp. 116 - 125, and 
Cluver, loc. cit., pp. 655 - 717). 
Before and immediately after the implementation of the 
present system of regulatory controls in 1966, serious 
problems were experienced with the quality of some of 
the medicines marketed in south Africa; particularly 
with regard to product safety and conditions of 
manufacture. The advent of the Medicines and Related 
Substances Control Act did not result in an immediate 
improvement in this state of affairs, due mainly to 
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the fact that it was impossible for the newly-
constituted Medicines Control Council to immediately 
screen all the thousands of products already on the 
market at the time. It was also not possible to 
conduct quality audits at all the manufacturing 
facilities that were in operation at the time. Once 
these audits were introduced a general concern was 
voiced within the pharmaceutical industry regarding 
the financial implications of the new quality control 
measures. This initial reticence however soon gave way 
to enthusiasm for the benefits derived therefrom 
(Schlebusch, 1990). 
The present author recently had occasion to gain 
insight into some of the conditions of manufacture 
that were likely to have been routinely encountered in 
some sectors of the pharmaceutical industry thirty or 
more years ago, during a visit to a non-pharmaceutical 
manufacturing facility where certain ointments 
intended for human use were being manufactured ille-
gally. Figure 3.l(a) depicts a general view of the 
production floor of this facility; dirty equipment and 
a general untidiness are apparent. The medicines in 
question were being manufactured in the green 200 
litre container featured in the centre of Figure 
3.l(a). The container had been fitted with a heating 
collar (visible around the base of the container) to 
melt the contents, which was mixed by means of an 
ordinary garden spade. This spade, which is depicted 
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Figure 3.l(a): General view of production floor 
Figure 3.l(b): Mixing implement Figure 3.l(c): Warehouse 
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in Figure 3.l(b), showed visible signs of rust as well 
as ointment residues of unknown origin. Figure 3.l(c) 
depicts a general view of the raw materials warehouse; 
bulk containers are shown to be stored directly on the 
warehouse floor (instead of being palletised), no 
status-labelling or physical quarantine system is 
evident, and there are signs of spillage on the 
warehouse floor around two bulk containers labelled to 
contain paraffin wax. The layout of this plant was of 
such a nature that production and storage areas were 
not segregated, access 
areas were 
personnel and 
address the 
open to 
materials. 
potential 
was not controlled, and both 
uncontrolled cross-flows of 
No attempt had been made to 
problems of environmental 
contamination and 
titanium dioxide 
cross-contamination; traces of 
(a raw material used in the 
manufacture of a non-pharmaceutical product in the 
same plant) were evident over the entire floor area, 
including the administrative offices, and had even 
been carried out to the parking area outside the 
building. What was most striking however, was the 
total lack of appreciation on the part of management 
of the implications to product quality of the 
above-mentioned aspects when it was brought to their 
notice. 
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3.3 THE SCOPE OF THE SOUTH AFRICAN REGULATORY CONTROL 
SYSTEM 
The scope of the South African regulatory control 
system is determined firstly by the legal definition 
of a medicine as given under Section One of the 
Medicines and Related Substances Control Act (South 
Africa, 1965, loc. cit.) and which reads as follows: 
"Medicine means any substance or mixture of 
substances used or purporting to be suitable for 
use or manufactured or sold for use in (a) the 
diagnosis, treatment, mitigation or prevention of 
disease, abnormal physical or mental state or the 
symptoms thereof in man; or (b) restoring, correc-
ting or modifying any somatic or psychic or 
organic function in man, and includes any 
veterinary medicine." 
In terms of the provisions of the Medicines and 
Related Substances Control Amendment Bill (South 
Africa, 1991, Section l(c)), medical devices such as 
instruments, appliances, materials, machines, 
implants, or diagnostic reagents used in the 
diagnosis, treatment or prevention of disease, or 
which affect bodily functions, or which are used in 
the diagnosis or prevention of pregnancy will, at a 
date still to be determined, become subject to the 
same regulatory control system which is presently 
applied to medicines. 
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The scope of the South African regulatory control 
system for medicines is determined, secondly, by the 
criteria which the Medicines Control Council by law 
must apply when deciding whether or not the regis-
tration or availability (i.e. marketing authorisation) 
of a particular product is in the public interest. In 
terms of the provisions of Section 1(3) of the 
Medicines and Related Substances Control Act (1965, 
loc. cit.), the Medicines Control Council (MCC) must 
base such a decision solely on criteria related to the 
safety, quality and therapeutic efficacy of the 
medicine in question. 
As is the case with regulatory authorities world-wide, 
the MCC has fairly wide discretionary powers with 
regard to the practical application of these criteria 
(see Section 2.4). In fact, one of the hallmarks of 
international pharmaceutical regulatory controls is 
the phenomenon that regulatory policies may differ 
markedly between countries. such variations may be due 
inter alia to specific therapeutic approaches; local 
therapeutic traditions; national medical practice and 
opinion; cultural traditions (as reflected in the 
prescribing habits of physicians, and public 
expectations); religious and ethical norms; and 
national economic structures (Dukes, loc. cit., pp. 
11 16). These variations may for instance be 
reflected in differences in the total number of 
products and dosage forms marketed in a particular 
country; differences in the list of approved 
indications and the dosage regimen for a particular 
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drug, and differing acceptance rates for new drugs. 
Variations also exist with regard to the so-called 
"intensity" or "density" of drug regulation, i.e. the 
extent to which matters other than safety, quality and 
efficacy are officially regulated (Dukes, ibid., pp. 
11-20). 
There 
the 
is, however, 
harmonisation 
an international movement towards 
of regulatory requirements. South 
a full member of the so-called Africa is now 
PER-Scheme (Scheme for the mutual recognition of 
evaluation reports on pharmaceutical products) which 
was established by countries belonging to the European 
Free Trade Association. This scheme provides for the 
mutual recognition 
of the scientific 
of a member authority's evaluation 
data that had been submitted by a 
manufacturer, 
authorisation 
granted. The 
and in 
(product 
respect of which 
registration) 
PER-Scheme applies to new 
marketing 
has been 
chemical 
entities only, and is aimed at eliminating a 
duplication of the regulatory evaluation process. The 
unconditional 
is however 
acceptance of foreign evaluation reports 
not obligatory, and the regulatory 
authority concerned remains autonomous with regard to 
its own decisions in this regard (MCC, 1993, Circular 
to applicants ref. 4/93). 
Table 
P • 20) I 
trial 
3.1, which is adapted 
depicts those specific 
cycle for pharmaceutical 
from Dukes (loc. cit., 
aspects of the indus-
products which are 
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TABLE 3.1 ASPECTS OF THE PHARMACEUTICAL INDUSTRIAL CYCLE 
WHICH ARE SUBJECT TO DIRECT REGULATORY CONTROL IN SOUTH AFRICA 
(a) DEVELOPMENT AND INVESTIGATION 
Animal studies (scientific and ethical aspects). 
Safety and comparative safety in man. 
Efficacy and comparative· efficacy in man. 
Clinical trials (protocols and 
investigators). 
Efficacy/safety ratio. 
licensing of 
Adverse reaction monitoring (throughout product life 
cycle). 
Product stability trials. 
(b) GOOD MANUFACTURING PRACTICE 
Quality control systems and procedures. 
Qualifications and training of personnel. 
Manufacturing documentation (records, procedures, 
etc.) 
Premises and equipment (suitability, product contami-
nation etc). 
Process controls (materials handling, in-process 
controls, process validation, etc.) 
Rewo!k policy and procedure. 
Complaints and recall procedures. 
Analytical laboratory controls (reliability of systems 
and procedures). 
(c) MARKETING 
Package insert (format). 
Advertising (written or oral claims). 
Distribution (conditions of sale and possession). 
Prescription requirements (to authorise a sale). 
Import-export transactions (including narcotic sub-
stances). 
Removal of violative products from the marketplace. 
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subject to regulatory control in South Africa, and 
also reflects the regulatory "intensityu of the South 
African regulatory control system. 
It is interesting to note in this regard that matters 
which are subject to official regulation in other 
countries include: (a) The classes of physicians who 
are permitted to prescribe certain drugs (in South 
Africa, this system is presently applied in State-
controlled hospitals and institutions but not in the 
private sector); (b) eligibility for health service 
payments; and (c) pricing policies (Dukes, ibid.). 
Norway has, since 1928, imposed additional criteria 
relating to the so-called "medical need" and 
"therapeutic value" as preconditions for the granting 
of marketing authorisation to pharmaceutical products 
in that country (Wardell, 1983, p. 7). 
An important 
role of the 
recent development concerning the future 
South African Medicines Control Council 
(MCC) is embodied in Section 10 of the Medicines and 
Related Substances Control Amendment Bill (loc. 
cit.), in terms of which the Council may, if it deems 
it expedient and in the public interest, disclose 
information in respect of the prescribing, dispensing, 
administration and use of a medicine, scheduled 
substance, or medical device. Moreover, the Director 
General of the Department of Health may publish this 
information or release it to the public in a manner 
which he thinks fit. 
Previously, 
terms of 
principal 
statutory 
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such information had to be withheld in 
a preservation of secrecy clause of the 
Act; this latest amendment brings the 
basis of the South African regulatory 
control system more closely in line with one of the 
main principles of consumer protection as applied in 
most developed countries, namely the right of the 
consumer to be informed (see Section 2.4.2). It may 
therefore be predicted that the MCC, through the 
Department of Health, will in future be a valuable 
source of unbiased information both to final consumers 
of medicines as well as to professional groups 
involved in the use of medicines, such as physicians, 
pharmacists and nurses. 
3.4 THE ORGANISATIONAL STRUCTURE OF THE SOUTH AFRICAN 
REGULATORY CONTROL SYSTEM 
Section 3 of the Medicines and Related Substances 
Control Act (South Africa, 1965, loc. cit.) provides 
for the establishment of a Medicines Control Council 
(MCC) consisting of not more than 24 members, as 
determined by the Minister of Health; council members 
must collectively possess prescribed academic qualifi-
cations and practical experience in the fields of 
human and veterinary medicine, pharmacology, 
pharmaceutical chemistry, and pharmaceutics. The 
council has a Chairman and Vice Chairman, both of whom 
are also appointed by the Minister of Health. 
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In terms of Section 9 of the Medicines and Related 
Substances Control Act (ibid.) I an Executive 
Committee may be appointed by the council from amongst 
its own members. The MCC may, subject to the approval 
of the Minister of Health, also appoint suitable 
persons to such other committees as it may deem 
necessary to investigate and report to it on any 
matter within the purview of the council. Nine such 
specialist sub-committees presently operate in terms 
of this provision, namely the clinical; veterinary; 
scheduling; homeopathic; medical devices; analytical; 
biological; old medicines; and pharmaceutical sub-
committees (see Figure 3.2). Any sub-committee may in 
turn consist of so-called working groups composed of 
persons attached to academic institutions nation-
wide, thereby giving the MCC access to highly 
specialised and experienced authorities in many 
different fields (Schlebusch, loc. cit.). 
A secretary to the council, who is termed the 
Registrar of Medicines, is appointed by the Minister 
of Health after consultation with the MCC (South 
Africa, 1965, Section 12). The Registrar of Medicines 
constitutes the Secretariat (see Figure 3.2), and is 
also the Chief Executive of the Directorate Medicines 
Control of the Department of Health. The Registrar is 
accountable to the Minister of Health, the Director 
General of the Department of Health, and the Chairman 
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of the MCC (Schlebusch, loc. cit.). The Directorate 
Medicines Control and Registration performs tasks 
delegated to it by the Registrar of Medicines, and 
consists of four Sub-Directorates: the Sub-Directorate 
Medicine Registration;· Medicine Control; Clinical 
Pharmacology; and Administrative Services (see Figure 
3.2). All personnel attached to the Directorate 
Medicines Control and Registration are employees of 
the Department of Health. 
3.5 THE MARKETING AUTHORISATION PROCEDURE 
This section of the dissertation gives a concise 
overview of the major stages of the review process for 
new chemical entities and certain generic medicines; a 
detailed description of the protocol for other product 
types or specific regulatory issues is beyond the 
scope of this dissertation. The procedure whereby the 
MCC - judges safety, quality and therapeutic issues 
relating to applications for marketing authorisation 
will therefore be described in general terms only. 
Applications for product marketing authorisation are 
submitted to the Registrar of Medicines (see Figure 
3.2) in the form of a Summary Basis for Registration 
Application (SBRA); this document is intended to be a 
summary of the core data contained in the formal 
application, or so-called MBR 1 registration dossier 
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(see Section 3.6), which is submitted once the SBRA 
document has been accepted. The SBRA document will 
contain a brief and concise overview of aspects such 
as a description of the product itself (e.g. the 
active ingredient(s) and the quantity thereof, the 
dosage 
details 
form, and the pharmacological classification); 
concerning the product's proven pharma-
action, based upon at least two key co logical 
supporting references; 
including details of 
main product safety 
evidence of product efficacy, 
the relevant clinical trials; 
issues and toxicological data, 
including human studies and pre-clinical studies (with 
reference to animal and in vitro toxicology); evidence 
of the product's long term safety and efficacy; 
evidence of the bioavailability and pharmacokinetics 
of the active component(s); the product's registration 
status in other countries (if applicable); and a 
motivated statement concerning the proposed scheduling 
status of the product (see Section 3.7 regarding the 
signi~icance of product scheduling status). The SBRA 
document is reviewed by technical personnel attached 
to the Directorate Medicines Control and Registration 
of the Department of Health. The applicant will be 
informed of the outcome of the review of the SBRA 
document within four weeks of its submission. If the 
SBRA document is accepted, submission of the MBR 1 
registration dossier for formal review by the MCC may 
proceed (MCC, 1986, Circular to applicants ref.15/86). 
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This system enables the applicant to receive an 
indication, which is not binding upon the MCC, of the 
likelihood of the proposal's success or failure. If 
the review of the SBRA document reveals that the 
formal MBR 1 application is unlikely to be successful, 
the document is returned to the applicant together 
with the appropriate comment. The applicant is not 
bound to accept this opinion, and is free to proceed 
with the formal MBR 1 application. 
To further expedite the review process of new applica-
tions by the expert committees of the MCC, one copy of 
the fully-completed MBRl dossier may be submitted to 
the Registrar 
stability data 
studies (which 
of Medicines for "Quick Screening" of 
and bioavailability or dissolution 
are submitted as proof of product 
efficacy). 
hours of any 
to 
the 
The applicant will be informed within 72 
deficiencies in this regard (MCC, 1992, 
Circular 
expedite 
which have 
applicants ref. 2/92). In order to 
evaluation of pharmaceutical products 
already been registered (granted marketing 
authorisation) 
has introduced 
in certain nominated countries, the MCC 
the so-called Abreviated Medicines 
Review Process (AMRP). The AMRP-system is aimed at 
reducing the evaluation time of applications for 
registration of products already registered in the 
United States of America, Great Britain, Canada, 
Sweden and Australia with respect to the evaluation of 
pharmacotoxicological and clinical data in particular 
(MCC, 1993, Circular to applicants ref. 4/93). 
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The information that must be submitted by an applicant 
in the MBR 1 registration dossier for formal review by 
the MCC, is described under Section 3.6 of this 
dissertation. 
submitted for 
subcommittees 
After 
formal 
of the 
the MBR 1 dossier has been 
review, the various specialist 
MCC will review individual 
aspects of the application; decisions made by the 
various subcommittees are subject to further review 
and confirmation at a plenary session of the MCC. The 
Medicines and Related substances Control Act empowers 
the MCC to impose any precondition it may deem 
necessary on the granting of marketing authorisation 
for a particular product. One of the preconditions 
routinely applied by the MCC relates to the require-
ment that an acceptable standard of good manufacturing 
practice (GMP) must be maintained in the place of 
manufacture. Members of the inspectorate attached to 
the Directorate Medicines Control and Registration 
(see- Figure 3.2) will inspect the plant concerned to 
verify adherence to good manufacturing practice 
principles (see Chapter 4), and the MCC will base its 
decision on whether or not to grant that plant 
manufacturing authorisation on the report submitted by 
the inspectorate to its plenary session. 
There are three possible outcomes to the formal review 
of the MBR 1 dossier: 
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(a) The MCC may decide to approve the application for 
marketing authorisation (product registration), 
whereaf ter the Registrar of Medicines enters the 
information prescribed by Regulation 7 of the 
Medicines and Related Substances Control Act 
(loc. cit.) into the Medicines Register, and 
issues the applicant with a Medicine Registration 
Certificate as prescribed by Regulation 8 of the 
Medicines and Related Substances Control Act 
(ibid.). The Registrar of Medicines also 
allocates a registration number to every product 
thus approved; this number is entered into the 
Medicines Register 
tion Certificate 
of Regulation 9 
and on the Medicine Registra-
and, in terms of the provisions 
of the Medicines and Related 
Substances Control Act 
appear on every product 
under which the MCC 
(ibid.), must also 
label. The conditions 
has granted marketing 
-authorisation 
Register and 
Certificate. 
is also entered into the Medicines 
on the Medicine Registration 
(b) The MCC may decide to defer the application for 
marketing authorisation subject to certain 
specified conditions, depending on the nature of 
the council's objection to the application. The 
applicant is informed in writing of the reason(s) 
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for the deferment. If the applicant does not 
accept the council's reasons, an appeal may be 
made directly to the council, provided that this 
is properly motivated and is done within one 
month after the -date of notification (South 
Africa, 1965, Section 15(3)(b)). If no such 
appeal is made, or if the MCC is still not 
satisfied, the application is rejected. The 
applicant may then appeal to an appeal committee 
appointed by the Minister, and which consists of 
a retired judge or advocate of the supreme Court, 
who shall be the chairman, a pharmacologist and, 
depending on the field to which the appeal 
relates, a veterinarian and a pharmacist; a 
homeopath; a medical practitioner and a 
pharmacist; or a specialist or technician with 
expert knowledge concerning medical devices 
(South Africa, 1965, Section 24). The appeal 
committee may confirm or set aside or vary the 
relevant decision by the MCC. In the case of an 
application having to be resubmitted, reentry 
into the evaluation system may occur at any one 
of several different levels, depending on the 
nature of the council's original objection. 
(c) The MCC may decide to reject the application for 
marketing authorisation, in which case the proce-
dure regarding the disclosure of the reasons for 
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the decision and the right of the applicant to 
appeal against such a decision is the same as 
that described under (b) above. 
3.6 THE MBR 1 REGISTRATION DOSSIER 
Section 14 of the Medicines and Related Substances 
Control Act (ibid.) may be regarded as the corner-
stone of the South African regulatory control system. 
This particular statutory provision empowers the MCC 
to declare a particular medicine or class or category 
of medicines to be registerable, and places a 
prohibition on the sale of any registerable medicine 
unless it has been so registered. Every application 
for marketing authorisation in respect of a medicine 
must be submitted to the Registrar of Medicines on the 
prescribed form, the so-called MBR 1 registration 
dossier, the only exception being biological medicines 
which are registered in terms of the format prescribed 
by Regulation 46 of the Medicines and Related 
Substances Control Act (ibid). For the purposes of 
this dissertation, only the data pertaining to the MBR 
1 dossier for non-biological medicines will be 
reviewed. 
The format of the MBR 1 
described under regulation 
Related Substances Control 
registration dossier is 
15 of the Medicines and 
Act (ibid.), and consists 
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of 25 annexures and sub- annexures in the case of a 
medicine intended for human consumption, and 26 
annexures or subannexures in the case of a veterinary 
medicine. The purpose of the MBR 1 dossier is to 
supply the MCC with s~fficient data on which to base 
its decision regarding the granting or refusal of 
marketing 
should be 
authorisation of the product concerned. It 
noted in this regard that the onus for 
submitting complete, accurate and truthful information 
concerning an application for marketing authorisation 
rests entirely with the applicant; it is not for the 
MCC to go in search of the relevant evidence, although 
the council may conduct any investigations of its own 
which it may deem necessary (Snyman, 1972, pp. 280 -
287). The cover page of the MBR 1 dossier contains a 
declaration by the applicant to the effect that all 
the information contained in the dossier is true and 
correct; and Section 29 (h) of the Medicines and 
Related Substances Control Act (loc. cit.) makes it 
an offence for an applicant to give false or mis-
leading information in this regard. Notwithstanding 
this statutory provision, it may be stated that the 
contractual relationship between the applicant and the 
MCC is one which is very much based on trust. 
The paragraphs which follow contain a summary of the 
information required to be submitted by the applicant 
in the various annexures of the MBR 1 dossier. The 
3.6.1 
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close relationship between this information and that 
which will routinely be generated during the 
activities associated with the implementation of a 
total quality system, will be highlighted. 
The package insert 
The printed information leaf let or package insert 
which accompanies each package of medicine, either as 
a separate entity or an integral part of the package, 
is by law required to disclose inter alia details 
concerning product composition; pharmacological 
action; clinical indications for use; contra-
indications; warnings; directions for use; side-
effects and special precautions; known symtoms of 
overdosage and details of its treatment; product 
identification (physical attributes); and storage 
conditions (South Africa, 1965, Regulation 10). All 
the - information contained in the product package 
insert has to be scientifically substantiated to the 
satisfaction of the MCC, and this information must be 
summarised in the prescribed format under Annexure lA 
of the MBR 1 dossier. In terms of Regulation 11(3) of 
the Medicines and Related Substances Control Act 
(ibid.), no advertisement for a medicine may contain 
a statement which deviates from or goes beyond the 
evidence submitted in the MBR 1 registration dossier. 
The information contained in the approved package 
3.6.2 
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insert of a pharmaceutical product thus defines the 
parameters of the promotional claims that may be made 
in connection with that particular product; the accent 
being on full disclosure of relevant product 
information, and accurate advertising. 
The product label 
Annexure lB of the MBR 1 dossier requires the 
applicant to provide a facsimile or specimen of the 
proposed product label in order to verify compliance 
with the labelling requirements detailed under 
Regulation 9 of the Medicines and Related Substances 
Control Act (ibid.). These labelling requirements 
include the disclosure of information relating to the 
identity and quantity of each active ingredient 
contained per dosage unit; indications for use; 
recommended dosage; the lot number; the expiry date; 
the ·name of the applicant; storage conditions; and 
prescribed warnings (e.g. "keep out of reach of 
children"). As in the case of the package insert (see 
Section 3.6.1), the accent here is on full disclosure 
of the relevant product information. 
These requirements are in keeping with modern thinking 
on labelling policy. The reason for the adoption of 
this particular policy by the American Food and Drug 
Administration (FDA) is related to the perception that 
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drug manufacturers were replacing medical schools as 
the principal source of information regarding their 
use of new drugs. The FDA felt that the informative 
labelling agreed upon with manufacturers in the course 
of processing new drug.applications, was not reaching 
potential prescribers of the products concerned. 
According to the legal requirements applicable at the 
time, this information was referred to on the product 
label as being "available to physicians on request". 
This informative labelling was, however, usually not 
part of the product pack, and there was no assurance 
that it would be included in a response to a request 
for such information. The pharmaceutical industry 
moreover was promoting the use of these potent new 
drugs to physicians through detail men, mailing 
pieces, medical 
publications that 
journal advertising, and reference 
frequently failed to disclose their 
the dangers of this situation were hazards. As 
recognised, the 
labelling to be 
FDA increasingly required informative 
made part of the prescription drug 
package; this in turn lead to the promulgation of the 
so-called "full disclosure" regulations in 1961. These 
regulations called for the disclosure of complete 
professional information to the prescriber of a 
medicine, including the specific hazards, side 
effects, and special precautions regarding its use; 
this information now had to be included in pre-
scription drug packages and the sales literature dis-
tributed to physicians (Janssen, loc. cit., p. 436). 
3.6.3 
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In South Africa, current legislation applies this 
requirement to all medicines, not only prescription 
medicines (South Africa, 1965, Regulation 10 and 11). 
The MCC is also presently engaged in compiling guide-
1 ines with regard to the use of layman's terminology 
in product package inserts, thereby further extending 
the doctrine of full disclosure of relevant product 
information (MCC, 1993, Circular to applicants ref. 
20/93). 
Product formulation 
Full details relating to product formulation (design) 
must be disclosed under Annexure 2 of the MBR 1 
dossier. The names and quantities of each active 
ingredient must be disclosed, and must conform to the 
relevant particulars in the package insert and on the 
label (see Section 3.6.1 and 3.6.2). The identity and 
quantity of each inactive ingredient, together with 
its purpose, must also be disclosed even when a 
particular ingredient may not be present in the final 
product (e.g. in the case of alcohol which is 
off evaporated 
purpose of 
in order to 
formulation, 
during the manufacturing process). The 
each inactive ingredient must be disclosed 
give the MCC an overall picture of the 
and because the same inactive may in some 
instances serve more than one function; for example, 
starch in a tablet formulation may serve as a dis-
3.6.4 
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integrating agent or a binding agent. Even the 
content of gelatine capsule shells (including the 
preservatives contained therein) and tablet coatings 
must be disclosed; details required include the colour 
index number of the colourants and the type of 
printing ink used to imprint tablets or capsule shells 
(Beaumont, 1991, pp. 18-19). 
Chemical details of active ingredients 
The chemical details of the active ingredient(s) of 
the formulation must be declared under Annexure 3A of 
the MBR 1 dossier with reference to the approved 
name(s) used under Annexure 2 (the formulation) of the 
application; structural formulae (i.e. formulae of 
organic compounds in which the covalent bonds between 
atoms are presented graphically) must be given; and 
the relevant data relating to solubility in water, and 
storage requirements, must be disclosed. Data relating 
to storage requirements must correspond to the 
stability data submitted under Annexure 10 of the 
application (see Section 3.6.16). Annexure 3A of the 
MBR 1 dossier relates only to the chemical details of 
active ingredients; raw material specifications for 
active as well as inactive raw materials are detailed 
under Annexure 4 of the MBR 1 dossier (see Section 
3.6.7). 
3.6.5 
3.6.6 
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Identification of vendors 
The names and addresses of primary and alternative 
suppliers of active ingredients must be declared under 
Annexure 3B of the MBR 1 dossier. The applicant will 
not be allowed to source active raw materials from any 
vendor other than those listed under this particular 
annexure. This implies that it would be in the 
interests of the applicant to initiate a formal vendor 
approval procedure (as would be done routinely during 
the implementation of a total quality programme) 
before nominating specific suppliers under this 
annexure. 
Description of the method of synthesis of the active 
ingredients 
Under Annexure 3C of the MBR 1 dossier, the applicant 
is required to refer specifically to impurities and 
degradation products which may be produced during the 
~ynthesis of the active ingredient(s) of the proposed 
product. The significance of the presence of these 
impurities and degradation products in the final 
pharmaceutical dosage form is therefore taken into 
account. 
3.6.7 
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Summary of raw material specifications 
Under Annexure 4 of the MBR 1 dossier, a summary of 
the specifications for all the active and inactive raw 
materials used in the. manufacturing process must be 
supplied, including the names of the tests, limits, 
and criteria of acceptance relating to every parameter 
contained in the specification. The data supplied in 
this annexure therefore details the parameters 
according to which a raw material will be accepted or 
rejected. The analytical and other control procedures 
whereby compliance with these specifications are 
monitored, are described under Annexure 5 of the MBR 1 
dossier (see Section 3.6.8). It should be noted that 
not all the specifications listed under Annexure 4 are 
necessarily tested for as a batch release requirement 
for raw materials; this aspect is explained more fully 
under Section 3.6.9. 
3.6.8. Raw material control procedures 
Annexure 5 of the MBR 1 dossier calls for a full 
description of the analytical and other (technical) 
control procedures relating to the raw material 
specifications disclosed under Annexure 4 (supra). 
In other words, full details of the inspection and 
test procedures that have to be carried out in order 
to accept or reject a raw material are given in this 
annexure of the MBR 1 dossier. 
3.6.9 
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Raw material release criteria and laboratory details 
Annexure 6 of the MBR 1 dossier calls for a 
description of those analytical and other (technical) 
control procedures that are actually carried out on 
raw materials as a batch to batch release requirement. 
The difference between the details that are disclosed 
under Annexures 5 and 6 of the MBR 1 dossier, is 
therefore related to the fact that only certain of the 
tests or procedures detailed under Annexure 5 (see 
Section 3.6.8) are in practice carried out as a batch 
to batch release requirement for raw materials. 
According to the guidelines issued in this regard by 
the Medicines Control Council, at least an 
identification test and assay must be performed on all 
active raw materials, although the council may demand 
any additional tests it may deem necessary for 
specific materials (MCC, 1983, Circular to applicants 
ref.- 4/83). Supplier's certification by means of a 
Certificate of Analysis may therefore reduce the 
number of analytical and other controls carried out by 
the applicant to identification and assay procedures 
only, subject to the approval of the Medicines Control 
Council. 
3.6.10 Final product specifications 
A summary of the specifications of the final product 
must be given under Annexure 7A of the MBR 1 dossier. 
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The title of the specifications (e.g. average tablet 
mass, hardness, and assay values), together with the 
limits and criteria of acceptance of all physical, 
chemical and, where necessary, microbiological 
parameters that are to be used as release criteria for 
the final product, must be included in this summary. 
Specifications will naturally differ according to the 
dosage form involved. For example, the final product 
specifications for an uncoated tablet would typically 
include criteria such as physical description (colour, 
size, markings, shape, etc.); theoretical mass; 
average mass; 
disintegration 
mass uniformity; hardness; friability; 
time (under specified conditions); 
dissolution time (under specified conditions); 
degradation products; 
maximum percentage 
assay values (e.g. minimum and 
purity); identification; and 
where applicable (Beaumont, loc. moisture content, 
cit., pp. 27 - 30). 
3.6.11 Final product control procedures 
Under Annexure 7B of the MBR 1 dossier, the applicant 
is required to give a full description of the 
analytical and other technical control procedures 
relating to the final product specifications set out 
in Annexure 7A. In other words, the applicant is 
required to give a full description of the analytical 
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and other (technical) control procedures that will be 
carried out to verify compliance with the final 
product specifications detailed under Annexure 7A (see 
Section 3.6.10). 
3.6.12 Container specifications 
Annexure BA of the MBR 1 dossier calls for detailed 
specifications of the type, nature, size and grade of 
the immediate container (i.e. the container which is 
in direct contact with the medicine), including the 
method of closure and the material used as wadding. A 
brief description of the outer container (if appli-
cable) must also be given, but specifications are not 
required in this case. The Medicines Control Council 
has adopted a policy which requires that, in the case 
of glass ampoules, statistically valid sampling 
procedures must be employed with respect to: (i) 
Complete physical specifications; (ii) a hydrolytic 
resistance test; (iii) a test for barium and other 
substances which may leach out of the glass; and (iv) 
validation of the cleanliness, sterility, and 
non-pyrogenicity of closed ampoules (MCC, 1983, 
Circular to applicants ref. 16/83). The Medicines 
Control council has furthermore determined that child 
protective measures must be employed with regard to 
containers used in the sale of salicylates, para-
cetamol, iron tablets or capsules, and certain liquid 
camphor products (MCC, 1984, Circular to applicants 
ref. 10/84). 
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3.6.13 Container control procedures 
Annexure 8B of the MBR 1 dossier calls for details 
concerning the control procedures that are carried out 
up to the point where the actual packaging process is 
about to take place, and therefore includes those 
control procedures relating to the specifications in 
Annexure 8A (see Section 3.6.12) as well as the 
additional checking procedures that are followed after 
overprinting and cleaning of packaging materials. It 
should be noted that some of the above-mentioned 
procedures will in fact be carried out by the 
vendor(s) concerned, but that final responsibility in 
this regard rests with the applicant. 
3.6.14 Final product control 
All control procedures that are carried out on the 
final product as a batch release requirement, and the 
name and address of the laboratory where these tests 
are to be carried out, must be disclosed under 
Annexure 9A of the MBR 1 dossier. It should be noted 
that not all of the control procedures detailed under 
Annexure 7A (see Section 3.6.10) are necessarily used 
as a batch release requirement for the final product. 
The inspection and test procedures detailed under 
Annexure 9A therefore relate only to those controls 
that are in fact used in the final release of the 
product. 
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In the case of products that are imported in finished 
form, the final product release controls must at least 
include an identification and assay in order to verify 
the maintenance of product integrity during transit. 
Samples may be drawn lo~ally and returned for analysis 
by overseas suppliers in accordance with the details 
disclosed by the applicant under this annexure of the 
MBR 1 dossier. 
The Medicines Control Council may exempt an imported 
product from having to be (chemically) identified and 
assayed, under certain prescribed conditions. These 
preconditions relate inter alia to the validation of 
conditions of transportation; a conclusive (not 
necessarily chemical) identification test performed in 
South Africa; the availability of product master 
specifications; certification of the quality control 
systems of the manufacturing plant; and a formal 
release procedure which includes details of the exact 
method and duration of transport, a certificate of 
analysis from the supplier, invoicing details, and 
confirmation of container integrity (South African GMP 
guide, 1992, Appendix II). 
3.6.15 Final container control 
Annexure 9B of the MBR 1 dossier calls for details 
concerning the analytical control procedures that are 
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to be 
behalf 
carried out on the immediate container by or on 
of the applicant, as well as the identity of 
the laboratory where these tests are to be performed. 
Summaries of all the tests listed under Annexures 8A 
and 8B (see Sections 3.q.12 and 3.6.13) must be given, 
in addition to which tests for cleanliness and accu-
racy of overprinting may be included here (Beaumont, 
loc. cit., p. 36). 
3.6.16 Stability data 
Under Annexure 10 of the MBR 1 dossier, the applicant 
is required to provide the Medicines Control Council 
with a description of the characteristics of the 
product's active ingredients in respect of normal 
degradation patterns, the identity of known degra-
dation products, and the storage conditions necessary 
to preserve raw material integrity. A full descrip-
tion- of the experimental details of stability testing 
carried out on the final product, an interpretation of 
the results 
suitability 
obtained, a description of the nature and 
of the analytical procedures employed, and 
a comprehensive description of the stability programme 
used to determine the product's shelf-life, must also 
be included under this annexure of the dossier. The 
actual design of the stability studies and tests that 
are employed will depend on the nature of the product 
concerned and the known stability characteristics of 
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its ingredients; the type of packaging which is to be 
used (the product must be tested in the container-
closure system in which it will be sold); and the 
variety of environmental conditions to which the 
product is likely to b~ exposed during its shelf-life 
(the product would typically be tested at elevated and 
cyclical temperatures, and under conditions of 
elevated humidity, as well as normal storage 
conditions). It is important to note that it is the 
responsibility of the applicant (not the regulatory 
authorities) to ensure that the stability testing 
methods and results accurately reflect expected 
stability characteristics during the product's entire 
shelf-life (MCC, 1991, Circular to applicants ref. 
12/91). 
The concept of product stability which is encountered 
in the pharmaceutical technical literature in many 
respects corresponds to the product reliability 
concept, which is an integral part of the total 
quality philosophy. Feigenbaum (1986, pp. 570 - 572) 
describes product reliability as being a quality 
characteristic, and defines the concept as follows: 
"Product reliability is the ability of a unit to 
perform a required function under stated conditions 
for a stated period of time." The prediction of 
product reliability and the demonstration that this 
reliability has been achieved, the improvement of 
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product reliability, the coordination of all the 
activities necessary to establish, achieve and 
maintain product reliability, and the integration of 
these activities into the complete company programme 
for quality, all form part of the product reliability 
activities of a total quality system. 
3.6.17 Manufacturing procedures 
Annexure 11 
step-by-step 
of the MBR 1 dossier calls for a 
description of all the manufacturing and 
packaging procedures 
carried out during 
and in-process controls that are 
the product's manufacture. The 
information which is disclosed under this annexure 
would typically include the exact items of equipment 
to be used, and would detail processing parameters 
such as mixing times and temperatures. The product 
formulation detailed under Annexure 2 (see Section 
3.6.3) will be repeated here, with quantities scaled 
up to the production batch size. All analytical and 
other (technical) in-process controls, their frequency 
and sequence, and the stage of production at which 
they are to be carried out, together with the relevant 
limits of acceptance, must also be disclosed under 
this annexure. 
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As soon as the Medicines Control council has approved 
the application for registration, processes and 
procedures have to be validated with reference to the 
first two production batches of product (MCC, 1983, 
Circular to applicants ref. 14/83). These data must be 
retained for inspection by inspectors attached to the 
Sub-Directorate Medicines Control of the Department of 
Health (see Section 3.4). The above-mentioned valida-
tion procedure is considered necessary in order to 
ensure uniform quality on a batch to batch basis 
(Beaumont, loc. cit., p. 39). 
3.6.18 Foreign Registration 
In order to expedite the registration process in South 
Africa of a product that has been registered in a 
foreign country, details concerning the conditions for 
registration in that country must be submitted to the 
Medicines Control Council under Annexure 12 of the MBR 
1 dossier. If foreign registration is still pending, 
then details concerning the progress already made in 
this regard must be submitted. The South African 
Medicines Control Council is therefore able to rely on 
the expertise of foreign regulatory authorities when 
making decisions concerning the availability of a 
particular product on the South African market. 
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Reference is made under Section 3.3 to the PER-Scheme 
for the mutual 
pharmaceutical 
recognition of evaluation reports on 
products between south Africa and 
countries belonging to the European Free Trade 
Association. See also the reference in Section 3.5 to 
the so-called Abreviated Medicines Review Process, 
which involves the use of evaluation reports sourced 
from certain foreign countries. 
3.6.19 Pharmaceutical and biological availability 
Annexure 13 of the MBR 1 dossier calls for the 
applicant to disclose the experimental details and 
results of tests carried out on the product to confirm 
its pharmaceutical and/or biological availability. 
Pharmaceutical availability in principle refers to the 
quantity of active ingredient(s) which is/are 
dissolved in vitro from a pharmaceutical dosage form 
(such as a tablet for instance) in a given dissolution 
medium, as 
reference 
a function of time, compared to a suitable 
standard. Biological availability may be 
defined as the quantity of, and the rate at which, an 
administered medicine appears in the relevant body 
fluid (blood, for example); the data may be required 
to be established in vivo (Beaumont, loc. cit., 
pp. 41 - 44). 
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The above 
Council in 
data are required by the Medicines Control 
support of the claims for safety and 
therapeutic efficacy made by the applicant for the 
product concerned, and will be of particular 
importance in the fol~owing circumstances: (i) When 
the results of clinical studies are not available; 
(ii) when clinical trial data are available, but 
relate to a product formulation which differs from 
that being submitted by the applicant; and (iii) when 
a new sustained release, repeat action or long acting 
dosage form is at issue (ibid., p. 41). 
3.6.20 Pre-clinical studies relating to toxicological data 
Under Annexure 14A of the MBR 1 dossier, the applicant 
is required to provide toxicological evidence of the 
safety of the proposed product. Such data may include 
test results relating to acute toxicity, terato-
genicity, carcinogenicity, and any other appropriate 
tests. In cases where well-known active ingredients 
are involved, 
exemption from 
information. 
the Medicines Control Council may grant 
the submission of some of the above 
3.6.21 Pre-clinical studies relating to product efficacy 
Annexure 14B 
applicant to 
of the 
disclose 
MBR 1 dossier 
experimental 
calls 
details 
for the 
and the 
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results of tests performed pre-clinically to demon-
strate the therapeutic efficacy of the proposed 
product. These test results in particular must 
substantiate the medicinal claims that are to be made 
in connection with th~ proposed product when it is 
used as directed. 
3.6.22 Clinical studies to demonstrate product safety 
Under Annexure 15A of the MBR 1 dossier, the applicant 
is required to provide full details (including dosages 
and routes of administration) regarding the tests 
performed on human beings during clinical trials, 
together with the results obtained; including the 
side-effects observed. In the case of a product 
intended for veterinary use, Annexures 15A, 15B, and 
15C are replaced by Annexures 17A, 17B, and 17C 
respectively. The above information enables the 
Medicines Control Council to evaluate the in vivo 
safety of the proposed product. 
3.6.23 Clinical studies to demonstrate product efficacy 
Under 
must 
details 
Annexure 15B of the MBR 1 dossier, the applicant 
provide the Medicines Control Council with 
regarding the tests conducted, and the results 
during clinical studies aimed at demon-
the therapeutic efficacy of the proposed 
obtained, 
strating 
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product. such studies would typically be based on any 
of a number of trial designs, such as double-blind, 
cross-over, or randomized trials for instance (MCC, 
1986, Circular to applicants ref. 15/86). 
3.6.24 Clinical data to support the claimed pharmacological 
action of the medicine 
Under Annexure 15C of the MBR 1 dossier, the applicant 
is required to submit data obtained during clinical 
trials on human beings to demonstrate that a particu-
lar and predictable pharmacological action is obtained 
from specified concentrations of an administered 
medicine in a relevant body fluid (blood, plasma, or 
spinal fluid for instance). 
3.6.25 Pharmaceutical development 
Annexure 16 of the MBR 1 dossier calls for disclosure 
of details concerning the experimental and production 
-sized batches of product from which the final product 
specifications stated in Annexure 7A (see Section 
3.6.10); the final product control procedures in 
Annexure 7B (see Section 3.6.11); the stability data 
in Annexure 10 (see section 3.6.16); the manufacturing 
procedures in Annexure 11 (see Section 3.6.17); and 
the pharmaceutical and bioavailability data in 
Annexure 13 (see Section 3.6.19) were derived. The 
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relevant working documents must be made available for 
inspection by members of the inspectorate of the 
Sub-Directorate Medicines Control of the Department of 
Health (see Section 3.4). 
3.7 Statutory controls over the advertising and sale of 
medicines 
Experience with modern medicines has shown that many 
of these products are of great value if used under 
professional direction, but could be dangerous if 
used in an uncontrolled manner by a lay person (see 
Section 2.3.3). Dangerous side-effects and adverse 
reactions, as well as the problem of drug abuse, are 
examples of problems which could be exacerbated by the 
uncontrolled use of some of these medicines (Snyman, 
1972, pp. 275 - 276). Self-medication is, however, a 
necessary and widely practised facet of health care, 
and - individual countries have to devise statutory 
controls over the advertising and sale of medicines to 
best suit their individual needs. In South Africa, 
these statutory controls have to accommodate the needs 
of a heterogeneous community with multiple strata of 
development, customs and traditions, education, 
facilities, and economic levels (ibid., pp. 287 -
288). 
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It was mentioned under Section 2.3.3 that earlier 
statutory controls over the sale of medicines in South 
Africa were instituted upon the advice of the Medical 
and Dental Council and the then Pharmacy Board. 
Following the promulgation of the Medicines and 
Related Substances Control Act, and the creation of 
the Medicines Control Council (MCC), a specialist 
sub-committee of the MCC, the Scheduling Sub-Committee 
(see Figure 3.2) now administers this task. The 
mission of this subcommittee is to advise the MCC on 
all matters regarding the scheduling of medicines; the 
MCC in turn advises the Minister who amends the 
Schedules to the Medicines and Related Substances 
Control Act by publication in the Government Gazette 
(Dreyer, 1986, p. 122). Depending on its particular 
risk/benefit profile, a medicine may be classified in 
one or more of nine schedules, or may remain 
unscheduled; specific preconditions for the 
advertising or sale of a medicine thus classified are 
prescribed by the Medicines and Related Substances 
Control Act in the interests of the final consumer. 
Unscheduled 
acceptable 
medicines are those which have an 
and which are deemed safety profile 
necessary for public 
service is available; 
use where no pharmaceutical 
these medicines generally do 
not require professional counselling on their use or 
storage, nor is a differential diagnosis necessary to 
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initiate their use. Shedule One medicines are those 
with a proven safety profile, but which still require 
a certain degree of professional control with regard 
to their storage, merchandising, and the furnishing of 
advice concerning their use. Schedule Two medicines 
are for use in less serious (usually self-limiting) 
diseases upon the advice of a competent professional 
person. Schedule Three medicines are mainly for use 
in chronic conditions such as hypertension, epilepsy, 
angina, diabetes, and thyroid dysfunction. Schedule 
Four medicines are medicines whose use should be 
initiated only after a differential diagnosis has been 
performed and/or should be used under the constant 
supervision of a physician, or which possess a 
relatively high toxicity potential. Schedule Five is 
reserved for centrally acting medicines which have a 
sedative and/or hypnotic activity, and which have a 
degree of abuse potential. Schedule Six medicines are 
potentially dangerous and dependence-producing. 
Schedule Seven medicines relate to the so-called habit 
forming drugs, such as morphine and pethidine, whereas 
Schedules Eight and Nine are reserved for the 
so-called banned substances, such as cannabis and 
amphetamines (Dreyer, ibid., pp. 122 - 125). 
Briefly stated, an unscheduled medicine may be sold 
without 
Schedule 
restriction by any licensed person, whereas 
One and Two medicines may be sold only by a 
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pharmacist, veterinarian, dentist or a physician under 
certain prescribed conditions. Schedule Three to Seven 
medicines may only be sold on the prescription of a 
physician, subject to certain preconditions regarding 
the number of repeat .issues that may be given; the 
quantity that may be supplied; the period of supply; 
and the records and registers that have to be kept 
with regard to such a sale. Schedule Zero 
(unscheduled) up to Schedule Two medicines are 
commonly ref erred to as "over the counter" or "OTC" 
medicines, whereas Schedule Three to Seven medicines 
are referred to as "prescription medicines" (see Table 
1.1). "Over the counter" medicines may be advertised 
to the lay public, whereas "prescription only" 
medicines may be advertised to the professions only 
(South Africa, 1965, Section 22A). The Medicines and 
Related Subtances Control Act furthermore stipulates 
that an advertisement may not go beyond the 
information approved by the MCC in the product's 
package insert (South Africa, 1965, Section 18 read 
with Regulation 11). 
3.8 SUMMARY 
The South African regulatory control system is founded 
upon the provisions of the Medicines and Related 
Substances Control Act. This Act provides for the 
creation of the Medicines Control Council (MCC), an 
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autonomous body with statutory powers, which is 
mandated to act in the public interest when making 
decisions regarding the granting or refusal of 
applications for marketing authorisation (regis-
tration) of medicines, and to determine the conditions 
under which medicines may be manufactured, sold or 
advertised. Administrative and executive support for 
the functioning of the MCC is provided by the 
Directorate Medicines Control and Registration of the 
Department of Health. 
Modern regulatory controls are applied to most aspects 
of the entire industrial cycle of a pharmaceutical 
product; from the commencement of clinical trials with 
experimental formulations to post marketing 
surveillance of the finished product. During the 
entire regulatory control process, information must be 
provided to the MCC regarding all aspects of product 
safety, quality and therapeutic efficacy. These 
regulatory requirements in many respects correspond to 
the new design control; incoming material control; 
product control; and post marketing surveillance 
activities of a total quality system. The regulatory 
authorities may 
role of external 
therefore be seen as performing the 
quality auditors within the pharma-
ceutical industry; this relationship is in many 
respects based on a mutual commitment to serving the 
public interest. 
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The regulatory decision making process is by its very 
nature not based exclusively on scientific criteria, 
but has to reflect the specific needs of the country 
concerned especially with regard to aspects such as 
local therapeutic conditions, national medical 
practice and 
and ethical 
opinion, cultural traditions, religious 
norms, and national economic structures 
(see Section 2.4). An important facet of what may be 
termed the current 
Africa relates to 
controls presently 
designed to cater 
First World needs; 
regulatory control 
"regulatory controversy" in South 
the fact that the regulatory 
applied in this country were 
predominantly for the country's 
the relevancy of the existing 
system is consequently being 
questioned. The application of a business economic 
approach to this problem is seen as being potentially 
valuable, both in terms of its market orientation and 
the emphasis that it places upon optimum resource 
utilisation. 
The MBR 1 registration dossier, which is discussed in 
Section 3.6, and the good manufacturing practice 
principles which are discussed in Chapter 4 of this 
dissertation, are 
guidelines to the 
decisions during 
both seen as providing valuable 
identification of quality-related 
each step of the industrial cycle. 
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The MBR 1 dossier in particular may be described as 
a valuable tool in the formulation of quality 
in the pharmaceutical industry (see Section 
Moreover, the MBR 1 dossier relates to many of 
being 
policy 
5.9). 
the key elements of the new design control; incoming 
material control; product control; and post-marketing 
surveillance activities of a total quality system. 
Similarly, the quasi-legal good manufacturing 
practice principles currently adhered to by the South 
African pharmaceutical industry upon the insistence of 
the MCC (see Chapter 4) also contain many elements 
which may be further developed and expanded into a 
formal total quality system. 
From a business economic viewpoint, however, a major 
criticism of the above-mentioned components of the 
South African regulatory control system is the fact 
that they are exclusively technically-oriented, with 
no managerial focus. This contrasts with the business 
economic viewpoint that quality is in essence a way of 
managing an enterprise, and that managerial control 
over quality is achieved in the same manner as control 
over the financial, marketing and other functions of 
the enterprise. Managerial control over quality in-
volves the continuous setting of the necessary quality 
standards, appraisal of quality conformance, correc-
tion of quality problems and their causes, and plan-
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ning for future improvements (see Section 5.4). With 
reference to the south African regulatory control 
system, there appears to be a need to distinguish 
between the value of what amounts to a mere declara-
tion of intent to adhere to certain (technically-
oriented) principles, and the creation of a dynamic 
company-wide managerial structure which is aimed at 
the disciplined achievement of the quality goal. 
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CHAPTER FOUR: A CRITICAL REVIEW OF CURRENT PHARMACEUTICAL GOOD 
MANUFACTURING PRACTICE PRINCIPLES 
4.1 GENERAL 
In the wake of 
described under 
the thalidomide disaster, which is 
Section 2.4.2.1, the so-called 
Kefauver-Harris amendment to Food and Drug Adminis-
tration (FDA) legislation was introduced in the United 
States of America during 1962. In terms of this 
amendment, the American regulatory authority (the FDA) 
was given control over production, distribution and 
advertising of prescription medicines, including 
quality control and periodic inspection of manufac-
turing facilities (Folb, 1977). The regulations 
promulgated in terms of this new legislation require a 
complete and full description of the controls employed 
by a manufacturer to assure the quality of all 
medicines produced. The first good manufacturing 
practice (GMP) regulations were published in the 
United States of America during 1963 (Lachman, et 
al., 1986, p. 829). The first World Health 
Organisation (WHO) draft text on GMP was prepared at 
the request of the Twentieth World Health Assembly in 
1967 by a group of consultants (WHO draft GMP guide, 
1990, p. ii). 
A great many GMP texts have subsequently been 
published worldwide, and these guidelines may be seen 
as representing the collective wisdom of the industry 
and the various regulatory authorities with regard to 
the assurance 
products. These 
maintenance of 
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of the quality of pharmaceutical 
guidelines are intended to ensure the 
high standards of quality in the 
development, manufacture and control of pharmaceutical 
products; to promote. uniformity in licensing 
decisions; and to facilitate the removal of barriers 
to trade in pharmaceutical products (PIC GMP guide, 
1989, p. 1). In some countries, such as the United 
States of America, these guidelines are intended to 
assist members of the industry to comply with the 
legal requirements in that regard. In other countries, 
such as South Africa and the United Kingdom, these 
guidelines do not enjoy legal force and are intended 
merely as a summary of generally-accepted principles 
rather than a set of inflexible rules. However, the 
South African Medicines Control Council (MCC) has 
adopted a policy whereby marketing authorisation 
(product registration or product licensing) is granted 
subject to the proviso that an acceptable standard of 
GMP be maintained at the place of manufacture of that 
particular product, thereby conferring a quasi-legal 
status upon local GMP guidelines. 
Medicines 
Medicines 
of Health 
control officers attached to the Directorate 
Control and Registration of the Department 
audit the standard of GMP maintained by the 
South African pharmaceutical industry. These audits 
are based upon a locally developed GMP checklist. 
When compiling 
Health borrowed 
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this checklist, the Department 
extensively from the British 
of 
GMP 
guide, as well as from other overseas GMP guidelines, 
while at the same time introducing various innovations 
that were developed i~ consultation with the local 
pharmaceutical industry (Kotze, 1990). In view of 
South Arica's expected admission to the "Convention 
for the Mutual Recognition of Inspection in respect of 
the Manufacture of Pharmaceutical Products" (PIC), 
local GMP requirements may also be influenced by the 
provisions of the PIC GMP guide. The practical effect 
of PIC GMP requirements is however likely to relate 
mainly to administrative matters such as the 
requirement for "site master files" to be prepared in 
respect of individual companies (Kotze, 1993). A site 
master file is a document which is prepared by the 
manufacturer, in which specified GMP information 
relating to the production activities at a specific 
plant is summarised for use by regulatory auditors 
(PIC, 1991, pp. 1-7). 
Important revisions of international GMP guidelines 
and new GMP guidelines which have been published in 
recent times include the British GMP guide (1983); the 
French GMP guide (1985); the European Economic 
Community (EEC) draft GMP guide (1989) which was 
implemented on 1 January 1992; the World Health 
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Organisation (WHO) draft GMP guide which was published 
for comment in 1990; and the GMP guide published by 
the Convention for the Mutual Recognition of 
Inspection in respect of the Manufacture of Pharma-
ceutical Products publis.hed in September 1989 (PIC GMP 
guide). Even more recently, a revised edition of the 
South African GMP guide was published in 1992 by the 
Pharmaceutical Manufacturers Association of South 
Africa and the Proprietary Association of South Africa 
to serve as a voluntary standard for the industry in 
this country. In view of the dynamic approach adopted 
by the south African regulatory authorities in this 
regard, it was considered appropriate for the purposes 
of this chapter of the dissertation to include 
extracts from all of these publi~ations in a review of 
the principles on which South African GMP theory is 
based. 
It must be stressed that this review is not aimed at 
providing 
of GMP 
a detailed summary of the technical aspects 
theory. It is intended instead to highlight 
those aspects of GMP theory that may either complement 
a total quality system, or which may be better 
achieved by a total quality system. 
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4.2 THE CONCEPTS OF QUALITY ASSURANCE, GOOD MANUFACTURING 
PRACTICE AND QUALITY CONTROL 
4.2.1 
Reference is made throughout most GMP texts to the 
terms quality assurance (QA), good manufacturing 
practice (GMP) and quality control (QC). A discussion 
of these concepts follows. 
Quality assurance 
This term is defined as follows in the British GMP 
guide (ibid., p. 10): 
"(Quality assurance) is the sum total of the 
organised arrangements made with the object of 
ensuring that products will be of the quality 
required by their intended use. It is good 
manufacturing practice plus factors outside the 
scope of this guide (such as original product 
- design and development)". 
This definition 
draft GMP guide 
is similar to that given in the EEC 
(loc. cit., p.15), and also to the 
following description of the objective of a quality 
assurance programme given in the technical literature 
by Lintner (1980, p. 1425): 
"The main purpose of a quality assurance 
programme is to implement systems and procedures 
that provide a high probability that each dose or 
package of a pharmaceutical product will have 
homogenous 
reasonably 
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characteristics and properties (within 
acceptable limits) to ensure both 
clinical safety and efficacy of the formulation". 
According to the South African GMP guide (1992, pp. 
1/1 1/2), the "requirements and objectives" of 
quality assurance are achieved when: 
(i) "Medicines are designed and developed in such a way 
that they can be produced to comply with the quality 
requirements and lot to lot conformity to specifi-
cations can be maintained". 
(ii) "The production operations and Good Manufacturing 
Practices are clearly specified and adhered to". 
(iii) "The production environment and services to the 
production operation are monitored". 
(iv) "Deviations are adequately recorded, investigated and 
responded to". 
(v) "The supply and use of adequate starting and packaging 
materials is assured". 
(vi) "All the 
products 
necessary controls on intermediate and final 
and other in process controls, validations 
and, if necessary, trend analysis are carried out". 
(vii) "No product 
pharmacist 
produced and 
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is sold or supplied until a responsible 
has ensured that each batch has been 
controlled in accordance with legal and 
other requirements". 
(viii) "Medicines are stored, handled and distributed so that 
quality is maintained". 
(ix) "Laboratory operation and Good Laboratory Practices 
are clearly specified and adhered to". 
(x) "The Quality Assurance system is regularly audited by 
self-inspection for effectiveness and applicability". 
4.2.2 Good manufacturing practice 
This term is defined as follows in the British GMP 
guide (loc. cit., p. 10): 
-"(Good manufacturing practice is) ... that part 
of quality assurance aimed at ensuring that 
products are consistently manufactured to a 
quality appropriate to their intended use. It is 
thus concerned with both manufacturing and 
quality control procedures". 
The narrow focus of this definition of the GMP concept 
is also apparent from the following definition given 
in both the EEC draft GMP guide (loc. cit., p. 17) 
and the WHO draft GMP guide (loc. cit., pp. 12 -
13): 
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"Good manufacturing practice is that part of 
quality assurance which ensures that products are 
consistently produced and controlled to the 
quality standards appropriate to their intended 
use as required by the marketing authorisation". 
According to the South African GMP guide (loc cit., 
pp. 1/2 1/3), the "basic requirements and objec-
tives" of good manufacturing practice are achieved 
when: 
(i) "The production processes are clearly defined, syste-
matically reviewed and validated to ensure that 
products are of the required quality". 
(ii) "All the necessary facilities are provided, including 
appropriately qualified and trained personnel; 
adequate premises and space; suitable equipment and 
services; correct materials, containers and labels; 
approved procedures and instructions; and suitable 
storage and transport". 
(iii) "Critical processing steps, key equipment and services 
are validated". 
(iv) "All production operations are conducted in such a way 
as to produce products of the required qualityn. 
(v) 
(vi) 
(vii) 
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"Instructions and procedures are written in an 
instructional from in clear and unambiguous language, 
specifically applicable to the facilities provided". 
"Operators 
correctly". 
are trained to carry out procedures 
"Records are made, manually and/or by recording 
instruments, during manufacture which demonstrate that 
all the steps required by the defined procedures and 
instructions were in fact taken and that the quantity 
and quality of the product was as expected. Any 
significant deviations are fully recorded and 
investigated". 
(viii) "In-process and final controls for materials, proces-
ses, imtermediates and products are adequate to 
determine suitability". 
(ix) "Records of production, control and distribution which 
enable the complete history of a batch to be traced, 
are retained in a comprehensible and accessible form". 
{x) "The distribution {wholesaling) of the products 
minimises any risk to their quality". 
(xi) "A system is available to recall any batch of product 
from sale or supply". 
(xii) 
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"Complaints about marketed products are examined, the 
causes of quality defects investigated and interpreted 
and appropriate measures taken in respect of the 
defective products to prevent recurrence". 
4.2.3. Quality control 
This concept is defined as follows in the British GMP 
guide (loc. cit., p. 10): 
"Quality control is that part of good manufactu-
ring practice which is concerned with sampling, 
specification and testing, and with the organi-
zation, documentation and release procedures 
which ensure that the necessary and relevant 
tests are, in fact, carried out and that 
materials are not released for use, nor products 
released for sale or supply, until their quality 
has been judged to be satisfactory. (The term) 
-"quality 
of the 
control" is sometimes used in the sense 
organisational entity which has responsi-
bility for these functions". 
Exactly 
concept 
18) and 
the same wording is used to define this 
in the EEC draft GMP guide (loc. cit., p. 
the WHO draft GMP guide (loc. cit., pp. 14 -
15), except for the rider which is added in the latter 
guide to the effect that quality control is not 
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confined to laboratory operations only, but" ... must 
be involved in all decisions which may concern the 
quality of the product". However, when describing the 
various functions of the quality control department, 
the WHO draft GMP gui.de (ibid., pp. 15 - 18) refers 
only to inspection and test procedures. 
According to the South African GMP guide (loc cit., 
p. 1/3) the "basic requirements and objectives" of 
quality control are as follows: 
(i) "Adequate facilities, trained personnel and approved 
procedures are available for sampling, inspecting and 
testing starting materials, packaging materials, 
intermediates, bulk and finished products, and where 
appropriate for monitoring environmental conditions 
for GMP purposes". 
(ii) 
(iii) 
(iv) 
"Samples of starting materials, packaging materials, 
intermediate products, bulk products and finished 
products are taken by personnel and by methods 
approved by Quality Control". 
"Test methods are validated". 
"Adequate standards and reagents are maintained". 
(v) "Records are 
instruments, 
-140-
made, manually 
which demonstrate 
and/or by recording 
that all the required 
sampling, 
actually 
inspecting and testing procedures were 
carried out. Any deviations are fully 
recorded and investigated". 
(vi) "The finished product complies with all legal require-
ments and is enclosed within its specified container 
and correctly labelled". 
(vii) "Records are made of the results of inspection and 
testing of materials, intermediates, bulk and finished 
products is formally assessed against specification. 
Product assessment includes a review and evaluation of 
relevant production documentation and an assessment of 
deviations from specified procedures". 
(viii) "No batch of product is released for sale or supply 
prior to certification by a qualified pharmacist that 
it is in accordance with all legal requirements". 
(ix) "Sufficient reference samples of starting materials 
and products are retained to permit future examination 
of the product if necessary, and the produc~ is 
retained in its final pack unless exceptionally large 
packs are produced". 
(x) "Follow-up stability trials in final packaging are 
conducted to assess the validity of the shelf-life". 
(i) 
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From the above review of key concepts, the following 
deductions may be made regarding current GMP philo-
sophy: 
Quality is defined 
use"-doctrine, with 
in terms 
special 
of the "fitness for 
reference to product 
safety and clinical efficacy, and not as a strategic 
business concept. 
(ii) Quality is seen as being affected mainly at the 
production stage of the industrial cycle; although it 
is recognised that factors such as original design and 
development play a role too, these factors are 
specifically identified as falling outside the scope 
of GMP guidelines. 
(iii) A quality 
mainly of 
technical 
focus, and 
coordinating 
assurance system 
a plant-based 
is seen as consisting 
series of interrelated 
activities, with no obvious managerial 
without reference to its role in 
the quality inputs of people, machines, 
and information. 
(iv) Quality control is defined in terms of the traditional 
inspection and test concept. 
(v) Quality control is seen as being the responsibility of 
the quality control function, rather than being a 
companywide and plantwide activity. 
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4.3 THE PURPOSE OF GMP GUIDELINES 
Good manufacturing practice guidelines may be 
described as being a collection of quality-related 
standards and procedures that are used by the 
pharmaceutical industry to complement relevant 
technical specifications during the production phase 
of the industrial cycle, with a view to assuring the 
quality (and related parameters of safety and 
efficacy) 
objective 
the more 
guidelines 
(see SABS, 
of medicinal products. Insofar as this basic 
is concerned, there is a similarity between 
generally-applicable quality systems and 
provided by the SABS ISO 9000 guidelines 
1987), and the GMP guidelines specifically 
developed for use in the pharmaceutical industry. 
A review by Anisfeld (1990) of the GMP codes, regula-
tions and guidelines currently in use in 23 countries 
around the world however reveals significant differ-
ences of opinion with regard to the stated purpose of 
these publications. For instance, Anisfeld (ibid., 
p. IT2) notes that the Italian GMP guide describes GMP 
as being a system of standards that have to be 
complied with in order to produce drugs of the 
specified quality. According to Anisfeld (ibid., p. 
IS2), the Israeli GMP guide on the other hand adopts a 
more cautious approach by referring to GMP as "comple-
menting" the various control procedures applied 
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during production in order to "contribute" to the 
manufacture of quality products. The British GMP guide 
(loc. cit., p. 6) states quite succinctly that "The 
objective of GMP and any guide to it is, initially, 
the assurance of the ,quality of the product, and 
ultimately the safety, well-being and protection of 
the patient". The purpose of the South African GMP 
guide (loc. cit., p. x) is stated as being" ... to 
set out (GMP) principles so that the quality, safety 
and therapeutic availability of medicines can be 
assured". Yet another perspective of the purpose of 
GMP guidelines is given by the French GMP guide (loc. 
cit., p. 5): 
" (GMP is intended to) specify the various 
means to be used in the manufacture and 
production of pharmaceuticals in order to ensure 
that marketed products are of the quality 
intended, and thus describe the objectives to be 
-reached in matters of organisation, personnel, 
equipment, premises, as well as control 
requirements and procedures". 
One common denominator may however be identified in 
the approach to GMP by countries worldwide, namely 
that GMP is considered to be the benchmark against 
which any pharmaceutical manufacturer's quality 
assurance system is to be measured. The WHO draft GMP 
guide (loc. cit., p. xii) for instance describes the 
purpose of that guide to be: 
(i) For use 
f acturing 
the WHO 
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in the assessment of applications for manu-
authorisation (see Chapter 3) in support of 
Certification Scheme on the Quality of 
Pharmaceutical 
Commerce. 
Products Moving in International 
(ii) To serve as a basis for inspection of manufacturing 
facilities. 
(iii) For use as training material for government drug 
inspectors (quality auditors). 
Moreover, it would appear from the wording of the 
objectives quoted above that GMP guidelines may be 
considered by industry and regulatory authorities 
alike to be in essence the equivalent of a total 
quality system. This deduction is supported by the 
fact that there is a tendency, especially amongst 
regulatory authorities, to look towards a tightening 
of GMP regulations as being a solution to quality 
problems experienced within the pharmaceutical 
industry. An example of this particular approach is 
provided by Food and Drug Administration (FDA) 
personnel who investigated the recurrence of 
labelling-related product recalls in the United States 
of America over the past several years. These investi-
gators generally found firms to have complied with 
current GMP requirements, and they then make the 
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following deduction (Anon, 1989b, p.3): "The 
inescapable conclusion is that maybe there is 
something in the regulations that needs to be fixed; 
that the (GMP) regulations are not addressing the 
right things or are mis.sing out some of the important 
elements." This same report states that the FDA is 
considering proposals aimed at "strengthening" GMP 
requirements in four "important" areas related to the 
problem of labelling and packaging mix-ups; namely 
gang-printing of labels, electronic label verifi-
cation, the use of cut labels (as opposed to labels on 
a continuous roll), and the handling of packed 
products 
of GMP 
which are not immediately labelled. The scope 
guidelines is generally characterised by a 
narrow, technically-oriented approach similar to that 
displayed in the above example. This aspect is 
discussed in the following section. 
4.4 THE SCOPE OF GMP GUIDELINES 
Good manufacturing practice is by definition concerned 
with the assurance of product quality during manufac-
ture (see Section 4.2.2), and it therefore follows 
that the scope of GMP guidelines will be limited to 
factors which may affect product quality during this 
particular phase of the industrial cycle. Some authors 
place an even narrower focus on their GMP texts, while 
others appear to be moving towards a recognition of 
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the fact that quality is affected at all stages of the 
industrial cycle, and not only during the manufac-
turing phase. 
According to Anisfeld (loc. cit., p. AT2) the 
Australian GMP guide for instance adopts a restrictive 
(narrow) approach: It specifically draws attention to 
the fact that it is intended to emphasise in 
particular technical aspects relating to labelling and 
contamination problems which experience within the 
pharmaceutical industry has shown to be the more 
frequent source of product recalls, and that it is not 
aimed at addressing all the factors which may affect 
product quality. The British GMP guide (loc. cit., 
pp. 5 6) encourages the reader to adopt a broader 
perspective by stating that a publication of that 
nature could not possibly cover every facet of good 
practice in the manufacture of medicinal products, and 
that- a full understanding and evaluation of the "total 
quality of the total (product) batch" may only be 
embraced by a consideration of many other factors; 
that is by a system of "quality assurance" which by 
definition includes aspects such as original product 
design and development (see Section 4.2.1). The French 
GMP guide (loc. cit., p. 11) states that a system of 
quality assurance should cover all phases of develop-
ment, manufacture and distribution, and specifically 
identifies GMP as being that part of the quality 
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assurance system which is concerned with the 
manufacturing process alone. According to Anisfeld 
(loc. cit., p. NE2), the Dutch GMP guide similarly 
describes GMP as being that part of an "integrated 
quality assurance syste~" which deals with aspects of 
production and quality control, while the other part 
of the system relates to the quality of design. These 
viewpoints serve to underline the fact that good 
manufacturing 
merely a 
practice should 
component part of 
activities necessary to assure 
final product. 
be 
the 
the 
viewed as being 
wider range of 
quality of the 
Any disagreement which there may be concerning the 
scope of GMP guidelines or principles, is probably 
related to inconsistencies in distinguishing between 
the concepts of quality assurance, good manufacturing 
practice, and quality control. All the latest GMP 
guidelines reviewed during this research define the 
concept of quality assurance in terms similar to that 
used by Feigenbaum (1986, p. 14) to define a quality 
system. In other words, quality assurance is defined 
as being a wide-ranging concept which covers all 
matters which individually or collectively influence 
the quality of a product (see WHO draft GMP guide, 
loc. cit., p. 10). These guidelines also define 
quality control as being a sub-component of GMP, which 
in turn is defined as being a sub-component of a 
quality assurance system (see Section 4.2). 
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The clear distinction which is thus made between the 
concepts 
practice 
maintained 
reviewed. 
of quality 
and quality 
throughout 
assurance, good manufacturing 
control, is however not 
the texts of the GMP guidelines 
This results in the interrelationship 
between these concepts being misunderstood, and may 
explain why GMP principles may be internationally 
perceived, by both regulatory authorities and the 
pharmaceutical industry, to be the equivalent of a 
total quality system despite the fact that most 
introductions to GMP guidelines specifically warn 
against such an interpretation (see Section 4.6.1). 
The technical literature also reflects similar 
sentiments regarding too broad an interpretation of 
the scope of GMP principles. Lachman, et al. (loc. 
cit., p. 829) for example remind the reader that 
current good manufacturing practice is an aid, not a 
substitute, for what is referred to as a "total 
quality assurance programme". 
Current good manufacturing practice theory is 
characterised by the emphasis it places upon the 
purely technical aspects of the production process, to 
the virtual exclusion of the role played by management 
skills. It is however now recognised even in the 
technical literature that good manufacturing practice 
is attained only when technical expertise is combined 
with the necessary management skills (see Begg, 1984, 
pp. 31 - 32). 
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A practical example of the consequences of a purely 
technical approach to the assurance of product quality 
is provided by Avallone (1990, pp. 228 - 230), who 
discusses a number of problem areas relating to the 
production of sterile products which were identified 
during regulatory inspections of pharmaceutical plants 
in the United States of America. He refers to problems 
related to the chemical aspects of parenteral process 
validation; biological and chemical aspects of the 
lyophilisation of a sterile product; several aspects 
relating to process-environmental monitoring; 
validation of cleaning procedures; and the manufacture 
and control of bulk sterile powders, and concludes 
that the underlying cause of the problems that had 
been encountered in these areas could in most cases be 
attributed to the lack of a quality commitment by top 
management. 
4.5 THE STATUS OF GMP GUIDELINES 
A fundamental determinant of the status accorded to 
GMP principles in a given country, appears to be the 
extent to which the relevant regulatory authority is 
willing to subscribe to the notion that GMP is the 
linchpin of quality assurance in the pharmaceutical 
industry. Anisfeld (loc cit., p. iii) singles out 
one of the most notable trends observed in GMP 
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philosophy internationally over the past ten years, to 
be the belief that GMP principles have to be comple-
mented by "efficient inspection and enforcement"; 
otherwise pharmaceutical "quality enhancement" will 
not occur. 
This observed trend, to which Anisfeld refers, would 
seem to point to yet another determining factor of GMP 
status; namely that regulatory authorities in general 
are of the opinion that a voluntary set of GMP 
guidelines is not as effective as one that is legally 
enforced, or that company top management in the 
pharmaceutical industry have to be coerced into a 
commitment to quality. If this were so, it is possible 
that, from the point of view of the pharmaceutical 
industry, the control of quality within that industry 
may then be limited to the field of reference dictated 
by regulatory requirements only. 
The 
as 
British 
being II 
consultation 
of inflexible 
GMP guide (loc. cit., p. 3) is described 
a work of guidance, produced in 
(with the industry), rather than as a set 
rules". The South African regulatory 
authorities also firmly subscribe to this particular 
philosophy. However, as a result of an incident during 
which a manufacturer questioned the authority of the 
regulatory inspectorate to conduct a GMP audit, the 
Medicines Control Council decided to make compliance 
with an acceptable standard of GMP (as evaluated by 
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the inspectorate at the place of manufacture), a pre-
condition for the granting of marketing authorisation 
of all medicines (Schlebusch, 1990). The practical 
effect of this decision was to elevate the status of 
GMP principles in South Africa to that of a 
quasi-legal requirement. 
According to Government Regulation no. 664 (France, 
1985), the French view GMP principles as being" ... an 
aid to the more accurate interpretation of general, 
legal and regulatory provisions regarding the manu-
facture of pharmaceutical products, and as a basis of 
dialogue between the industry and the regulatory body 
of control." This approach is similar to that of the 
Canadian GMP guidelines (Anisfeld, loc. cit., pp. CN 
1 15), which are presented as being an "interpre-
tation" of the Food and Drug Regulations, and also to 
the approach adopted within the United States of 
America (Begg, 1992). The GMP principles published per 
regulation in the United States of America are however 
described as representing the minimum statutory 
requirements with which industry must comply 
(Anisfeld, loc. cit., pp. US 1 13), and are 
therefore basically prescriptive in nature. Japanese 
GMP principles may similarly be described as being 
prescriptive, in that they are embodied in the 
so-called "Pharmaceutical Affairs Law Concerning GMP" 
(Anisfeld, ibid., pp. JA 1 - 32). 
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It would therefore be correct to state that GMP 
principles/guidelines occupy a strategic position in 
governing the relationship between the pharmaceutical 
industry and the regulatory authorities in South 
Africa, and also interna~ionally. 
All internationally accepted systems of regulatory 
control are concerned with assuring that only licensed 
manufacturers (who comply with GMP principles) produce 
medicinal products. GMP principles are also used as a 
basis for the inspection (auditing) of licensed 
manufacturing facilities by regulatory auditors (EEC 
draft GMP guide, loc. Cit. I p. 7, WHO draft GMP 
guide, loc. Cit. I p. xii). GMP principles 
furthermore play an important role in bilateral 
international trade in pharmaceutical products. The 
first World Health Organisation (WHO) draft text on 
good manufacturing practice was accepted as an 
integral part of the WHO Certification Scheme on the 
Quality of Pharmaceutical Products moving in 
International Commerce in 1969 (WHO draft GMP guide, 
ibid., p. ii). A Member State who wishes to use the 
WHO Certification Scheme in connection with the 
exportation of pharmaceutical products and substances, 
must ensure inter alia that all manufacturers of 
such products conform to GMP requirements consonant 
with those recommended by the WHO (1989, p. 110). 
South Africa is a signatory to the WHO Certification 
Scheme (see Anisfeld, loc. cit., pp. iv - vii for a 
complete list of signatories). 
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4.6 THE PRINCIPLES ON WHICH SOUTH AFRICAN GMP THEORY IS 
BASED 
The purpose of this section of the dissertation is to 
provide an overview of the GMP principles according to 
which the South African pharmaceutical industry is 
evaluated for regulatory purposes. The checklist used 
by regulatory auditors to evaluate GMP compliance in 
South Africa, is largely based on the British GMP 
guide (see 
GMP guide 
section 4.1). Moreover, the South African 
which was produced by the local industry to 
serve as a voluntary standard, is also principally 
based on the requirements of the British GMP guide, as 
will be shown in the paragraphs which follow. 
Due to 
general, 
to as 
the dynamic nature of GMP principles in 
these principles are more correctly ref erred 
"current" good manufacturing practice 
The South African regulatory control principles. 
authorities have furthermore shown a propensity to 
adapt and improve domestic GMP principles in line with 
current international thinking in this regard. It was 
consequently decided to include references to other 
recently revised international guidelines, in addition 
to the British and south African GMP guidelines, in 
this review of the principles on which South African 
GMP theory is based. 
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The British GMP guide is based upon eight general 
principles that are considered important to the 
assurance of quality in the pharmaceutical industry. 
These 
4.6.8 
principles 
under the 
are discussed 
headings of 
in Sections 4.6.1 to 
quality management; 
premises and personnel 
equipment; 
complaints 
laboratory 
manufacture 
and training; documentation; 
manufacture; recovered materials; 
procedure and product recall; and good 
practice. Specialised topics such as the 
of sterile products, biological medicines 
or radiopharmaceuticals, and technical aspects 
relating specifically to the manufacture of powders, 
liquids, creams, ointments and medical gases, as well 
as safety and security aspects, will not be included 
in this review. The rationale behind this approach to 
the research is that this review is not aimed at 
providing a detailed summary of the technical aspects 
of GMP theory, but is aimed instead at highlighting in 
particular the limitations of GMP principles as a 
quality management tool. 
In order to present a more complete review of 
international thinking on the subject, it was decided 
to include under Section 4.6.9 a number of additional 
principles which appear in some of the latest GMP 
publications, but which are not specifically high-
lighted in the British GMP guide. 
4.6.1 
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The French GMP guide was included in this review not 
only because it is one of the most recently updated 
GMP texts, but because it impressed as being the most 
management-oriented publication amongst those 
reviewed; despite this fact, it however shares most of 
the other shortcomings of GMP guidelines in general. 
The GMP principle regarding quality management 
This principle is worded as follows in the South 
African GMP guide (loc. cit., p. 1/1): 
"There should be a comprehensively designed and 
correctly implemented quality management system 
which is fully documented, effectively controlled 
and adequately staffed with competent personnel, 
suitable and sufficient premises, equipment and 
facilities, so as to provide the assurance that 
-products have the necessary quality, safety, 
efficacy and therapeutic availability, comply 
with the requirements of the regulatory 
authorities and are fit for their intended use. 
This quality management system is the respons-
ibility of senior management and invelves them 
and all those concerned with the design, 
development, 
purchasing, 
medicinal 
components". 
manufacture, packaging, control, 
storage, handling and distribution of 
products or their ingredients and 
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This definition recognises the need for some form of 
quality system which is aimed at assuring customer 
satisfaction in terms of the "fitness for use" 
doctrine, and that this system should be based upon 
the involvement of all the different functionaries at 
all stages of production. The principle regarding 
quality management, as defined in the British GMP 
guide (loc. cit., p. 10) and the EEC draft GMP guide 
(loc. cit., p. 15), is couched in similar terms but 
the latter guide makes specific mention of the fact 
that the attainment of the quality objective is the 
responsibility of "senior" management, and that it 
requires the participation and commitment of staff at 
all levels and across all functional boundaries. 
Moreover, the EEC draft GMP guide also broadens the 
scope 
quality 
of this quality commitment and participation in 
activities by specifically including the 
company's suppliers and distributors in this 
collective effort. 
Having 
quality 
control 
thus identified the need for an integrated 
management system to give top management 
over the quality activities of all functional 
groups at all levels within the company, the texts of 
all the GMP guidelines reviewed during this research 
are essentially concerned only with the technical 
aspects of the production stage of the industrial 
cycle. This is in fact the logical consequence of the 
4.6.2 
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narrow, production-oriented, focus of GMP theory which 
by definition is concerned with quality-related 
aspects of production only (see section 4.2.2). This 
particular limitation should be seen as being the 
primary reason for the caveat which is added to most 
GMP texts to the effect that GMP guidelines should not 
be interpreted as being the equivalent of a total 
quality system (see Section 4.4); although, in 
practice, this appears to be precisely how GMP 
principles are viewed in a number of countries (see 
Section 4.3). 
The GMP principle regarding personnel and training 
This principle is worded as follows in the British GMP 
guide (loc. cit., p. 13): 
"There should be sufficient personnel at all 
levels with the ability, training, experience 
-and, where necessary, the professional/technical 
qualifications and managerial skills appropriate 
to the tasks assigned to them. Their duties and 
responsibilities should be clearly explained to 
them and recorded as written job descriptions or 
by other suitable means. Training should cover 
not only specific tasks but good manufacturing 
practice generally and the importance of personal 
hygiene." 
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In terms of the definition quoted above, the scope of 
personnel training is thus restricted to individual 
(technical) tasks, general GMP principles, and the 
maintenance of acceptable standards of personal 
hygiene. The important . role played by people in the 
assurance of product quality is also stressed in the 
South African GMP guide (loc. cit., p. 2/1), the EEC 
draft GMP guide (loc. Cit. I P· 21) I the French GMP 
guide (loc. Cit. I p. 17), and the WHO draft GMP 
guide (loc. Cit. I p. 32). However, all these texts 
specify a personnel training programme which is 
focused on GMP theory which, by definition, is only a 
component part of the quality assurance system (see 
Section 4.2.2.). 
Specific aspects regarding personnel and training that 
are highlighted in the British GMP guide (loc. cit., 
pp. 13 15) and the EEC draft GMP guide (loc. cit., 
pp. 21 - 26) include the following: 
(i) The establishment of an organisation chart and written 
job descriptions, in order to outline authorities and 
responsibilities with regard to the application of 
good manufacturing practice in particular. 
(ii) Identification of "key personnel", namely the heads of 
production and quality control (who should be indepen-
dent from one another). According to the EEC draft GMP 
guide (ibid., p. 22), one of these functionaries may 
(iii) 
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also be a "Qualified Person" or, alternatively, a 
third person may be appointed to fulfil that role. The 
"Qualified Person" referred to here is a legal term 
which is used to describe a specially-trained person 
who assumes legal responsibility with regard to 
product quality and whose responsibilities, which are 
defined by statute, may be delegated only to another 
"Qualified Person" (see Article 22 of Directive 75/319 
quoted in the EEC draft GMP guide, ibid., p. 89). 
In South Africa, section 29 of the Pharmacy Act (South 
Africa, 1974) requires a pharmacist to fulfil this 
function. 
Job descriptions for both the head of the production 
department and the quality control department. Table 
4.1 depicts the job descriptions of the production and 
quality assurance managers, as described in the text 
of the South African GMP guide (loc. cit., p. 2/2) 
and the British GMP guide (loc. cit., p. 14). 
From the information contained in Table 4.1 it will be 
noted that the quality control manager in particular 
is given responsibility for mainly technical func-
tions, some systems responsibilities, and no strategic 
business responsibilities. 
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Table 4.1: Job descriptions of the production and quality 
assurance managers in terms of GMP theory. 
PRODUCTION MANAGER: 
Direct responsibilities: 
+ Production areas, equipment, operations, and 
records 
+ Management of production personnel. 
+ Manufacture of products in accordance with the 
approved master formula and method. 
Shared responsibilities: 
+ Protection of products and materials against 
spoilage and deterioration. 
+ Authorisation of written procedures. 
+ Monitoring and control of the manufacturing 
environment. 
+ Plant cleanliness. 
+ 
+ 
+ 
-Process validation. 
Personnel training. 
Vendor approval and 
approval. 
+ Retention of records. 
QUALITY ASSURANCE MANAGER: 
Direct responsibilities: 
third party contactor 
+ Establish, verify, and implement all quality 
assurance procedures. 
+ Approve or reject starting; bulk; and finished 
materials. 
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(iv) The need for structured training and continuing 
education programmes for all personnel whose 
activities could affect product quality, and the 
recording and periodic evaluation of such programmes. 
(v) Personnel hygiene, with particular reference to 
procedures relating to the health, hygiene practices, 
and clothing of personnel. 
According to the EEC draft GMP guide (loc. cit., p. 
22), the duties of the "Qualified Person" can be 
summarised as follows: 
(i) A "Qualified Person" must ensure that each batch of 
product manufactured within the EEC has been produced 
and tested or checked in accordance with the 
Directives relating 
authorisation. 
to GMP and the marketing 
(ii) A "Qualified Person" must ensure that each batch of an 
imported product has undergone, in the importing 
country, a "full qualitative analysis, a quantitative 
analysis of at least all the active constituents, and 
all the other tests or checks necessary to ensure the 
quality of proprietary medicinal products in accor-
dance with the requirements of the marketing authori-
sation" (paragraph l(b) of Article 22 of Directive 
75/319 quoted in the EEC draft GMP guide, ibid., pp. 
22 and 89). 
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With reference to the fact that the EEC draft GMP 
guide (ibid., p. 22) states that the "Qualified 
Person" may also function either as production manager 
or quality control manager, it can be deduced that 
this person would not necessarily occupy a top 
management position but is more likely to function at 
middle-management level. Moreover, in term:s of Article 
25 of Directive 75/319 (EEC draft GMP guide, ibid., 
p. 90), the regulatory agencies of Member States 
within the EEC assume responsibility for ensuring that 
the duties of the "Qualified Person" are in fact 
carried out " either by means of appropriate 
administrative measures or by making such persons 
subject to a professional code of conduct". 
From the above description of the functions of a 
"Qualified Person", it is clear that the elements of 
the quality activities and decisions involved are only 
vaguely defined, and that basic quality responsi-
bilities rest in the hands of a functional component 
(under regulatory control), rather than with top 
management. This vertical functional structure, which 
is complicated by the arbitrary involvement of a 
government agency, can be expected to experience some 
difficulty in effectively and timeously resolving 
multifunctional quality problems in particular. 
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French legislation, on the other hand, demands the 
presence of a "Pharmacien Responsible.. (Responsible 
Pharmacist) who must personally perform at least the 
following functions (French GMP guide, loc. cit., 
pp. 15 - 19): 
(i) He should participate in the setting up of the company 
programme for research and development. 
(ii) He should sign the application for marketing authori-
sation after taking due note of the expert's reports. 
(iii) 
(iv) 
He should organise and supervise in particular the 
manufacture, packaging, storage, physical control and 
supply, as well as the advertising of medicines. 
He 
who 
should exercise control over assistant pharmacists, 
are in charge of the following departments: 
purchasing and control of raw materials, manufacturing 
operations, control of finished products, preparation 
of orders for delivery, and storage, sale and supply. 
(v) He should alert the other directors of the company "to 
any difficulties inherent in the operating conditions 
which are likely to hinder the performance of his 
responsibilities", and he should refer any dispute 
regarding the application of GMP regulations within 
the company to the Regional Pharmacist Inspector of 
the French Department of Health. 
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The functions of the "Pharmacien Responsible" are thus 
more broadly-defined than those of the "Qualified 
Person" described above. In addition to his 
responsibilities and authorities with regard to the 
manufacturing function, . he is also directly involved 
with other functional aspects such as research and 
development, purchasing, advertising and distribution. 
Moreover, the "Pharmacien Responsible" functions at 
top management (director) level, and has recourse to 
arbitration by a statutory authority in the event of a 
dispute with company management on matters pertaining 
to product quality. 
The basic criticisms of the GMP-approach to quality 
management are however also applicable to the French 
system. Firstly, the technical (GMP) principles on 
which the quality management activities of the 
"Pharmacien Responsible" are based, cannot be equated 
-to an operation systems network which provides for 
powerful managerial and engineering decision making, 
and which gives quality organisationwide impact. 
Secondly, the approach to quality control which is 
adopted in the French GMP guide is again restricted to 
the traditional inspection and test approach. 
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With regard to the statutory requirements relating to 
the organisation and management of a South African 
pharmaceutical manufacturing concern, no reference is 
made to a functionary such as a "Qualified Person" or 
a "Responsible Pharmac:i,st", nor does any GMP require-
ment apply in this regard either. Section 22 of the 
Pharmacy Act (South Africa, 1974) does, however, 
require a pharmacist who is also the managing director 
to manage the business of a company registered under 
that Act. The responsibilities of this pharmacist/ 
managing director are not detailed other than by way 
of a broad statement regarding the fact that the 
managing director must in fact "manage the business" 
of his company. Moreover, Section 29 of the Pharmacy 
Act (ibid.) stipulates that a pharmacist must 
supervise the actual manufacture of a medicine, 
thereby establishing a managerial hierarchy of 
pharmacists which stretches from the production floor 
right up to the level of the managing director. There 
are sound reasons for this requirement, related mainly 
to ethical and disciplinary considerations, in view of 
the perceived need to protect the public interest in 
matters pertaining to a professional activity. 
These statutory requirements ·are however based on the 
assumption that a person who received training in the 
natural sciences only, will have the managerial skills 
necessary to effectively delegate the quality respon-
4.6.3 
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sibilities which rest upon the managing director 
within the modern enterprise; the managerial hierarchy 
dictated by statute may consequently be distorted by 
the practical realities being faced by the pharma-
ceutical industry in t~is country. This appears to 
represent a major flaw in South African legislative 
and GMP requirements, and is seen as an area in which 
the adoption of a system of total quality will be able 
to make an important contribution. 
The GMP principle regarding documentation 
This principle is worded as follows in 
African GMP guide (loc. cit., p. 8/1) 
British GMP guide (loc. cit., p. 16): 
the South 
and the 
"Documentation is a prime necessity in quality 
assurance. Its purposes are to define the system 
of control, to reduce the risk of error inherent 
-in purely oral communication, to ensure that 
personnel are instructed in the details of, and 
follow, the procedures concerned, and to permit 
investigation and tracing of defective products. 
The system of documentation should be such that 
the history of each batch of product, including 
the utilisation and disposal of starting 
materials, packaging materials and intermediate, 
bulk, and finished products, may be determined." 
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An important feature of the above definition is the 
emphasis it places upon product and component 
traceability, from the point of incoming materials 
inspection through all the manufacturing and distri-
bution processes and activities, right up to the final 
consumer. 
activity of 
805) terms 
Product traceability is an important 
what Feigenbaum (loc. cit., pp. 737 -
the product control job of total quality 
Moreover, from the wording of the GMP 
regarding documentation which is quoted 
control. 
principle 
above, it is clear that documentation is viewed as 
being an important planning and control tool. The GMP 
principle regarding documentation is therefore an 
example of one facet of GMP theory which is entirely 
compatible with the total quality concept. However, it 
should be noted that the working documents required in 
terms of current GMP theory relate primarily to 
tactical decision making (i.e. the day-to-day control 
of quality), and not to strategic decision making. The 
total quality concept may therefore make a valuable 
contribution to the present system in this regard. 
A summary of those aspects relating to documentation 
which are highlighted in GMP publications is presented 
in the paragraphs which follow. It will however be 
noted that these aspects are mainly of a technical 
nature. 
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4.6.3.1 General considerations relating to documentation 
According to the British GMP guide (loc. cit., pp. 
16-17) and the South African GMP guide (loc. cit., 
pp. 8/1 8/2), document layout should be orderly; 
revision systems should exclude the possibility of 
superseded documents being used; instructions should 
be written in the imperative, as numbered steps; 
entries made by persons should be confirmed by means 
of their signatures or initials; entries should be 
made in ink or other indelible medium; consideration 
should be given to the size, shape, paper quality and 
colour of the document; documents should not contain 
superfluous data; amendments should be formally 
authorised and signed. It is furthermore stated in 
the British GMP guide (loc. cit., pp. 16 - 17) that 
" it may be useful (sic) to prepare a manual which 
describes the overall quality assurance system, the 
procedures employed, and the documents used". The 
South African GMP guide (loc. cit., p. 8/2 and the 
EEC draft GMP guide (loc. cit., p. 33) state that 
documents should correspond to the relevant parts of 
the product registration dossier (see Section 3.6), 
thereby highlighting the importance of the registra-
tion dossier as a basic planning tool. 
In terms of 
recorded by 
photographic 
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current GMP principles, data may be 
electronic data processing systems or by 
or other reliable means, provided that 
access to data can be limited to authorised persons 
furthermore that data remain 
the experience of the author, 
usually photocopied to obtain 
documents (i.e. working docu-
copies of master documents are 
only, 
readily 
master 
batch 
men ts), 
and provided 
available. In 
documents are 
manufacturing 
while back-up 
stored in more than one secure location. 
4.6.3.2 Suggested format for specification documents 
According to the EEC draft GMP guide (ibid., p. 33), 
specification 
describe in 
products or 
documents are defined as documents which 
detail the requirements with which the 
materials used or obtained during 
manufacture have to conform, and which serve as a 
basis for quality evaluation. A specific format for 
master specification documents is suggested by the 
South African GMP guide (loc. cit., pp. 8/3 - 8/4) 
and the EEC draft GMP guide (loc. cit., pp. 35-36) 
with reference to starting materials packaging 
materials, intermediate or bulk products, and finished 
products. 
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These documents should 
responsible for quality 
guide (loc. cit., p. 8/4). 
be approved by the "person 
control" (South African GMP 
Specifications for 
materials should 
sta~ting materials and packaging 
be dated and include, if applicable, 
the following information: 
(i) A description of the materials concerned. This would 
include references to the designated name and in-house 
code reference of the material; a description of the 
physical form of the material; reference to a 
pharmacopoeia! monograph (if applicable); the name(s) 
of the approved supplier(s) and, if possible the name 
of the original producer of the material (with 
reference to active raw materials, these data should 
correspond to the information disclosed under 
Annexures 3B and 3C of the MBR 1 registration dossier 
descFibed in Section 3.6); and, in the case of printed 
packaging components, a specimen of the item 
concerned. 
(ii) Directions for sampling and testing, or reference to 
such procedures. This information should correspond to 
that disclosed under Annexure 5 (raw material control 
procedures); Annexure 6 (raw material release 
criteria); Annexure SB (container control procedures); 
and Annexure 9B (final container control laboratory) 
of the MBR 1 dossier (see Section 3.6) 
(iii) 
(iv) 
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Qualitative and quantitative requirements, together 
with acceptance limits. This information should 
correspond to the data disclosed under Annexure 4 (raw 
material specifications), and Annexure 8A (final 
container specifications). of the MBR 1 dossier. 
Storage conditions and safety precautions, where 
applicable. This information should correspond to that 
given under Annexure 3A of the product's MBR 1 
dossier. 
(v) The retest date, i.e. the maximum period of storage of 
the material 
With regard 
before re-examination becomes mandatory. 
to the drug substance or bulk drug 
substance, this information should correspond to that 
disclosed under Annexure 10 of the MBR 1 dossier. 
Specifications for finished products should be dated 
and include: 
(i) The designated name of the product and the in-house 
code of reference where applicable. 
(ii) The formula, or a reference thereto. This information 
should correspond to the data disclosed under Annexure 
2 (formulation) of the MBR 1 dossier (see Section 
3.6.3). 
(iii) 
(iv) 
(v) 
-172-
A description of the pharmaceutical dosage form and 
package details. This information should correspond to 
that disclosed under Annexure 1 of the MBR 1 dossier 
with respect to data which appears on the product 
label and package insert (see Section 3.6.1). 
Directions for sampling and testing, or reference to 
such procedures. This information should correspond to 
the data disclosed under Annexures 7B (final product 
control procedures) and 9A (final product control) of 
the product's MBR 1 dossier (see Sections 3.6.11 and 
3.6.14 respectively). 
The qualitative and quantitative requirements, and 
acceptance limits, to be used as release criteria for 
the final product. This information should correspond 
to the data disclosed under Annexure 7A (final product 
specifications) and Annexure 9A (final product release 
criteria) of the MBR 1 dossier (see Sections 3.6.10 
and 3.6.14 respectively). 
(vi) Storage conditions and safety precautions, where 
applicable. These data will have been determined 
experimentally in the course of generating the product 
stability data detailed under Annexure 10 of the 
product's MBR 1 dossier (see Section 3.6.16). 
(vii) 
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The shelf-life of the stored product. The shelf-life 
of the final product is based upon the extrapolated 
stability data detailed under Annexure 10 of the MBR 1 
dossier. 
4.6.3.3 Manufacturing and packaging instructions 
These are defined as documents which detail all the 
starting materials to be used, and lay down all 
processing and packaging operations (EEC draft GMP 
guide, ibid. I P· 33) . These documents are usually 
issued by the production planning department, and 
signal the formal commencement of the production 
process. A suggested format for these documents 
follows, based on that given in the South African GMP 
guide (loc. cit., pp. 8/5 8/6), the British GMP 
guide (loc. cit., pp. 19-21 and the EEC draft GMP 
guide (loc. cit., pp. 36-38). 
A formally authorised manufacturing formula and 
processing instructions should exist for each product 
and batch size; these are often combined into one 
document known as the master manufacturing formula 
instructions (this document is also referred to as the 
"master formula and method"). Formal authorisation of 
this document would typically require the signatures 
of the managing director, quality control manager, and 
production manager. 
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The manufacturing instructions should be dated and 
include the following details: 
(i) The name of the product, together with a unique 
in-house product reference code relating to its 
specifications. 
(ii) 
(iii) 
A description of the dosage form and potency of the 
product, and a reference to the standard batch size. 
A list of all the starting materials to be used, with 
the amount of each, as per Annexure 2 of the MBR 1 
dossier (see Section 3.6.3). Each material should be 
described by the use of the designated name and a 
in-house reference code which is unique to that 
material. 
(iv) A statement regarding the expected intermediate and/or 
final yields, together with the acceptable limits. 
Processing instructions should include: 
(i) A statement regarding the processing location and the 
principal equipment to be used. 
(ii) The methods, or reference methods, to be used for 
preparing these items of equipment (i.e. cleaning, 
assembling or calibrating such equipment). 
(iii) 
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Detailed stepwise processing instructions, as detailed 
under Annexure 11 of the product's MBR 1 dossier (see 
Section 3.6.17), including details of in-process 
controls and their limits of acceptance. 
(iv) Where necessary, the requirements for bulk storage of 
the product, including the identity and labelling of 
the storage vessel, and special conditions for 
storage. 
(v) Special precautions (if any) to be observed during 
this stage of production. 
The South African GMP guide (loc. cit., p. 8/6), the 
British GMP guide (loc. cit., p. 21), as well as the 
EEC draft GMP guide (loc. cit., pp. 37-38) require 
that formally authorised packaging instructions should 
be drafted for each product, pack size and dosage 
form~ These instructions, which are referred to as 
"master packaging instructions", should include or 
refer to the following aspects: 
(i) The name of the product. 
(ii) 
(iii) 
A description of 
applicable (e.g. 
the dosage form and potency, where 
tablets, each containing 500mg of 
active raw material). 
The pack size expressed in terms of the number, 
weight, or volume of product in the final container. 
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(iv) A complete list of all the packaging materials 
required for a standard batch size (i.e. a bill of 
materials or picking list), including details 
relating to quantities, sizes and types, with the 
in-house reference code _relating to the specifications 
of each packaging material. 
(v) Where appropriate, an example or reproduction of the 
relevant printed packaging materials, and specimens 
indicating where data relating to the product lot 
number and expiry date are to be applied during the 
packaging process. 
(vi) The line opening procedure to be carried out and 
verified in writing by the pharmacist in charge. This 
procedure should include verification that the line is 
clean, is free of any foreign packaging materials and 
(vii) 
product residues, and that the correct packaging 
components and bulk product have been staged for the 
packaging operation to commence. 
A description of the packaging operation and the 
equipment to be used, including special precautions to 
be observed and any significant subsidiary operation 
(e.g. temperature and/or humidity control, agitation 
of the bulk product, etc). 
(viii) Details of in-process controls, together with sampling 
instructions and acceptance limits. 
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4.6.3.4 Standard operating procedures 
According to the South African GMP guide (loc. cit., 
p. xvi), a standard operating procedure (SOP) is a 
written authorised proc.edure which gives instructions 
for performing operations not necessarily specific to 
a given product or material, but of a more general 
nature. The EEC draft GMP guide (loc. cit., pp. 
40-42) requires that "written procedures" be available 
with reference to the receival of incoming materials; 
sampling and testing materials and products at 
different stages of manufacture; quarantine proce-
dures, including the disposal of accepted or rejected 
materials; batch distribution records of finished 
products; process validation procedures; equipment 
assembly and calibration; maintenance, cleaning and 
sanitazation of the manufacturing facility; personnel 
matters, including training, dress requirements and 
personal hygiene; environmental monitoring; pest 
control; a product complaints procedure; a product 
recall procedure; and a procedure for handling 
products returned to the plant. In addition, the EEC 
draft GMP guide (ibid., p. 42) requires that written 
operating instructions be available i.r.o. major items 
of manufacturing and test equipment; that the valida-
tion (qualification), calibration and maintenance of 
such items of equipment be recorded in log books; and 
that the use of major or critical equipment (and the 
production areas where products have been processed) 
be recorded. 
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The South African GMP guide (loc. cit., p. 1/5) 
identifies the following as being "critical proce-
dures": 
(i) Self-inspection (audits) .. 
(ii) 
(iii) 
(iv) 
(v) 
Recall of medicines from the market. 
Handling of technical complaints. 
Handling of returned goods. 
Vendor inspection/approval of 
materials. 
printed packaging 
(vi) Purchasing procedures. 
(vii) Procedure for handling and disposal of dangerous, 
highly toxic or sensitising materials. 
(viii) Rodent and pest control. 
Caplan (1980, pp. 8-9) views the process of communi-
cating a quality policy to all functionaries within 
the organisation as consisting of an interlinked chain 
of documents at four levels, the third and fourth 
levels consisting of procedures and instructions 
respectively. In view of the limited scope of the 
"critical procedures" 
GMP guide (supra) it 
identified in the South African 
may be concluded that these 
procedures are intended primarily as working documents 
rather than vehicles for the communication of quality 
policy. 
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4.6.3.5 Records 
Records are defined 
(loc cit., p. xv) 
in the South Arican GMP guide 
and the EEC draft GMP guide (loc. 
cit., p. 33) as docume.nts which provide a history of 
each batch of product, including its distribution, and 
also of all other relevant circumstances pertinent to 
the quality of the final product. A suggested format 
for documents relating to starting materials; 
packaging materials; batch manufacturing records; 
batch packaging records; intermediate, bulk and 
finished product records; distribution records; 
analytical records and complaints records is given in 
the South African GMP guide (loc. cit., pp. 8/6 -
8/13). 
The South African GMP guide (ibid., p. 8/12) 
recommends that 
records, as well 
retained for at 
batch manufacturing and packaging 
as the relevant test records, be 
least one year after the expiry date 
of the batch; and that finished product samples be 
retained for at least one year after the expiry date 
of the product concerned. Moreover, it is suggested 
that records of starting materials should be retained 
until at least the expiry date of the product batch in 
which they are used. 
4.6.4 
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The GMP principle regarding premises and equipment 
This principle is worded as follows in the British GMP 
guide (loc cit., p. 28): 
"Buildings should. be located, designed, 
constructed, adapted and maintained to suit the 
operations carried out in them. Equipment should 
be designed, constructed, adapted, located and 
maintained to suit the processes and products for 
which it is used. Building construction, and 
equipment layout, should ensure protection of the 
product from contamination, permit efficient 
cleaning and avoid the accumulation of dust and 
dirt." 
Aspects that are addressed in the text of this 
particular chapter of the British GMP guide (ibid., 
pp. 28 32), the south African GMP guide (loc. 
cit.,- pp. 3/1 3/5), and the EEC draft GMP guide 
(loc. cit., pp. 27 - 32) include the following: 
(i) Premises should be constructed, situated, equipped and 
maintained in such a manner as to limit the risk of 
contamination to materials or products, provide a 
suitable environment for the manufacture and storage 
of medicinal products, and control unauthorised 
access. The British GMP guide makes special mention of 
the construction requirements for floors, pipework, 
service points, drains, lighting and ventilation. 
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(ii) The production area in particular should be designed 
with a view to the prevention of cross-contamination 
by highly sensitizing materials (such as penicillins 
or micro-organisms, for instance). The British GMP 
guide (loc. cit., pp .. 89 - 90) includes an appendix 
which deals specifically with the control of 
cross-contamination. 
(iii) The layout of the production area should correspond to 
the logical sequence of operations, with adequate 
provision for in-process storage space and the logical 
positioning of equipment and materials " to avoid 
cross-contamination and to minimise the risk of 
omission or wrong application of any of the 
manufacturing or control steps" (EEC draft GMP guide, 
loc. cit., p. 28). The British GMP guide (loc. cit., 
p. 30) furthermore recommends that manufacturing 
areas should not be used as a general right of way for 
personnel or materials. 
(iv) Packaging areas should be specifically designed so as 
to avoid mix-ups and cross-contamination. 
(v) Weighing of starting materials should preferably be 
carried out in a separate weighing room designed for 
that purpose, with particular emphasis on dust 
extraction. 
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(vi) Storage areas should have sufficient capacity, provide 
optimal conditions of storage, and should also provide 
adequate protection from the weather at receiving and 
despatch bays. 
(vii) Storage areas should include segregated quarantine 
areas (with access restricted to authorised personnel 
only); a separate sampling area for starting 
materials; segregated areas for the storage of re-
jected, recalled or returned materials or products; 
and separate and secure areas for the storage of 
highly active materials (such as hormones, narcotics 
and flammable substances for instance). 
(viii) Quality control laboratories should be separate from 
production areas (to avoid cross-contamination), and 
should themselves have sufficient space to avoid 
mix-ups and cross-contamination; including the 
provision of separate rooms for the protection of 
instruments that are sensitive to vibration, elec-
trical interference, humidity, etc. Separate 
facilities should be provided for the handling of 
biological and radioactive samples. 
(ix) Ancillary areas such as rest- and refreshment rooms 
should be separate from other areas; toilets should 
not directly communicate with production and storage 
areas; maintenance workshops should as far as possible 
be separated 
should be 
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from production areas; and animal houses 
well isolated from other areas, with 
separate entrances and air handling systems. 
(x) Manufacturing equipment should be designed, located 
and maintained to suit its intended purpose; should be 
easily cleaned; should not present a hazard to the 
product in process; and should be calibrated and 
checked at defined intervals where appropriate. 
(xi) Waste material should not be allowed to accumulate, 
and special care is necessary for the disposal of 
highly toxic or highly active materials. Disposal of 
rejected raw materials, printed packaging materials 
and finished products should be carefully controlled 
and documented (e.g. by means of certified disposal). 
All the above requirements may therefore be stated to 
be of a technical nature. 
4.6.5 The GMP principle regarding manufacture 
This principle is worded as follows in the British GMP 
guide (loc cit., p. 33): 
"Manufacture should follow 
procedures which are known 
previously defined 
to be capable of 
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yielding finished products which are those 
intended and which conform to their specif ica-
tions. Special attention must be paid to labels 
and labelling throughout the entire production 
cycle." 
The South African GMP guide (loc. cit., pp. 5/1 -
5/4) lists the production of products of the requisite 
quality as well as compliance with the relevant 
"manufacturing documents" and legal requirements as 
being the objective of pharmaceutical manufacturing 
operations. Specific guidelines are given regarding 
the dispensing of starting materials, technical 
aspects of manufacturing operations and in-process 
controls, as well as the prevention of contamination 
and cross-contamination of raw materials and product. 
Guidelines regarding the technical aspects of re-
processing are also given in this section of the South 
African GMP guide, whereas the British GMP guide 
treats this as a separate GMP principle (see section 
4.6.4). 
The South African GMP guide (ibid., pp. 4/1 - 4/3, 
pp. 6/1 6/4, and pp. 9/1 - 9/2) on the other hand 
identifies "materials management", "packaging" 
(operations), and (product/process/analytical method) 
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"validation" as being separate GMP principles, whereas 
the British GMP guide (loc. cit., pp. 33-39 and pp. 
44-48) discusses these aspects under the GMP 
principles 
laboratory 
of "manufacture" and "good control 
practice" (the latter aspect is discussed 
under section 4.6.8). 
The following, mainly technical, aspects regarding 
manufacture are highlighted in the British GMP guide 
(ibid., pp. 33 39) and the EEC draft GMP guide 
(loc. cit., pp. 43 - 52): 
(i) General concepts relating to the manufacture of the 
product in accordance with the "master formula and 
method" and/or the "master packaging instruction" (see 
Section 4.6.3.3), supplemented where necessary by 
standard operating procedures (see Section 4.6.3.4), 
and the recording of data on the batch manufacturing 
record (see Section 4.6.3.5), including supervision by 
competent personnel; handling of materials in 
accordance with written instructions; incoming 
material receipt and quarantine; reconciliation of 
quantities and checks on yields; segregation of 
operations on different products; identification of 
all materials, bulk containers, major items of equip-
ment and rooms or cubicles used; identification of 
pipelines used for the transportation of products or 
materials; approval of deviations from procedures by a 
competent person; and restricted access to production 
areas. 
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(ii) The prevention of cross-contamination during pro-
duction, with specific reference to production in 
segregated areas, or by campaign (i.e. separation in 
time), followed by appropriate cleaning; provision of 
appropriate air locks ~nd air extraction; minimising 
the risk of contamination caused by the recirculation 
or re-entry of untreated air; use of protective 
clothing; the use of validated decontamination 
procedures; the use of "closed" production systems 
(i.e. isolated from the production environment); and 
(iii) 
testing for 
addressed in 
British GMP 
residues on equipment. 
greater detail in 
guide (loc cit., pp 
These aspects are 
an appendix to the 
89 90), which 
deals specifically with the subject of 
cross-contamination during production. 
Procedures relating to validation studies. The 
suitability 
method of 
for routine processing of a new formula or 
preparation should be demonstrated with 
to its ability to consistently yield a 
of the required quality; similarly, any 
reference 
product 
significant amendments to the manufacturing process 
(such as a change in equipment or materials for 
instance) which may affect product quality and/or the 
reproducibility of the process, should be validated. 
The South African GMP guide (loc. cit., pp. 9/1 -
9/2) refers to 
principle which 
"validation" 
is aimed 
as a separate GMP 
at achieving process 
(iv) 
"efficacy" 
rejects, a 
reduction 
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and reliability, 
reduced risk of 
in the "extent" 
a reduced number of 
product recall, and a 
(sic) of the quality 
control programme. The South African Medicines 
Control council (MCC) .requires the first two produc-
tion batches to be validated by means of all the 
analytical control procedures described in Annexure 7A 
of the product's MBR 1 registration dossier (see 
Section 3.6.10), whereas subsequent production batches 
need to be subjected only to the batch release 
criteria described in Annexure 9A of the registration 
dossier (see Section 3.6.14). The WHO draft GMP guide 
(loc. cit., pp. 10 & 19) identifies process and 
procedure validation as being one of the essential 
elements of what it terms "quality management in the 
drug industry". The MCC (1983, Circular to applicants 
ref. 14/83) has formally declared process and system 
validation to be "an essential component of quality 
assurance". According to the EEC draft GMP guide 
(loc. cit., pp. 23 24), it is the responsibility 
of the quality control manager to ensure that the 
proper validation studies are done, while process 
validation (and presumably machine qualification too) 
is stated to be the shared responsibility of the 
quality control and production managers (see Table 
4.1). 
Procedures· relating to 
approved vendors may be 
starting materials. Only 
used (as would be specified 
under Annexure 3B of the product's MBR 1 dossier); the 
(v) 
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vendor contact programme should involve discussion of 
the specifications stipulated, aspects relating to the 
production and control of starting materials, inclu-
ding handling, labelling and packaging requirements, 
as well as the complaints and rejection procedures to 
be followed. Procedures should exist for the receipt, 
sampling, quarantining and dispensing of starting 
materials; each delivery or batch of material should 
be assigned a reference number which will identify 
that specific delivery (or batch) throughout storage 
and processing. 
Processing 
products. 
operations for intermediate and bulk 
The processing area and equipment must be 
clean and free from any starting materials, products, 
product residues, or documents not required for the 
current operation before any processing operation is 
started; conditions for storage, in-process controls 
and - yield reconciliation should receive special 
attention. 
(vi) Packaging materials. The method of purchasing, 
handling and control of packaging materials shall be 
identical to that employed for all starting materials; 
particular attention should be given to the 
identification and control of printed packaging 
materials in order to guard against mix-ups and the 
unauthorised use of such materials. 
(vii) 
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Packaging operations. Steps must be taken to minimise 
the risk of cross-contamination, mix-ups or substitu-
tion. These steps include the physical segregation of 
packaging lines; line opening procedures; in-process 
controls relating to physical specifications, proof 
reading of overprinting, and checks on the correct 
functioning of line monitors; disposal of rejected/ 
unused materials; and the reconciliation of materials. 
(viii) Finished product disposal. Quarantine procedure and 
storage after release are the main considerations in 
this regard. 
4.6.6 The GMP principle regarding recovered materials 
This principle is worded as follows in the British GMP 
guide (loc. cit., p. 40): 
"Material may be reworked or recovered by an 
-appropriate and authorised method, provided that 
the material is suitable for such reprocessing, 
and that the resultant product meets its 
specification and there are no significant 
changes in product quality. Documentation should 
accurately record the reworking process carried 
out". 
This principle is not accorded a separate chapter in 
the EEC draft GMP guide, but is instead included under 
the text dealing with manufacturing operations. 
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The following aspects are highlighted in this section 
of the EEC draft GMP guide (loc. cit., pp. 51 - 52) 
and the British GMP guide (loc. cit., pp. 40 - 41): 
(i) Disposal of product residues. Product residues and 
reworked or recovered materials should not affect the 
quality of subsequent batches of product; their 
inclusion should be specifically authorised and 
documented according to the limits set by the quality 
control department; batches of final product 
containing such residues should not be released until 
the batches from which the residues originated have 
been released. All recovered materials should be 
clearly identified and stored separately in restricted 
areas. 
(ii) 
(iii) 
Reprocessing. 
permitted only 
Reprocessing of rejected products is 
if the quality of the final product is 
not affected, if the final product specifications are 
met, and if it is done according to a defined and 
authorised procedure which includes record-keeping; 
additional testing of the final product is also 
recommended. 
Returned goods. Refurbishing of final product labels/ 
cartons which are returned due to being soiled or 
damaged, may be carried out according to a speci-
fically authorised and documented procedure aimed at 
4.6.7 
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maintaining product quality and the avoidance of 
mix-ups or mislabelling; such products must first be 
assessed by the quality control department, who must 
make the final decision in this regard. 
The South African GMP guide (loc. cit., p. 10/1) 
treats the subject of returned goods as a separate GMP 
principle which is worded as follows: "A clearly 
defined policy must be followed to ensure that 
returned goods are of an acceptable quality and have 
not expired before they are taken back into stock; 
otherwise they must be destroyed". 
The GMP principle regarding complaints procedure and 
product recall 
This principle is worded as follows in both the 
British GMP guide (loc. cit., p. 42) and the South 
African GMP guide (loc. cit., p. 11/1): 
"The full significance of a complaint may only be 
appreciated by certain responsible persons, and 
then possibly only with the knowledge of other 
related complaints. A procedure must therefore 
exist to channel complaint reports appropriately. 
A complaint, or otherwise reported product defect 
may lead to the need for a recall. Any action 
taken to recall a product suspected or known to 
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be defective 
in accordance 
procedures to 
writing and 
concerned." 
or hazardous, should be prompt and 
with a predetermined plan. The 
be followed should be specified in 
made known to all who may be 
In the South African context, certain statutory 
requirements determine the procedure to be followed 
with regard to product complaints and recalls. Insofar 
as product complaints are concerned, regulation 12(4) 
of the Medicines Control Act (South Africa, 1965) 
places a legal obligation upon a manufacturer to 
inform the Medicines Control Council (MCC) immediately 
of any formulation, labelling, or other error relating 
to its products, and also to inform the MCC of the 
steps taken, or which are intended to be taken, in 
order to rectify such error or with regard to the 
suspension of the sale of such a medicine. Regulations 
12(3}(b) and (c) of the Medicines Control Act (ibid.) 
require the same actions to be taken with regard to 
any adverse drug reactions experienced with any of a 
company's products. A written and authorised procedure 
must be followed when dealing with these matters; this 
procedure must be coordinated by a designated 
functionary, and the action taken must be recorded and 
the record filed. 
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Insofar as product recall procedure is concerned, the 
MCC has issued a general circular (MCC, 1988, Circular 
to applicants ref. 7/88) in which the following 
procedure 
market of 
is prescribed for the removal from the 
any product r.epresenting a heal th hazard to 
the consumer or user: 
(i) Immediately upon becoming aware of the problem, a 
designated functionary of the manufacturer must notify 
the Registrar of Medicines (see Section 3.4) and must 
disclose the following information: The name, 
strength, pack size and batch number of the product; 
details concerning the quantities, dates, and areas of 
distribution; the nature of the defect; suggested 
action to be taken and its urgency, and a fully 
motivated indication of the health risk involved. 
(ii) The Registrar 
with- the MCC, 
of Medicines will, after consultation 
make a health hazard evaluation based 
inter alia upon certain prescribed factors. 
The affected manufacturer is 
tunity to contribute to the 
this evaluation is based. 
evaluation, either a Class 
"C" recall-classification is 
accorded every oppor-
inf orma t ion upon which 
As a result of this 
"A", Class "B", or Class 
assigned by the MCC. 
(iii) 
(iv) 
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A Class "A" recall will be required in a situation 
where there is a reasonable probability that the use 
of or exposure to the defective product will cause 
serious 
recall 
exposure 
adverse 
adverse health reactions or death. A Class "B" 
is indicated in ~ situation where the use of or 
to the defective product may cause temporary 
health reactions or where the probability of 
serious adverse health reaction is remote. A Class "C" 
recall will be conducted in a case where the use of or 
exposure to the defective product is not likely to 
cause any adverse health reactions. The ease of 
identifying the product concerned, the extent to which 
the product's deficiency is obvious to the consumer or 
user, and the risk/benefit ratio of the product, will 
be taken into account when deciding on the recall 
classification to be applied to a particular 
situation. 
The -recall strategy will determine the level in the 
distribution chain to which the recall must be 
extended, as well as the communications medium and 
content of a recall notice. 
The MCC must be furnished with a report within 30 days 
of the recall having been instituted, in which certain 
specified information is to be given. This report must 
description of the steps taken by the include a 
manufacturer concerned to prevent a recurrence of the 
problem. 
(v) Within 
full 
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90 days of the recall having been instituted, a 
reconciliation of recalled product (with 
reference to the relevant distribution records) must 
be submitted to the MCC. 
(vi) A recall is terminated when the MCC and the 
manufacturer concerned are in agreement that the 
defective product has been removed from the 
marketplace, and proper disposition or correction has 
been made. A firm's recall action does not preclude 
enforcement actions being taken by the MCC, as may be 
deemed appropriate, either during or following the 
completion of a recall. 
In order to minimise the disruptive effect on a firm's 
business operations, pharmaceutical manufacturers are 
advised to establish a detailed written recall system 
or plan; to ensure batch-to-batch identification of 
products; and to facilitate location of products 
through the maintenance of comprehensive distribution 
records. These aspects form part of the pharma-
ceutical manufacturing facility audit checklist used 
by regulatory auditors when evaluating a firm's 
ability to effectively deal with any product complaint 
or product recall, should the need arise (South 
African GMP guide, loc. cit., Appendix 1). 
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With reference to product complaints and product 
recall procedure, the texts of the British GMP guide 
(loc. Cit. I pp. 42 43) I the EEC draft GMP guide 
(loc. Cit. I PP· 63 65), and the WHO draft GMP 
guide (loc. Cit. I pp .. 22 - 23) correspond in essence 
to the guidelines given in this regard by the MCC in 
South Africa and the South African GMP guide (loc. 
cit., pp. 11/1 - 11/2). In particular, the need for 
an authorised, written recall procedure which is 
coordinated by a designated functionary and which is 
capable of being put into operation at any time, is 
also emphasised in those texts, together with the need 
to be able to give progress reports on a particular 
recall, and to effectively quarantine any recalled 
products. 
From the above review, the basic requirement may be 
restated as being that of an in-house mechanism which 
will- enable a manufacturer of medicinal products to 
systematically and timeously deal with product quality 
problems. This mechanism will include activities aimed 
at identifying the nature and source of a quality 
defect, the improvement of product quality characte-
ristics, and steps to ensure that such improvements 
are of a permanent nature. 
4.6.8 
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This mechanism therefore 
of a total quality 
Feigenbaum (loc. cit., 
"special process studies". 
closely resembles that part 
control programme to which 
pp. 806 821) refers as 
The GMP principle regarding control laboratories 
This principle is worded as follows in the British GMP 
guide (loc. cit., p. 44): 
"It is essential that control laboratories should 
have appropriate facilities, with properly 
trained, managed and motivated staff, in order 
that reliable results may be obtained from any 
analytical or other test procedure, whether its 
nature is chemical, physical, biological or 
microbiological. Steps should be taken to ensure 
the reliability of the laboratory's own systems 
and test methods." 
The following aspects relating to control laboratories 
are highlighted in this chapter of the British GMP 
guide (ibid., pp. 44 - 48): 
(i) The design and maintenance of premises, with specific 
reference to the prevention of cross-contamination, 
and the disposal of waste materials. 
(ii) 
(iii) 
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Aspects relating to 
laboratory equipment, 
systems to indicate 
to equipment (gas or 
servicing and calibration of 
operating instructions, warning 
failure of equipment or services 
electricity for instance), and 
qualification of equipment. 
Aspects relating to basic hygiene; including the need 
for written cleaning schedules, the use of protective 
clothing , and the safe disposal of waste materials. 
(iv) Aspects relating to expiry dating of reagents; 
preparation of reagents according to written 
procedures; validation of reagents; tests for 
suitability of microbiological culture media; as well 
as the storage; handling; and use of reference 
standards. 
(v) 
(vi) 
Aspects relating to 
4.6.3.2); labelling 
sampling procedure (see Section 
of sampling containers; handling 
of sampling equipment; and precautions to prevent 
contamination and cross-contamination of the materials 
sampled. 
Documentation, which should 
general guidance given (see 
keeping of retention samples 
records. 
be in line with the 
Section 4.6.3), and the 
as part of laboratory 
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(vii) Aspects relating to records of analysis. Details are 
to be recorded of the receipt and testing of starting 
materials; packaging materials; and intermediate, 
bulk, and finished products; analysts' laboratory 
records are to be re~ained together with basic data 
such as weighings, readings, recorder charts and 
calculations. 
(viii) Specifications approved by the quality control 
(ix) 
department should be established for all starting 
materials; packaging materials; and bulk, intermediate 
and finished products (see Section 4.6.3.2). 
Laboratory management is responsible for the 
validation of all test methods; test methods used must 
be in accordance with those prescribed by the relevant 
specification; in-house controls to be carried out by 
production personnel must be approved by the quality 
control manager. 
(x) Aspects relating to contract analysis. This refers to 
laboratory work which is contracted out to third 
parties, and relates in particular to the following 
requirements: clearly-defined contractual agreements 
are necessary; the responsibility of the quality 
control department cannot be delegated to a third 
party; it should be confirmed that the test methods 
used by the contract analyst are correct; and 
§ 
arrangements should be made for the retention of 
samples and records of test results. 
4.6.9 
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The aspects ref erred to above are addressed under the 
chapter dealing with quality control principles in the 
EEC draft GMP guide (loc. cit., pp. 53 - 57) as well 
as the WHO draft GMP guide (loc. cit., pp. 14 - 18, 
pp, 45 46, and p .. 85). This section of both the 
abovementioned guides is reviewed under Section 
4.6.9.2 of this dissertation. 
Additional GMP principles 
The following principles are not specifically defined 
in the British GMP guide, but do appear in other 
recently published GMP guidelines. 
4.6.9.1 Self-inspection, audits and quality evaluation audits 
The GMP principle 
worded as follows 
cit.; p. 67): 
relating to self-inspection is 
in the EEC draft GMP guide (loc. 
"Self-inspection should be conducted in order to 
monitor the implementation and the respect 
(sic) of good manufacturing practice principles 
and to propose necessary corrective measures". 
It should be noted that this guide does not 
specifically state wether the self-audit is product; 
procedure; or systems oriented, other than its focus 
on personnel matters, premises, equipment, 
documentation, technical aspects of production and 
quality control, distribution of final products, and 
-201-
the arrangements for dealing with product complaints 
and recalls in order to verify their conformity with 
the principles of quality assurance. It would appear 
from the wording of this objective, and that of the 
general principle regarding self-inspection (supra), 
that the terms "good manufacturing practice" and 
"quality assurance" are again considered to be 
synonymous. 
The south African GMP guide (loc. cit., pp. 1/4 -
1/5) refers to the subject of self-inspection under 
the heading of quality (management), and refers to the 
need for regular audits on all "systems, procedures 
and operations" in order to monitor compliance with 
and the effectiveness of "good manufacturing practice 
and quality assurance" principles and to allow for 
improvement and corrective measures where required. 
It states that audits should be conducted by 
"competent and impartial persons from the company", 
and possibly external auditors as well. Audit reports 
should be made, corrective measures agreed upon should 
be recorded and followed up; no guidelines regarding 
the relevant authorities and responsibilities are how-
ever given. Audits should follow a pre-arranged 
programme and include inspection of the following: 
(i) Organizational matters and responsibilities. 
(ii) Qualifications and training programmes. 
(iii) 
(iv) 
(v) 
(vi) 
(vii) 
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Compliance with hygiene requirements and access 
control (to production areas). 
Cleaning and disinfection programmes. 
Medical checks on personnel. 
Production facilities, premises and equipment. 
Production operations, procedures and documentation. 
(viii) Storage, handling, distribution and materials 
management. 
(ix) Quality assurance aspects such as complaints, returned 
goods and "validation". 
(x) Suppliers 
material. 
of starting materials and packaging 
(xi) Third party contractors (including distributors of 
finished products). 
The South African GMP guide (ibid., pp. 1/4 - 1/5) 
furthermore refers to the need for "quality evaluation 
audits" which relate to a review of production records 
(see section 4.6.3.5) in order to "determine the need 
for changes in product specifications or manufacturing 
and control procedures". 
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Quality evaluation audits should include: (i) A 
review of every batch manufacturing record irres-
pective of wether the batch was approved or rejected; 
and (ii) A review. of complaints, recalls, returned or 
salvaged products, and investigations conducted during 
normal product record reviews before a batch is 
released. Again, no guidelines are given regarding 
the relevant authorities, responsibilities and 
follow-up procedure in this regard. 
The WHO draft GMP guide (loc. cit., pp. 28 - 31) 
distinguishes between what it terms self-inspection 
and the quality audit. The purpose of self-inspection 
is stated to be the detection of any shortcomings 
regarding the implementation of GMP, and to recommend 
the necessary corrective action. A quality audit, on 
the other hand, is seen as being more broadly aimed at 
an assessment of " all or part of a qualitr 
system", with the specific purpose of improving it, 
and it is thus seen as a useful supplement to 
self-inspection activities. It is furthermore 
recommended that such audits be extended to include 
suppliers and third party contractors. A "partial" 
self-inspection should be performed routinely and also 
under special circumstances such as after a product 
recall or repeated quality problems, or "when an 
inspection by the (regulatory inspectorate) is 
announced" (sic). 
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A "complete" self-inspection should be conducted at 
least once a year. No other guidelines are given 
regarding the timing of quality audits, except to 
state that vendor audits should be conducted before a 
supplier is included in specifications. Self- inspec-
tions should be conducted by a team of "experts" from 
inside or outside the company, whereas a quality audit 
is described as being a procedure which is usually 
conducted by "independent specialists" designated by 
management. 
The French GMP guide (loc. cit., pp. 12 - 13) is 
more consistent in its use of terminology and also 
more explicit in describing the managerial authorities 
and responsibilities involved in what it terms the 
"self-inspection and quality audit". The purpose of 
the self-inspection and quality audit is stated as 
being the assessment " of the quality assurance 
system and to ensure the application of good 
pharmaceutical manufacturing practices " The 
nature of the self-audit is described as being" ... a 
periodic, detailed examination of the conditions and 
working procedures by a team from the production 
plant ... (and) .•. an examination and assessment of all 
or part of the system of quality assurance". Both the 
functionaries involved as well as their relationship 
within the managerial hierarchy are described in more 
detail than in the EEC draft GMP guide. 
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It is stated that the self-audit is to be carried out 
by a team from the production plant or by 
specialist(s) designated for that purpose. A detailed 
report of the observations made and the corrective 
measures proposed must be submitted to the "Pharmacien 
Responsible" (see Section 4.6.2), as well as the head 
of the production department. Moreover, these self-
audits are to be conducted over and above inspections 
by the French regulatory authorities (i.e. external 
audits performed by the regulatory inspectorate). 
4.6.9.2 Functional aspects of quality control 
The concept of quality control is defined in the South 
African GMP guide, the EEC draft GMP guide and the WHO 
draft GMP guide in terms similar to those used in the 
British GMP guide (see Section 4.2.3 of this 
dissertation); however, these guides devote a separate 
section to this particular subject. Aspects regarding 
the independence of the quality control department 
vis a vis other functional groups within the organi-
sational structure and requirements relating to 
documentation, sampling and analytical records are 
identical to those referred to in the British GMP 
~i~. 
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The WHO 
14 18, 
draft 
and 
GMP guide (loc. cit., pp. 45 - 46, pp. 
pp. 85 91) briefly refers to the 
physical 
control 
requirements of 
area", the duties 
what 
of 
it terms the "quality 
the quality control 
department, and the sampling and testing procedures 
for the various materials handled, including stability 
studies. In general, the provisions of the South 
African GMP guidelines the WHO draft GMP guidelines, 
and the EEC draft GMP guidelines correspond very 
closely to one another and differ from those of the 
British GMP guide mainly with regard to the emphasis 
placed upon the viewpoint that quality control 
activities are 
only. However, 
not 
both 
confined to laboratory operations 
the EEC and WHO draft GMP guide-
lines do 
quality 
not adequately define those functions of the 
control department that lie outside the field 
of inspection and testing. For instance, no mention 
is made of the business and systems responsibilities 
of the quality control function. The South African 
GMP guide (loc. cit., p. 7/1) does, however, state 
that the functions of the quality control department 
includes "the review of all plant systems and 
procedures, audits, organization and documentation" as 
well as the "validation" of critical equipment and 
procedures, the approval of all deviations and reworks 
and the approval of third party contractors and 
vendors. Apart from the latter aspect, the functions 
of the quality control department set out in the South 
African GMP guide are therefore largely plant-based. 
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4.6.9.3 Contract manufacture and analysis 
This principle is worded as follows in the EEC draft 
GMP guide (loc. cit., p. 59): 
''Contract 
correctly 
to avoid 
a product 
There must 
manufacture and analysis must be 
defined, agreed and controlled in order 
misunderstandings which could result in 
or work of unsatisfactory quality. 
be a written contract between the 
contact 
clearly 
giver and the contract acceptor which 
establishes the duties of each party. The 
contract must clearly state the way in which the 
Qualified Person (see Section 4.6.2) releasing 
each batch of product for sale exercises his full 
responsibility." 
The WHO draft GMP guide (loc. cit., p. 24) defines 
this principle in identical fashion. The following 
aspects are highlighted in this particular chapter of 
the EEC draft GMP guide (loc. cit., pp. 59 - 65): 
(i) General aspects. All technical and other changes made 
in terms of the written agreement between parties must 
accord with the provisions of the marketing authori-
sation (see Section 3.5) of the product concerned. 
(ii) Aspects relating to the contract giver. The contract 
giver is responsible for assessing the competence of 
the contract acceptor, for providing the contract 
acceptor with all necessary information regarding 
(iii) 
technical 
and for 
products 
-208-
and legal details relating to the product, 
assuring that all materials and processed 
delivered to him by the contract acceptor 
comply with their relevant specifications. 
Aspects relating to the contract acceptor. The 
contract acceptor must himself be the holder of a 
manufacturing authorisation, and must have adequate 
premises, equipment and suitably qualified personnel 
to carry out the work ordered by the contract giver; 
he must ensure that all products and materials 
delivered to him comply with the relevant specifi-
cations; he should not subcontract any work entrusted 
to him without the prior consent of the contract 
giver. 
(iv) Aspects relating to the contract itself. The contract 
should be drawn up by a person with the necessary 
technical knowledge; it should specify the way in 
which each batch will be checked for compliance with 
the marketing authorisation; it should specify who is 
responsible for purchasing materials, testing released 
materials, carrying out production and quality 
controls (including in-process controls), sampling and 
analysis; 
records, 
available 
empowered 
acceptor. 
manufacturing, analytical 
together with reference 
to the contract giver 
to visit the facilities 
and distribution 
samples, should be 
who should also be 
of the contract 
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According to the British GMP guide (loc. cit., pp. 
77 79), the GMP principle regarding contract manu-
facture, analysis and servicing is considered to be a 
specialised topic; in other words, it is not 
considered to be part . of generally-applicable GMP 
principles. This principle is worded as follows: 
"The relative responsibilities of the contract 
giver and the contract acceptor should be clearly 
understood and agreed, with the object of 
avoiding misunderstandings which could result in 
a product or work of unsatisfactory quality. In 
contract manufacture the contract giver bears the 
ultimate responsibility for ensuring that the 
product specification complies with the relevant 
legal requirements, that the product as 
manufactured meets that specification, and that 
the specified quality is maintained during 
storage, transport and distribution". 
The South African GMP guide (loc. cit., pp. 12/1 -
12/3) treats this as a separate GMP principle, but 
defines it in almost identical terms. 
It will 
definition, 
be noted that, in terms of the above 
the British and South African GMP guides 
consider aspects such as storage, transport and 
distribution to be an integral part of the contractual 
agreement with third parties. 
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The South African GMP guide (ibid., pp. 18/l - 18/3) 
in fact refers to "good pharmaceutical wholesaling 
practice" as a separate GMP principle which is worded 
as follows: "Good wholesaling practices should be 
seen as an extension of the manufacturer's endeavours 
to assure the maintenance of product quality by having 
adequate storage conditions, record keeping and 
compliance with legal requirements". The recommen-
dations of the south African GMP guide in this regard 
relate to the competence of personnel, suitability of 
premises, storage conditions, special precautions to 
be taken during transport, documentation, and control 
procedures. In most other respects, this definition 
corresponds to that given in both the EEC draft GMP 
guide and the WHO draft GMP guide. 
The EEC 
emphasises 
deals only 
draft GMP guide (loc. cit., p. 59) 
the fact that this particular GMP principle 
with the responsibilities of the manufac-
turer towards the relevant regulatory authorities, and 
that it is not intended to affect the respective 
liability of contract givers and contract acceptors to 
consumers. This fact is also apparent from the text of 
the French GMP guide (loc. cit., p. 95), which 
states that a manufacturer is legally required to 
inform the French Ministry of Health of any arrange-
ments relating to the subcontracting of manufacture, 
packaging, and analytical laboratory work. 
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It is important to note, for the purposes of this 
research, that GMP principles in general play an 
important role in the relationship between the pharma-
ceutical industry and the regulatory authorities, as a 
result of which GMP principles are most likely to be 
based upon regulatory demands rather than consumer 
demands. This would imply that there is a danger of 
the scope of quality control within the pharmaceutical 
industry being limited to the field of reference 
dictated by legally enforceable regulatory require-
ments only. 
4.7 SUMMARY 
The good manufacturing practice (GMP) principles 
currently applied by regulatory authorities in South 
Africa are largely based upon the British GMP guide, 
and this chapter of the research is consequently 
devoted mainly to a review of the GMP principles 
contained in that guide. However, due to the dynamic 
nature of GMP principles in general, and the 
propensity of the South African regulatory authorities 
to adapt domestic GMP principles in keeping with local 
and international trends, a review of other recently 
published GMP guidelines is included in this chapter 
of the research. It should be noted that this review 
is not aimed at providing a detailed summary of the 
technical aspects of GMP theory, but is aimed instead 
at evaluating the suitability of GMP principles as a 
quality management tool. 
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Good manufacturing practice may be described as being 
a system of quality-related standards and procedures 
which is based upon the collective wisdom of the 
pharmaceutical industry and regulatory authorities, 
and which is designed to complement relevant technical 
specifications with the aim of assuring the quality 
(as well as the safety and efficacy) of medicinal 
products. Insofar as this basic objective is 
concerned, there is a similarity between the GMP 
principles embraced by the pharmaceutical industry, 
and the more generally applicable quality system 
standards and guidelines embodied in the SABS ISO 9000 
guidelines, for instance (see SABS, 1987). 
From the status accorded to GMP guidelines (see 
Section 4.5), it appears that GMP is considered by the 
international industry and regulatory authorities 
alike to be the benchmark against which any quality 
assurance system may be measured. There also appears 
to be a tendency, especially amongst regulatory 
authorities, to look towards a tightening of GMP 
regulations as being a solution to quality problems 
still experienced within the pharmaceutical industry. 
GMP principles are in fact used by regulatory author-
-213-
ities as a basis for assessing applications for 
manufacturing authorisation and for the inspection of 
manufacturing facilities (see Section 4.3). The legal 
status of GMP guidelines published internationally 
appears to depend mainly on two factors; firstly, the 
extent to which the relevant regulatory authority 
subscribes to the viewpoint that GMP is the linchpin 
of quality assurance in the pharmaceutical industry 
and, secondly, the viewpoint that a voluntary set of 
GMP guidelines is less effective than one enforced by 
statute. 
Good manufacturing practice is by definition concerned 
with the assurance of product quality during manufac-
ture, and it therefore follows that the scope of GMP 
guidelines will be limited to that particular stage of 
the industrial cycle. Some authors place an even 
narrower 
to be 
quality 
focus on their GMP texts, while others appear 
moving towards a recognition of the fact that 
is affected at all stages of the industrial 
cycle. Inconsistencies in distinguishing between the 
concepts of quality assurance, good manufacturing 
practice, and quality control may be responsible for 
differences of opinion regarding the scope of GMP 
guidelines, and the viewpoint that GMP principles are 
the equivalent of a total quality system. 
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The British GMP guide is based upon eight general 
principles that are considered applicable to the 
manufacture and 
GMP principle 
control of all medicines, namely the 
relating to quality management; 
personnel and training; documentation; premises and 
equipment; manufacture; recovered materials; 
complaints procedure and product recall; and control 
laboratories. These principles are reviewed in 
Sections 4.6.1 to 4.6.8 of this chapter. Some 
additional principles mentioned in other international 
GMP guides are also reviewed in this chapter of the 
research; (see Sections 4.6.9.1 to 4.6.9.3). Despite 
the fact that most of the GMP guides reviewed 
recognise the need for an integrated management system 
to give top management control over the quality 
activities of all functional groups at all levels 
within an organisation, the texts of all these GMP 
guides are essentially concerned with the technical 
aspects of the production stage of the industrial 
cycle only. The important role played by people in the 
assurance of product quality is stressed in these GMP 
texts, but they all specify a personnel training 
programme that is focused on GMP theory which, by 
definition, is only a component part of the quality 
assurance system (see Section 4.2.2). Quality control 
is defined in terms of the traditional inspection and 
test concept, and most of the GMP guides reviewed 
during the course of this research do not mention the 
business and systems responsibilities of the quality 
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control function for instance. Moreover, quality 
is seen as being the responsibility of the assurance 
quality control function, rather than being a 
and plantwide activity. Quality is itself 
terms of the "fitness for use" doctrine 
companywide 
defined in 
only, and not as a strategic business concept; this is 
most likely due to the fact that compliance with 
statutory requirements relating to product quality is 
such a dominant consideration within the pharma-
ceutical industry. 
Despite these 
GMP principles 
attainment and 
standards of 
criticisms, it cannot be gainsaid that 
have played an important role in the 
maintenance of generally very high 
product quality in the modern 
pharmaceutical industry. These principles have for 
advanced degree of 
regard to incoming 
aspects of process 
instance ensured not only an 
technical sophistication with 
material control and certain 
control, but have been instrumental in the creation of 
a quality awareness amongst shop floor personnel and, 
to a lesser extent, top-level management as well. 
Moreover, current GMP principles already contain 
certain important elements that could be further 
developed and expanded into a formal system of total 
quality control. The GMP principle regarding 
documentation (see Section 4.6.3) for instance 
-216-
embraces inter alia the need for accurate lot and 
serial number tracking which Feigenbaum (loc. cit., 
p. 804) describes as being a basic production-quality 
requirement. The GMP principle regarding complaints 
and recall procedure .(see Section 4.6.7) closely 
resembles the objective of the special process study 
activity of a total quality control programme (see 
Feigenbaum, ibid., p.807). Moreover, the GMP prin-
ciple regarding self-inspection contains some of the 
basic elements of the quality audit activity (see 
Section 4.6.9.1). 
In the context of domestic and international trade, 
GMP principles occupy a strategic position in the 
relationship between the pharmaceutical industry and 
the respective regulatory authorities primarily as a 
result of the legal or quasi-legal status accorded 
to those principles. This may, however, result in GMP 
principles becoming an end to themselves rather than a 
means to an end. Moreover, there remains an apparent 
need to expand in practical terms the organisationwide 
scope of quality management within the pharmaceutical 
industry, and for the introduction of modern quality 
management techniques, in order to acquaint both 
industry and regulatory authorities with the benefits 
of a system of total quality. These aspects are 
addressed in the chapters which follow. 
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CHAPTER FIVE: THE APPLICATION OF QUALITY MANAGEMENT PRINCIPLES 
TO THE PHARMACEUTICAL INDUSTRY 
5.1 GENERAL 
Dale, et al. (1990, p. 6) state that one of the most 
important factors which has stimulated the development 
of a process of total quality management amongst 
companies in the United Kingdom, has been the 
realisation that a quality assurance system does not 
necessarily, of itself, encourage continual quality 
improvement; it may mean only·. that an organisation 
has quality control procedures in place. Crosby 
(1984, p. 6) notes that it is by not doing what they 
already know they should do, that companies get into 
trouble over quality. Feigenbaum (1986, pp. 78 - 79) 
draws attention to the fact that customer quality 
satisfaction cannot be achieved by concentrating upon 
any -one area of the plant or company, and that 
technical activities must be accompanied by the 
creation of equally powerful managerial and 
engineering decision making and operating quality 
systems. 
The abovementioned comments are considered to be 
particularly relevant to the pharmaceutical industry 
in the light of a possible preoccupation with 
regulatory demands regarding the quality of pharma-
ceutical products, rather than with the application of 
the basic principles of quality management. The scope 
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of current good manufacturing practice principles, on 
which the quality control activities of the pharma-
ceutical industry are largely based (see Chapter 4), 
is limited by definition to the production function 
alone. 
There is also a danger that the creation of a quality 
assurance 
principles, 
comply with 
system which is based exclusively on these 
may be motivated more by the desire to 
regularatory demands than by a genuine 
to quality by top management. The same 
may be levelled at the new design control, 
commitment 
criticism 
incoming material control, product control, and post 
marketing surveillance requirements of the current 
regulatory control system (see Chapter 3). 
Successful quality management requires not only the 
establishment and maintenance of a quality control 
system, 
system. 
quality 
but also the continued improvement of that 
This chapter is devoted to an overview of the 
management concepts that would contribute to 
the achievement of these objectives in the context of 
the regulatory controls presently applied to the South 
African pharmaceutical industry. 
5.2 THE STRATEGIC BUSINESS VALUE OF THE TOTAL QUALITY 
CONCEPT 
Many modern publications on operations management in 
general and quality management in particular, ascribe 
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current interest in these specific areas of management 
to the loss of market share by American and European 
industries at the hands of Japanese competitors. The 
pressures of worldwide competition were no doubt 
exacerbated by the glqbal recession of the late ?O's 
and the early 80's, and its accompanying slow economic 
growth. Higher quality and higher productivity gained 
prominence in modern corporate strategies as a result 
of these trends (Chu, 1988, pp. 30 - 32; Maani, 1989, 
pp. 11 - 23; and Schroeder, 1985, pp. 8 - 10). 
Feigenbaum (loc. cit., pp. 23 24) states that 
experience in recent years has shown quality control 
programmes to be one of the most important 
return-on-investment opportunities available to 
business management today. Fortuna (1990, p. 5) 
refers to the strong correlation between quality and 
profitability, which is related to the fact that 
quality impacts both on the revenue and cost elements 
of the profit equation. Mortiboys (1990, p. 39) 
states that the cost of quality mismanagement is 
typically 15 to 30 per cent of sales revenue. Sound 
economic reasoning therefore indicates that quality 
will play an increasingly important strategic role in 
the modern enterprise. 
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With reference to the increasing number of companies 
that have developed or are developing a total quality 
system in the United Kingdom, Dale, et al. (loc. 
cit., pp. 3 17) advance the following factors as 
having provoked this interest: 
(i) The realisation that compliance with the requirements 
of a particular quality system is not necessarily a 
quarantee against producing and shipping nonconforming 
products This viewpoint is seen as being of parti-
cular importance to the pharmaceutical industry, in 
view of the status accorded to so-called good 
manufacturing practice (GMP) principles by that 
industry and the relevant regulatory authorities (see 
Chapter 4). 
(ii) The imposition of stringent quality requirements by 
major customers. With reference to the pharmaceutical 
industry, it is submitted that these quality demands 
would include those made by regulatory authorities on 
behalf of final consumers of medicinal products (see 
Chapters 3 and 4). 
(iii) National quality campaigns which stress the need for 
cost-effective quality management systems. The 
quality systems guidelines known as the SABS ISO 9000 
series (SABS, 1987) serve as an example of such a 
campaign which is applicable to South African industry 
in general. 
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(iv) The teachings of internationally respected experts 
such as Crosby, Demming, Feigenbaum, Ishikawa, Juran, 
Shingeo and Taguchi. 
(v) Published case studies of the benefits achieved 
through total quality management. 
(vi) Loss of market share to competitors. 
Feigenbaum 
benefits of 
(loc. cit., pp. 22 23) divides the 
total quality control into what he terms 
"customer satisfaction oriented benefits", and "major 
economic improvements". He considers the following to 
be "customer-satisfaction oriented" benefits: Improve-
ment in product quality; product design; production 
flow; product service; marketplace acceptance; and 
employee 
following 
morale 
to 
and 
be 
quality-awareness. He lists the 
"major economic improvements": 
Reduced operating costs; operating losses; field 
service costs; and liability exposure. 
From 
that 
the literature 
quality is 
it 
the 
is thus possible to conclude 
cutting edge of successful 
competition in the modern marketing environment. In 
fact, Fortuna (loc. cit., p. 3) states that quality 
is the most important strategic issue facing top 
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management in the 1990's. Where lives may depend on 
the predicted functioning of a product, as is the case 
with a pharmaceutical product for instance, quality 
becomes an absolute sine qua non to participation in 
international markets. 
Due to the fact that quality is a crucial determinant 
for business success or failure in today's quality 
performance-orientated markets, it has become a major 
area in its own right and a strategic business 
significant factor 
strategic business 
in what has come to be called 
planning. The key is that quality 
control must be structured explicitly and measurably 
so as to contribute to business profitability and 
positive cash flow (Feigenbaum, loc. cit., pp. 
17-18). This need for positive managerial leadership 
in quality underlines the truism that quality is in 
its essence a way of managing the organisatior. it is 
not ·something that is achieved by chance. Moreover, 
it underlines the fact that proactive quality 
management within the modern pharmaceutical enterprise 
should be considered to be an example of intelligent 
self-interest, rather than a mere palliative for 
regulatory demands in that regard. 
5.3 THE QUALITY CONCEPT DEFINED 
Numerous definitions of the quality concept, as it 
applies to medicines, may be found in the literature. 
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Benney (1980, p. 1434) quotes the Pharmaceutical 
Manufacturers Association of the United States of 
America as stating that quality relates to the degree 
in which a particular product performs its intended 
function when used as .directed and, futhermore, that 
product quality is the sum of all factors which 
contribute directly or indirectly to the safety, 
effectiveness and acceptability of that product. 
For the purposes of this dissertation, however, the 
quality of a pharmaceutical product will be expressed 
in terms of how closely that product conforms to 
specified standards, as judged by the consumer's 
actual experience with an affordable product which 
satisfies the consumer's requirements. This approach 
to the quality concept is relied upon firstly because 
it emphasises the need for a product to conform to 
predetermined specifications and, secondly, the need 
to satisfy the requirements of the final consumer. 
Moreover, this particular interpretation of the 
quality concept is in line with that which is 
applicable to industry in general. 
Terms such as "safety" and "therapeutic efficacy", as 
used in Subsection 1(3) of the Medicines and Related 
Substances Control Act (South Africa, 1965) to de-
scribe the criteria against which the availability of 
a medicine shall be considered to be in the public 
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interest, are seen being individual characteristics 
which make up the composite of product quality (see 
Feigenbaum, loc. cit., p. 7). The terms "safety", 
"effectiveness", and "acceptability" of a medicinal 
product, as quoted by. Benney (loc. cit.,), may be 
interpreted in similar fashion. This viewpoint is 
supported by Evans & Cunliffe (1987, pp. 12 and 18), 
according 
synonymous 
statutory 
Britian. 
to whom product quality is considered to be 
with safety and efficacy in terms of the 
controls applied to medicines in Great 
(loc. cit., pp. 4 5) highlights an 
aspect by expanding on the "fitness for use" 
of quality originally attributed to Juran, 
is based on the parameters of quality of 
Fortuna 
important 
definition 
and which 
design and quality of conformance, by including 
additional design-dependant elements such as 
reliability, durability, and relative cost. This 
viewpoint is considered to be important in the present 
context because the concepts of quality and quality 
control in the pharmaceutical industry have tradition-
ally been associated mainly with the production 
function (see Chapter 4). Moreover, due to the nature 
of the regulatory control system applied to the south 
African pharmaceutical 
issue of quality of 
industry (see Chapter 3), the 
design has traditionally gained 
prominence more as a regulatory, rather than a quality 
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issue. Fortuna's viewpoint corresponds to that of the 
total quality philosophy which is based, inter alia, 
upon the fact that quality is affected at every stage 
of the industrial cycle, including the product design 
stage (see Section 5.5) •. 
5.4 CONTROL AS A MANAGEMENT, NOT A TECHNICAL, FUNCTION 
Control is one of the basic functions of management. 
According to Radel & Reynders (1980, p. 281), control 
constitutes the rounding-off of the management 
function and also forms the basis for planning and 
action. Feigenbaum (loc. cit., p. 10) defines the 
meaning of "control", in the industrial context, as 
being a process for delegating responsibility and 
authority for a management activity while retaining 
the means of assuring satisfactory results. 
He ·describes this process as consisting of the 
following four steps: 
(i) Setting standards. In the context of quality control, 
this step will involve setting the appropriate cost-
quality; performance-quality; safety- quality; and 
reliability-quality standards for the product concer-
ned. 
(ii) Appraising conformance; 
to the standards set. 
i.e. monitoring conformance 
(iii) 
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Acting when necessary; i.e. correcting problems and 
their causes throughout the full range of marketing, 
design, engineering, production, and maintenance 
factors which influence user satisfaction. 
(iv) Planning for improvements; i.e. developing a 
continuing programme to improve standards of cost, 
performance, safety and reliability. 
(i) 
(ii) 
This viewpoint contrasts with that found in the tech-
nical literature relating to industrial pharmacy, 
where control is often viewed as consisting of 
individual (not necessarily inter-related) technical 
functions. Benney (loc. cit., pp. 1434 - 1437) for 
instance describes the following separate and distinct 
activities as constituting control functions in the 
pharmaceutical industry: 
The · analysis function. 
performance of appropriate 
biological tests prior to 
significant phase in the 
particular batch of product. 
The monitoring function. 
This relates to the 
physical, chemical and 
or upon completion of a 
production process of a 
This relates to the 
in-process 
materials 
control or monitoring function applied to 
while they are being processed, and includes 
an environmental monitoring function where necessary 
(e.g. during the production of a sterile product). 
(iii) 
(iv) 
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The record review and release function. Many docu-
ments are routinely used to 
pharmaceutical 
4.6.3). Batch 
manufacturing 
manufacturing 
document a product's entire 
particularly with regard to 
guide and record the 
process (see Section 
records are used to 
manufacturing history, 
the completion of the 
necessary activities relating to control and pro-
duction processes. As part of the final product 
release function, a detailed audit is performed on the 
relevant batch manufacturing records to verify the 
completeness and accuracy of those records. 
The quality 
describes the 
areas 
audit function. 
quality audit as 
Benney (ibid. ) 
being designed to 
where standard operating procedures detect 
(SOP's) relating to the research, development, 
production, 
functions, 
based on 
control, purchasing and distribution 
are not being followed. These SOP's are 
current good manufacturing practice (GMP) 
(see Chapter 4). According to Benney principles 
(ibid., p. 1436), the quality control audit is 
performed by an individual or by a multidisciplinary 
team which is "frequently" headed by personnel from 
the quality control function. Deviations should be 
reported to 
uncorrected 
the relevant 
deviations found 
supervisors, whereas 
during follow-up audits 
should be "periodically" reported to higher management 
for resolution" 
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The viewpoint put 
as an example of 
forward by Benney (supra) serves 
the functional approach to quality 
control which is generally adopted in the technical 
literature. This approach in effect results in top 
management being involv~d only in an incidental manner 
in quality issues, because the functional activities 
described above are not necessarily directly connected 
to the managerial decision making process. One of the 
primary objectives of this research is in fact to 
demonstrate the relevance to the pharmaceutical 
industry of the principle that quality is a result of 
the way in which an enterprise is managed, and the 
consequent need to revise present day concepts of 
quality control which are based upon purely technical 
philosophies. 
5.5 THE TOTAL QUALITY CONCEPT 
Numerous definitions and acronyms associated with the 
term "total quality control" are to be found in the 
literature. The reason for this surfeit appears to be 
related to the fact that often only selected aspects 
of the quality paradigm are addressed by each. 
The approach adopted by Feigenbaum and also that of 
Hohner were found to be particularly useful for the 
purposes of this research. Feigenbaum (loc. cit., 
p. 6) defines the concept of total quality as follows: 
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"(Total quality) 
integrating the 
is an effective system for 
quality-development, quality-
maintenance, and quality-improvement efforts of 
the various groups in an organisation so as to 
enable marketing, _engineering, production, and 
service at the most economical levels which allow 
for full customer satisfaction". 
Hohner (1988, p.43) describes total quality as being a 
management philosophy which incorporates technical 
skills at all levels of the organisation. He empha-
sises in particular the broad functional scope of 
total quality control (which encompasses all manu-
facturing, engineering, marketing and sales func-
tions); a commitment towards continuous quality 
improvement; and the achievement of reliability and 
consistency in the delivered product. 
The -total quality concept may also be defined in terms 
of an orientation to the following principles, which 
are based on Feigenbaum (loc. cit., p. 94), and 
Fortuna (loc. cit., pp. 11-12): 
(i) Basic quality responsibility rests with top manage-
ment; quality control is a management tool which 
enables top management to fulfil a leadership role 
with regard to product quality. 
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(ii) The formulation and communication of specific quality 
policies and objectives which have a customer-first 
orientation. 
(iii) Organisationwide integration of all the activities 
necessary to achieve company quality policies and 
objectives. 
(iv) Provision of ongoing quality education and training to 
all employees in order to promote quality-mindedness 
and organisationwide quality motivation. 
(v) Active involvement of all employees in the quality 
establishment, maintenance, and improvement process. 
(vi) 
(vii) 
Defined and effective quality information flow, 
processing, and control. 
Continuous f eedforward and feedback of information 
relating to measurements and standards of organisation-
wide quality performance, including quality cost data. 
(viii) Periodic audit of quality system activities. 
(ix) A structured approach towards timeous and effective 
corrective action with regard to quality problems. 
(x) A focus on continuous improvement. 
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(xi) Reduction of product and process variation. 
(xii) Emphasis on the prevention of quality deviations, 
rather than their detection. 
(xiii) Extension of quality control activities beyond the 
(internal) organisation 
instance, vendor-control 
lance activities. 
itself to include, for 
and post-marketing surveil-
5.6 THE CONCEPTUAL EVOLUTION OF QUALITY CONTROL IN THE 
PHARMACEUTICAL INDUSTRY 
The industrialisation of the pharmaceutical industry 
followed a pattern similar to that of industry in 
general, but on a slightly different time scale. The 
extemporaneous dispensing of medicine by individua~ 
apothecaries before the twentieth century gradually 
gave- way to mass production techniques, and the 
pharmaceutical industry as it is known today came into 
being as recently as the second World War. The 
postwar period has in turn been characterised by 
extremely rapid technological change, as evidenced by 
the technologically highly complex nature of modern 
pharmaceuticals (South Africa, 1978, pp. 4 - 5). 
(i) 
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Sharp {1990, pp. 296 - 299) classifies the conceptual 
evolution of quality control in the pharmaceutical 
industry to date as consisting of the following three 
distinct phases: 
The initial phase, during 
entirely upon preparative 
the professional apothecary). 
which emphasis was placed 
methods (as exemplified by 
(ii) The second phase, during which end-product testing was 
considered to be all important (e.g. compliance with 
specifications detailed in official pharmacopoeias). 
(iii) The third phase, to which he refers as the "modern 
view" that true assurance of quality can only be 
achieved when end-product testing is integrated within 
"a more general framework of a detailed understanding 
and appraisal of the conditions of manufacture". He 
is furthermore of the opinion that current good manu-
facturing practice {GMP) principles provide such a 
framework. 
The good manufacturing practice concept is by 
definition concerned with manufacturing and quality 
control procedures only (see Chapter 4). The quality 
assurance concept, on the other hand, is described in 
the techinical literature as relating to good manu-
facturing practice as well as other (undefined) 
factors outside the production function which 
influence product quality. 
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It may therefore be concluded from the litera~ure that 
a purely technical approach to the control of pharma-
ceutical product quality does not place emphasis on 
factors such as basic responsibility for quality 
resting with top management; the organisationwide 
integration of quality activities; continuous 
evaluation of quality performance (including quality 
cost analyses); a structured approach to corrective 
action relating to quality problems; the quest for 
continuous improvement; and the importance of 
prevention rather than detection of quality 
deviations. Moreover, it may be concluded from the 
literature that the total quality concept does have a 
clear orientation to these specific aspects of product 
quality. 
Dale,et al., (loc. cit., pp. 3 17) distinguish 
between four distinct stages in the progression from 
inspection activities to total quality management, 
namely inspection; quality control; quality assu-
rance; and total quality management. The first stage 
relates to a simple inspection-based system which is 
in effect an after-the-fact screening procedure that 
is carried out on incoming materials, in-process 
and finished product. The system has no 
content other than the possible identifi-
materials, 
prevention 
cation of 
producing 
suppliers, 
substandard 
workers, 
products. 
or processes that are 
The second stage 
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refers to a system of quality control, which is 
described as including some form of elementary new 
design control, raw material- and intermediate product 
testing, self-inspection by operators, logging of 
elementary process performance data, and the feedback 
of process information to supervisors. The third 
stage of the evolutionary process relates to a system 
of quality assurance, which is described as featuring 
the use of a comprehensive quality manual, the 
(limited) use of quality costs, and the use of statis-
tical process control and quality systems. What is 
more important, however, for the purposes of this 
research is the view that a system of quality 
assurance incorporates a shift in emphasis from mere 
detection towards the actual prevention of non-
conf ormance. Dale, et al., (ibid.) also make the 
interesting comment that this particular stage of the 
evolutionary process is likely to have third party 
approval from a recognised authority (see Chapter 4 of 
this dissertation regarding the regulatory status of 
the so-called good manufacturing practice principles 
used by the pharmaceutical industry). 
The fourth, and 
relates process 
management 
Individual 
than for 
management, 
highest, 
to the 
level of the evolutionary 
application of quality 
principles 
departmental 
a "quality 
but will 
on an organisationwide basis. 
standards may be no higher 
assurance"-level of quality 
pervade the entire organisation 
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(not only the production function), and would in fact 
extend beyond the organisation itself to include 
"partnerships" with suppliers and consumers. 
Mr Sharp (loc. cit., .pp. 296-299) is described in 
that publication as being a widely experienced 
Industrial Pharmaceutical Consultant, and it may 
therefore have been anticipated that he would be a 
proponent of the movement towards a higher level of 
the evolutionary process relating to quality control; 
namely total quality management. However, he de-
scribes any suggestion of such a movement away from 
GMP towards what he terms "total quality assurance", 
or "quality management", as involving "no more than 
mere semantics". Moreover, he refers to concepts such 
as quality management, total quality systems, and 
just-in-time as "current hot topics" and "buzz-words" 
(sic). 
The opinions expressed by Sharp (supra) may be 
better understood when seen in the broader context of 
yet another characteristic of the evolutionary 
development of the pharmaceutical industry; namely 
the propensity for quality problems within that 
industry to elicit highly publicised, and often very 
emotional, public response. Because of the fact that 
human (and animal) lives may be at stake, it stands to 
reason that quality issues such as adverse drug reac-
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tions, misla.belling, product mix-ups, adulteration, 
and contamination are more likely to elicit such 
public (and political) responses than would be the 
case involving a product where the risks of failure 
are not as serious.. Government agencies have 
responded to public and political demands for protec-
tion against these potential dangers by imposing 
various regulatory controls on the pharmaceutical 
industry (see Section 2.3.3). The need for some form 
of regulatory control over the manufacture and sale of 
pharmaceutical products has historically been shown to 
be a generally accepted principle (see Section 1.1). 
The modern history of the pharmaceutical industry has 
in fact been characterised by sporadic quality-related 
"disasters", of which the thalidomide disaster, which 
occured during the early Sixties, is the classic 
example (see Section 2.4.2.1). 
Every such "disaster" is usually followed by public 
protest and demands for more stringent regulatory 
controls. The argument against what is often 
considered to be excessive regulation has been put 
forward mainly by the pharmaceutical industry, on the 
basis of an alleged prejudice to both public and 
national interests, as well as increased financial 
risk to the industry itself. The industry has also on 
occasion managed to mobilize opinion within the 
medical profession on the grounds that the physician's 
freedom to prescribe is endange~ed by regulatory 
trends. 
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The international debate concerning the regulatory 
controversy has swung pendulum-fashion from one 
extreme to the other, depending on events. In the 
wake of the thalidomide incident, for instance, there 
was overwhelming support for greater regulatory 
control. This event was, however, followed by a 
decade without major drug dramas, and arguments in 
favour of relaxing regulatory controls were increasing-
ly heard. In 1974, problems surrounding the drug 
practolol again swung the debate in the opposite 
direction, only to be followed by a new wave of 
protest against regulation which reached a climax 
around 1979 and 1980. During the four years that 
followed, a series of major drug incidents involving, 
amongst other, benoxaprofen, controled release 
indomethacin ("Osmosin" and "Indosmos"), oxyphenbuta-
zone, and phenylbutazone, caused opinion to again 
swing in favour of more extensive regulatory controls 
(Dukes, 1985, pp. 24 - 30). 
The period following the thalidomide affair may there-
fore be said to have been characterised by the fact 
that the pharmaceutical industry has increasingly been 
involved in fighting a rearguard action against what 
is perceived to be excessive or inappropriate 
regulatory demands. Sharp (loc. cit., p. 296) in 
fact is of the opinion that there have been no 
important conceptual or technical developments in the 
control of quality in the pharmaceutical industry in 
Europe since the establishment of GMP principles, and 
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that the most important developments in this regard 
have occured in the field of what he describes as the 
"formalisation" or "bureaucratization" of quality 
issues. 
This preoccupation with regulatory demands and the 
confrontational nature of the ensurning debate (wether 
such confrontation is intended or not), is likely to 
continue for as long as total quality management and 
related concepts are considered to be an exercise in 
semantics or mere "buzz-words". Moreover, the 
viewpoint that good manufacturing practice (GMP) 
principles represent the ultimate framework for a 
modern quality assurance system cannot be supported 
from a business economic perspective, particularly 
insofar as the emphasis on defect prevention (rather 
than detection) and the organisationwide scope of 
quality management (rather than a technical 
orientation to the production function only) is 
concerned. 
5.7 THE INTEGRATION OF A QUALITY SYSTEM INTO PRODUCTION 
CONTROL SYSTEMS 
The technical 
practice (GMP) 
orientation of 
principles 
the good manufacturing 
currently applied to 
pharmaceutical production, was discussed in Chapter 
4. From a business economic point of view, the 
relationship between GMP principles and any particular 
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production control system is therefore of an 
incidental nature only. On the other hand, there 
exists a strong inter-dependence between the total 
quality approach and JIT production systems. Hohner 
(loc. cit., p.42) for instance describes a quality 
commitment to be the pivotal point of a JIT 
programme's success, and he considers the implemen-
tation of a total quality methodology to be a crucial 
step in the establishment of a successful JIT produc-
tion system. Ray (1990, pp. 179 - 190) refers to the 
need to focus upon a fundamental improvement in the 
capability and reliability of the total production 
system as a prerequisite for the successful implemen-
tation of a JIT production control system, and notes 
that these preconditions are in essence quality 
issues. 
Many of the elements inherent in the JIT production 
philosophy are directly applicable to the pharma-
ceutical production process. The emphasis that is 
placed upon the identification and elimination of the 
root causes which create the demand for inventory and 
the resultant improvement in the capability and 
reliability of the total production system; the 
achievement of a high degree of process capability; 
the achievement of tooling and equipment reliability; 
the immediate feedback and response to quality 
problems; the achievement of reduced set-up times for 
equipment; and the establishment of a carefully eval-
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uated supplier base, are for instance entirely compa-
tible with the quality objectives of pharmaceutical 
production as exemplified by the GMP principles 
currently applied within the industry. The "do it 
right first time" phi~osophy is an integral part of 
both JIT/total quality and GMP principles; however, 
whereas GMP methods seek to achieve this by 
prescriptive means JIT/total quality systems rely 
instead upon the self-actualisation of the worker 
through participatory problem solving techniques and a 
discipline that is inherent in the system itself. 
Moreover, the JIT/total quality system feeds back 
information which is relevant to the managerial 
decision making process, whereas GMP principles are 
concerned primarily with technical data only. 
Galomski (1987, p. 230) criticises the latter approach 
by noting that American executives in general have 
lost control of the management of quality because they 
have- delegated that activity to quality specialists 
who are mainly interested in the technical aspects of 
products and processes. 
A major difficulty with the application of JIT 
production techniques to pharmaceutical manufacture 
however appears to be the fact that JIT production 
requires a stable master schedule which is uniform 
from day to day and even hour to hour (Schroeder,loc. 
cit., pp. 485 - 486). In other words, the use of JIT 
techniques is essentially restricted to repetitive 
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production (i.e. 
discrete products 
the production of standardised or 
in high volume) such as is the case 
in the 
household 
automotive, 
appliance 
electronics, machinery, and 
industries. Batch manufacturing 
production, as applied in the pharmaceutical industry, 
on the other hand relies on a highly variable master 
schedule. Work centres or flow lines must generally 
be capable of handling a wide variety of products, 
dosage forms, and 
finished products 
Cough and cold 
pack sizes. Moreover, demand for 
may be seasonal or very erratic. 
remedies for instance experience peak 
demand in winter and virtually no demand during summer 
whereas expected demand may be severely distorted by 
an influenza epidemic. 
The materials requirements planning (MRPI, II and III) 
system of production planning and control appears to 
be more suited to pharmaceutical production than the 
JIT ·system, due mainly to the fact that it allows the 
use of a highly variable master schedule. In the 
context 
however 
of pharmaceutical 
appears to have 
production, the MRP system 
weaknesses or potential 
weaknesses in important areas. 
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According to Schroeder (ibid., p. 485), the MRP 
approach to quality is based upon a policy which 
tolerates a degree of wastage through scrap, and which 
places greater emphasis on the prediction of 
scrap-losses than their .prevention. The MRP system in 
fact stands accused of neglecting quality (Anon, 
1989a, pp. 95-96). JIT production, on the other hand, 
aims for zero defects because if quality is not one 
hundred per cent, production is in jeopardy due to the 
starvation of work centres further down the line. 
According to Schroeder (loc. cit., pp. 485 - 486), 
the MRP approach to workers may be characterised as 
"management by edict", whereas the JIT approach is 
based on "management by consensus". MRP is basically 
a planning philosphy which requires workers merely to 
follow the plan, whereas the JIT approach encourages 
worker participation in problem solving in order to 
continually improve quality and productivity. The 
strategic role played by people in the pharmaceutical 
production process is generally recognised in the 
technical literature. Sharp (1986, p. 45) for 
instance states that science and technology are, 
relatively speaking, the easy part of pharmaceutical 
production, and that "people problems" are the really 
difficult part. It is therefore important to take 
note of this particular criticism of the MRP concept 
by Schroeder (supra), especially in the context of 
pharmaceutical manufacture. 
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From the above discussion it may be concluded that 
both the JIT and MRP production control systems 
contain elements which may be successfully applied to 
pharmaceutical production, but that both systems also 
contain important elements that are not entirely 
compatible with the specific requirements of the 
pharmaceutical production process. The JIT and MRP 
systems however appear to complement each other in 
these areas of possible weakness, and it would 
therefore seem logical to suggest that the two systems 
should be used in combination with one another. 
Goodrich (1989, pp. 46 - 48) is of the opinion that 
JIT and MRP systems are not only compatible, but that 
the benefits derived from each are greatly increased 
when the two systems are used together. The rationale 
behind this viewpoint becomes apparent when MRP is 
viewed as the planning half of the operation, and JIT 
as the execution half (Boccard, 1990, pp. 39 - 40). 
Duncan (1989, p. 84) states in this regard that a 
sound requirements plan is especially important to the 
manufacturer of complex products, i.e. products with 
multiple components having different properties, 
processes, resource requirements, and lead times (as 
is the case in pharmaceutical production), and that 
MRP is in fact a prerequisite to JIT implementation 
under these circumstances. Discenza & McFadden (1988, 
pp. 49 53) describe the integration of MRP II and 
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JIT systems through software unification in companies 
where MRP is used as the planning system while JIT is 
used as the execution system. 
Heiko (1989, pp. 62 - .63) regards the integration of 
JIT with MRP as one of the four basic principles on 
which the practical implementation of a JIT system 
depends; together with the need to streamline 
manufacturing operations, the implementation of total 
quality, and group improvement activities which 
encourage worker creativity. 
Yamaha Motors has developed a system termed Synchro-
MRP, which combines the features of MRP and the Kanban 
subsystem of JIT, and which is intended for use in a 
high-volume manufacturing company with a broad line of 
products (Esparragio, 1988, pp. 9 - 10). The system 
appears to be flexible enough for application to 
pharmaceutical production. 
It is concluded from the above discussion that the 
implementation of a system of total quality may 
enable management in the pharmaceutical industry to 
effectively integrate its quality control system with 
modern production planning and control systems. It is 
furthemore concluded that the total quality concept 
may be uniquely suited to such integration because it 
forms an integral part of JIT/MRP systems. Due to its 
purely technical orientation, the GMP principles cur-
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rently applied within the pharmaceutical industry have 
only limited application in this regard. 
5.8 QUALITY COSTS 
Maani (loc. cit., p. 18) states that quality costs 
are costs of waste; in other words, the cost of "not 
doing it right first time". Feigenbaum (loc. cit., 
p. 109) agrees with this viewpoint, and equates 
unsatisfactory quality to unsatisfactory resource 
utilisation due to wastage of material, labour, and 
equipment time, which lead to higher costs. Batson 
(1988, pp. 61 - 64) refers to the following definition 
of quality costs by Montgomery: "(Quality costs are) 
those categories of cost associated with producing, 
identifying, avoiding or repairing products that do 
not meet requirements". Plunkett & Dale (1990, pp. 
167 168) refer to the following definition of 
quality costs: "(Quality costs relate to) the 
expenditure incurred in 
appraisal activities and 
defect prevention and 
the losses due to internal 
and external failure of a product or service through 
failure to meet agreed specifications". Campanella & 
Corcoran (1987, p. 210) draw attention to the fact 
that quality costs should not be viewed as consisting 
of the expenses of the quality control function of the 
enterprise. 
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For the purposes of this research, the various 
categories of quality costs will be classified 
according to the system suggested by Feigenbaum (loc. 
Ci t • I PP o 1Q9 145). He divides quality costs into 
two principal categories; namely the cost of control, 
and the cost of failure to control. 
He refers to these costs collectively as operating 
quality costs. The cost of control may furthermore be 
subdivided into prevention costs and appraisal costs, 
whereas the cost of failure to control may be 
subdivised into internal failure costs and external 
failure costs. 
Insofar as quality costs in general are concerned, the 
basic objective of management is to reduce total 
quality cost to a minimum while at the same time 
maintaining the required levels of quality. With 
reference to the pharmaceutical industry in 
particular, quality costs are central to the current 
debate concerning the possible revision and relaxation 
of the regulatory controls currently applied to that 
industry. It is for instance argued that present-day 
regulatory requirements may cause a decline in the 
industry's return on investment to a point where its 
very survival will be at risk (Dukes, loc. cit., pp. 
4 25). This particular aspect of the regulatory 
debate may be said to centre around the determination 
of the optimum balance between the cost of quality and 
the value of quality. 
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The purely technical approach to quality control which 
is embodied in current principles of good pharma-
ceutical manufacturing practice (see Chapter 4) en-
courages an inspection and test approach to quality 
control. This traditional approach typically 
emphasises expenditure on appraisal costs (rather than 
prevention costs), thereby ignoring the effect on 
total quality costs; total quality costs remain 
virtually unchanged due to the decrease in external 
failure costs being offset by the increase in 
appraisal costs and internal failure costs (Quinn & 
Bhatty, 1987, p. 217). These good manufacturing 
practice principles cannot therefore be expected to 
positively contribute to the debate on the cost of 
quality. Similarly, the present focus on quality 
costs as an expense, rather than an investment, will 
result in the positive contribution of a quality 
control system to the industry's return on investment 
being overlooked. 
The total quality concept, on the other hand, 
encourages increased expenditure on prevention 
activities; this results in the reduction of internal 
and external failure costs. Apprasal costs may also 
decrease, due to the need for routine inspection and 
test activities being reduced. The net result is an 
improvement in the level of quality with a concomitant 
decrease in the total cost of quality up to the point 
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of optimal cost of quality (Quinn & Bhatty ibid., p. 
218). Moreover, Feigenbaum (loc. cit., pp. 112 -
114) points out that the major part of the savings 
generated from a reduction in total quality costs goes 
into profit improvement. He is of the opinion that 
this makes the total quality system one of the most 
attractive return on investment apportunities 
available. Dukes (loc. cit., pp. 21 - 30) refers to 
the fact that the current regulatory control debate is 
often conducted at a very unsophisticated and some-
times emotional level. It may therefore be concluded 
that the availability of accurate quality cost data 
will make an important contribution to this debate. 
Plunkett 
quality 
& Dale (loc. cit., pp. 165 - 182) note that 
costs may be regarded as a criterion of 
quality performance only if valid comparisons can be 
made between different sets of cost data. Consequent-
ly, -defining the various cost categories and the 
various elements of each category is of fundamental 
importance to such a comparison, both within the 
individual enterprise as well as the industry within 
which it operates. Differentiating between costs that 
are quality-related and those that are not, is however 
often a matter for individual judgement, and many grey 
areas exist. 
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It may for instance be debated whether test procedures 
relating to the identification and assay of incoming 
materials, or in-process controls such as those 
relating to tablet mass, uniformity, and friability, 
are indeed peripheral .quality activities, or should 
rather be considered to be an integral part of the 
pharmaceutical manufacturing process. If the manu-
f acturer of a sterile product cannot be certain of 
making a product which is fit for its intended use 
without first having conducted a test for product 
sterility on every batch produced, should the cost of 
' the test be considered to be quality-related or 
process-related? 
Plunkett & Dale (ibid., p. 169) are of the opinion 
that it is not possible to offer general solutions in 
this regard other than to suggest that if there is 
serious doubt, the cost should not be defined as being 
quality-related where it is unlikely to be amenable to 
change by quality management. Pharmaceutical 
production is however characterised by the fact that 
quality costs may have to be incurred at the insis-
tence of an external regulatory control authority (see 
Chapter 3). Should company management choose not to 
comply with regulatory demands in this regard, the 
South African Medicines Control council is empowered 
by law to cancel the marketing authorisation (product 
registration) of a violative product, and/or to recall 
• 
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any such product from the marketplace. In terms of 
the approach advocated by Plunkett & Dale (supra) it 
may therefore be argued that quality costs thus 
incurred are part of process costs, and not quality 
costs, because quality ~anagement is not autonomous in 
that regard . 
It should, however, be borne in mind that the South 
African regulatory authorities have adopted an 
approach which relies to a large extent upon consul-
tation with the industry as part of their own decision 
making procedure. This approach, which is based upon 
the audi alterem partem rule of natural justice, is 
exemplified by the Medicines Control Council's applica-
tion of so-called current good manufacturing practice 
(GMP) priciples to the pharmaceutical industry; the 
requirements relating to the quality objective(s) to 
be achieved in this regard are clearly stated, but the 
actual method whereby those objectives are achieved is 
left to the discretion of individual company manage-
ment (see Chapter 4). Moreover, a person or company 
affected by a decision of the Medicines Control 
Council has a right of appeal against that decision 
(see Section 3.5). Company management may therefore 
be considered able to participate, albeit to a limited 
extent, in the establishment and implementation of 
quality goals. When viewed from this perspective, it 
is submitted that the validity of the approach 
advocated by Plunkett & Dale (supra.) is not 
affected 
Medicines 
industry 
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by the statutory 
Control Council 
in South Africa. 
relationship between the 
and the pharmaceutical 
The fact that this 
process of dif f eren-
are quality-related and 
relationship complicates the 
tiating between costs .that 
those that are not, can however not be gainsaid. 
Plunkett & Dale (ibid., p. 165) state that quality-
related costs commonly range from five to 25 per cent 
of company turnover, depending on the industry and the 
way in which quality is managed by the company, with 
appraisal and failure costs traditionally making out 
95 per cent of this total. The prevention-orientated 
focus of the total quality concept makes significant 
savings in quality costs possible; Plunkett & Dale in 
fact believe that quality costs may be reduced to one 
third of their level prior to the introduction of cost 
effective quality management systems. This research 
revealed no reference in the literature to support 
such an opinion relevant to the South African 
pharmaceutical industry. The companywide scope of the 
total quality concept, and its application to the 
entire industrial cycle, does however suggest that its 
inherent potential to achieve such savings must be 
accepted as being superior to that of the current good 
manufacturing practice (GMP) principles presently 
employed by that industry. Moreover, the total 
quality concept embraces the identification, callee-
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tion and reporting of empirical cost data, whereas the 
application of GMP principles does not supply 
management with this type of information. 
5.9 FORMULATION OF QUALITY POLICY 
The management policy for any area within an 
organisation relates to the aggregate of management 
decisions necessary to achieve stated operational 
objectives. In particular, a quality policy is 
established to stipulate the limits within which all 
quality-related management decisions are taken in 
order to meet quality objectives. The quality policy 
should be designed for use as a delineation of the 
quality objectives and quality policy of a company and 
is considered to be a prerequisite to the implemen-
tation of a total quality programme (Caplan, 1980, pp. 
8 9; and Feigenbaum, loc. cit., pp. 237 - 240). 
According to Feigenbaum, the process of quality policy 
formulation involves the identification of quality-
related decisions at each step of the industrial 
cycle; the identification and analysis of all 
quality-related problems experienced with the product 
during the entire 
documentation of 
industrial 
quality policy 
cycle; 
in 
and 
order 
the 
to 
communicate the quality policy to all functionaries 
throughout the organisation. 
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With reference to the identification of 
quality-related decsions, the MBR1 registration 
dossier (see Section 3.6) may be viewed as a valuable 
guideline during this particular phase of quality 
policy formulation. Regulatory requirements such as 
the appointment of a pharmacist as managing director 
in terms of section 22(c) of the Pharmacy Act (South 
Africa, 1974) and Medicines Control Council require-
ments relating to major changes (as defined) to the 
method of manufacture (MCC, 1988, Circular to 
applicants ref. 13/88), may therefore have a 
substantial influence on the formulation of quality 
policy in the pharmaceutical industry. These 
requirements may however be viewed as merely providing 
a framework for policy formulation in certain 
particularly critical areas without entirely removing 
the discretion of management to define the parameters 
within which alternative decisions or courses of 
action may be taken to achieve the stated quality 
objectives. 
The current regulatory control system assures the 
efficient identification of (technical) quality-
related problems and their (physical) analysis. No 
regulatory guidelines are, however, given regarding 
the identification and analysis of non-technical 
quality- related problems. In terms of the total 
quality concept, this phase of quality policy 
formulation is approached from a broader (not 
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exclusively technical) perspective, and is a sustained 
process which is aimed at achieving continual quality 
improvement (see Feigenbaum, loc. cit., p. 239). 
Caplan (loc. 
communicating 
throughout an 
linked chain 
cit., PP~ 8 - 9) views the process of 
a quality policy to all functionaries 
organisation as consisting of an inter-
of documents at four levels. The first 
level comprises the broad statement of quality policy. 
The second level of documents addresses more specific 
aspects of the quality system, such as new design 
control or product control. The third level of 
documents are termed procedures, which indicate how 
policy is to be carried out; who does it; when it 
has to be done; and under what circumstances it is to 
be done. The fourth level of documents comprises 
instructions, which are 
statements regarding the 
tasks. 
detailed and very specific 
performance of individual 
The use of formal documentary methods of communication 
and documentary control measures to verify adherence 
to policies, procedures and instructions, is one of 
the basic principles of current good manufacturing 
practice (GMP) routinely applied in the south African 
pharmaceutical industry (see section 4.6.3). It will 
be noted however that the working documents that are 
required in terms of current GMP principles relate to 
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tactical decision making only, i.e. the day-to-day 
control of quality. No specific reference is made in 
current GMP theory of strategic quality decision 
making, either with reference to the orientation of 
top management in terms.of the GMP principle regarding 
quality management (see Section 4.6.1), or the orien-
tation of employees in terms of the GMP principle 
regarding personnel and training (see Section 4.6.2). 
Feigenbaum (loc. cit., pp. 237 - 238) considers the 
communication of quality policy to be a valuable 
instrument whereby management can emphasise quality as 
being an 
with which 
individual 
important strategic 
to highlight the 
attitudes, knowledge 
business concept, and 
vital role played by 
and skills in the 
achievement of the corporate quality objective. 
5.10 ORGANISING FOR QUALITY 
In order to attain the objectives identified by its 
quality policy, it is necessary for management to 
co-ordinate the actions of people, machines and infor-
mation flow across all functional boundaries within 
the enterprise. Feigenbaum (ibid., p. 149) bases 
the development of such an organisational framework on 
three considerations: Firstly, the identification of 
key organisationwide quality responsibilities and 
authorities; secondly, the identification of the key 
quality control responsibilities and authorities of 
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the quality control function itself; and thirdly, the 
leadership role of management in the establishment and 
maintenance of a quality organisation. A discussion 
of these aspects, as they relate to pharmaceutical 
manufacture, follows. 
5.10.1 Key Organisationwide 
Authorities 
Quality Responsibilities and 
The MBRl registration dossier (see Section 3.6) may be 
viewed as a valuable guideline regarding certain 
primary quality responsibilities of the product 
engineering function. These responsibilities would 
for example relate to the original product design or 
formulation as detailed under Annexure 2 of the MBRl 
dossier (see Section 3.6.3); the establishment of 
specifications for raw materials, final containers, 
and finished product as detailed under Annexures 4, 7A 
and -8A of the MBRl dossier (see Sections 3.6.7, 3.6.10 
and 3.6.12 respectively); the determination of 
product stability under anticipated conditions of use, 
as detailed under Annexure 10 of the MBRl dossier (see 
Section 3.6.16); pre-clinical and clinical studies to 
demonstrate the safety and therapeutic efficacy of the 
proposed product design, as detailed under Annexures 
14A to 15C of the MBRl dossier (see Sections 3.6.20 to 
3.6.24); obtaining and collating experimental data 
relating to the pharmaceutical and biological avail-
ability characteristics of the product in support of 
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the claims made with regard to product safety and 
efficacy, as detailed under Annexure 13 of the MBRl 
dossier (see Section 3.6.19); and establishing and 
maintaining all working documents relating to product 
development, as summarised under Annexure 16 of the 
MBRI dossier (see Section 3.6.25). 
Similarly, current good manufacturing practice (GMP) 
guidelines may be viewed as providing valuable guide-
lines concerning certain of the primary quality 
responsibilities of the production engineering func-
tion. For example, the selection of suitable proces-
sing equipment; the establishment of optimum environ-
mental conditions for the manufacturing process; the 
planned maintenance of production equipment and facili-
ties; the establishment of step-by-step operating 
instructions for each item of equipment; the estab-
lishment of step-by-step processing in~tructions; and 
the -establishment of the necessary in-process con-
trols, are aspects of pharmaceutical production that 
are specifically addressed in current GMP guidelines. 
It may 
latory 
quality 
therefore be concluded that the current regu-
control system identifies many of the key 
responsibilities associated with pharma-
ceutical production. 
specifically address 
identification of key 
However, this system does not 
the formal organisationwide 
quality responsibilities and 
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authorities and can at best be considered to provide 
certain basic guidelines 
important to note that 
in this regard. It is also 
the South African regulatory 
control system is prescriptive only with regard to 
minimum quality requirements, and that the onus is 
therefore on the industry to take any additional steps 
that it may deem necessary to assure product quality 
(see Snyman, 1972, pp. 280 287). The use of a 
relationship chart in conjunction with a product's 
MBRl dossier, the relevant process flow diagram, and 
the organogram of the plant concerned, may be a 
particularly valuable technique in this regard. 
5.10.2 Key Responsibilities of the Quality Control Function 
Feigenbaum (loc. cit., pp. 159 160) is of the 
opinion that, in terms of the modern quality manage-
ment concept, two basic authorities should be assigned 
to the quality control function; namely to fulfil a 
leadership role in the attainment of the company 
quality objectives and, secondly, to assist in 
assuring optimum quality costs for the company's 
products. In order to accomplish this, he is of the 
opinion that three principal responsibilities must be 
assigned to the quality control function; namely a 
business responsibility, a systems responsibility, and 
a technical responsibility. From the discussion of 
the conceptual evolution of quality control in the 
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pharmaceutical industry (see Section 5.6) it may be 
concluded that, in terms of current good manufacturing 
practice principles, the quality control function is 
assigned technical quality responsibility only. A 
discussion of the main features of the approach 
suggested by Feigenbaum follows. 
5.10.2.1 The Business Responsibility of the Quality Control 
Function 
According to Feigenbaum (ibid., pp. 17-19), the 
principal characteristic of orienting quality as a 
primary business strategy is that the quality control 
programme must foster sound business growth. It must 
be structured explicitly and measurably so as to con-
tribute to business profitability, and to provide a 
major competitive advantage to the company. 
Current good 
South African 
manufacturing 
phamaceutical 
practices applied by the 
industry (see Chapter 4) 
do not focus on aspects such as efficient operations 
management systems, ongoing productivity enhancement, 
and quality cost management for instance. This 
approach to quality instead centres around a desire to 
comply with the legal and regulatory requirements 
pertaining to the pharmaceutical industry. In terms 
of the total quality concept, on the other hand, the 
quality control function must make a direct contri-
bution to strategic business planning as part of its 
business responsibility (see Feigenbaum, ibid., p. 
160). 
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5.10.2.2 The Systems Responsibility of the Quality Control 
Function 
In terms of the total quality concept the quality con-
trol function provides 'the primary leadership for the 
rational structuring of effective people; machine; 
and information quality systems, as well as the admin-
istrative process of assuring the effective and 
improved operation of the quality system. In other 
words, in terms of the total quality approach, the 
quality control function is given the responsibility 
for leading the integrated quality activities through-
out the organisation (see Feigenbaum, ibid., pp. 84 
- 85, and p. 160). 
It is noted in Chapter 4 of this dissertation that 
current good manufacturing practice (GMP) principles 
are generally silent with regard to the systems 
responsibility of the quality control function in the 
pharmaceutical industry (see Section 4.6.9.2). More-
over, whereas GMP principles are by definition limited 
in scope to the production function only, the systems 
responsibilities assigned to the quality control 
function in terms of the total quality philosophy 
emphasises the need for a co-ordinated, organisation 
-wide approach to quality management during the entire 
industrial cycle. 
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5.10.2.3 The Technical Responsibility of the Quality Control 
Function 
In terms of current good manufacturing practice prin-
ciples, the various functions of the quality control 
department relate primarily to inspection and test 
procedures (see Section 4.2.3). The current regula-
tory control system requires that the technical 
quality responsibilities of the quality control 
function must include the following aspects: 
i) Development of the raw material control procedures 
that have to be carried out to determine whether or 
not raw materials comply with the relevant specifi-
cation parameters. These procedures may be of an 
analytical or technical nature, full details of which 
must be disclosed under Annexure 5 of the MRBl 
registration dossier (see Section 3.6.8). 
ii) Determination of those control procedures that are to 
be carried out on raw materials as a batch to batch 
release 
disclosed 
Section 
that are 
(supra) 
requirement, details of which must be 
under Annexure 6 of the MBRl dossier (see 
3.6.9). These are the tests and procedures 
from those listed under Annexure 5 
to 
selected 
be used as a raw material batch release 
requirement. 
-262-
iii) Development of the final product control procedures 
that have to be carried out to verify compliance with 
the final product specifications, and which are 
disclosed under Annexure 7B of the MBRl dossier (see 
Section 3.6.11). 
iv) Determination of those control procedures that are to 
be carried out as a lot release requirement for the 
final product, as detailed under Annexure 9A of the 
MBRl dossier (see Section 3.6.14). 
v) Development of the control procedures that are to be 
applied to the container which is in direct contact 
with the product, to verify compliance with container 
specifications. These control procedures are de-
scribed under Annexure 8B of the MBRl dossier (see 
Section 3.6.13). 
vi) Determination of the specific control procedures that 
are to be carried out as a lot release requirement for 
final container supplies, as detailed under Annexure 
9B of the MBR 1 dossier (see Section 4.6.15). 
vii) Establishment of the in-process controls which are to 
be performed during manufacturing and packaging opera-
tions, as detailed under Annexure 11 of the MBR 1 
dossier (see Section 3.6.17). 
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From the literature it may therefore be concluded that 
both the total quality approach as well as the current 
pharmaceutical regulatory control system recognise the 
technical responsibility of the quality control func-
tion. The difference between these two approaches 
however lies in the fact that, in terms of the total 
quality concept, this is not considered to be the only 
function of the quality control department (see 
Feigenbaum, ibid., p. 149). 
5.10.3 The leadership role of management 
Mortiboys (loc. cit., pp. 33-43) succinctly states 
that quality management starts at board level; all 
directors and managers must therefore be committed to 
effective leadership and cost-effective qaulity 
management. The changes which must be made to 
traditional managerial structures are so fundamental 
and far-reaching, that they cannot be made simply by 
the adoption of new techniques or by working harder. 
Nor will it suffice to appoint or designate a single 
person or group to manage quality as part of the 
traditional managerial structure. It is in fact 
necessary to create a new organisational culture, and 
the board must take the lead in its establishment. 
Executives need to change their management style from 
that of maintaining personal control (i.e. reacting to 
events as and when they occur), and "fire- fighting" 
(i.e. forever trying to rectify what has gone wrong), 
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to that of "planning to the job right first time". 
The objective of cost-effective quality management is 
achieved when every employee (including top 
management) does his job right the first time. 
According to Mortiboys (ibid., pp. 37-38), the imple-
mentation of a management style which is based upon 
evaluation and planning to do the job right the first 
time will involve four activities: 
(i) Identifying the situation to be managed, and clearly 
defining management's 
in Section 5.9 to 
objectives as part 
formulation. 
objectives. Reference was made 
the clear delineation of quality 
of the process of quality policy 
(ii) Planning the achievement of these objectives by 
identifying and providing the necessary resources; 
communicating the plan; and obtaining the commitment 
of all concerned. Feigenbaum (lac. cit., pp. 160 -
161) considers the quality organisational structure to 
be the conduit along which the formally documented 
quality policy of management is achieved in practice. 
It enables the communication of quality responsi-
bilities to all employees; the identification of the 
principal areas of teamwork and co-operation; and the 
co-ordination of companywide and plantwide quality 
relationships between individuals and groups. 
(iii) 
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Implementing the plan 
Mortiboys (loc. cit., 
and monitoring its progress. 
p.41) notes that appropriate 
information should not only be passed down through the 
organisational structure, but that employees should 
also be encouraged to pass information up through that 
structure. Badiru (1990, pp. 33 - 36) emphasises the 
value of communication, co-operation and co-ordination 
as being fundamental to the total quality concept. 
(iv) Taking corrective action when necessary, either by 
helping people to perform better; by modifying the 
plan; or even by changing the objectives where 
appropriate. The accent is therefore upon the 
continuous improvement of quality standards. 
From the literature it may therefore be concluded 
that, in terms of the total quality concept, top 
management is required to be actively and continuously 
involved in guiding the quality efforts of all employ-
ees. The commitment to quality by top management is 
expressed in terms of a formal quality policy which is 
communicated to all functionaries within the enter-
prise, and also to vendors and customers outside the 
enterprise. Moreover, rather than seeking to provide 
a "checklist" of quality control principles (i.e. a 
so-called "cookbook-approach" to quality control), top 
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management is required to seek the active and construc-
tive participation of all employees to continually im-
prove their quality efforts. The positive feedforward 
and feedback of quality-related information, within 
the parameters delineated by the quality policy, is an 
essential component of this process of continuous 
improvement. 
5.12 SUMMARY 
A review of the literature relating to the total 
quality concept reveals a number of quality management 
principles which may be applied within the framework 
of regulatory controls pertaining to the pharma-
ceutical industry. It is concluded that the total 
quality approach may be considered to be a valuable 
adjunct to the current pharmaceutical regulatory 
control system particularly in the following areas: 
(i) Defining quality and the control of quality. The 
total quality concept defines quality not only in 
technical terms (i.e. adherence to specifications), 
but also in terms of consumer satisfaction (i.e. the 
satisfaction of consumer needs). Quality is further-
more defined to include related parameters such as 
safety, reliability, durability and effectiveness. 
The total quality philosophy also views quality to be 
affected at every stage of the industrial cycle, not 
just the production stage. 
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The business economic approach to the quality concept 
presented in Section 5.3 differs in all the above 
respects 
regulatory 
regulatory 
concluded 
from the approach inherent in the current 
control system. From the discussion of the 
perspective· in Section 4.2 it may be 
that this approach to quality and quality 
control is limited to technical aspects only, and that 
good manufacturing practice principles are limited by 
definition to the production phase of the industrial 
cycle. 
(ii) The strategic business value of quality. Quality is 
today a crucial determinant for business success or 
failure in modern performance-orientated markets (see 
Section 5.2). In terms of the total quality concept, 
top management will resolutely pursue a quality policy 
aimed at maximising the benefits that may be achieved 
from a quality control programme. These benefits are 
of a strategic business nature and include the improve-
ment of the enterprise's competitive position, in-
creased productivity, and increased profitability. 
This approach may be contrasted with the requirements 
of the current regulatory control system which dis-
regards the strategic value of quality. Regulatory 
requirements relate exclusively to the adherence by 
the enterprise to certain technical aspects of quality 
control as a pre-condition to manufacturing and 
(iii) 
(iv) 
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marketing authorisation. Adherence to these require-
ments are therefore conditional to the enterprise 
gaining access to a particular market; under these 
circumstances, the strategic business value of quality 
is of a purely coincidental nature. 
The conceptual evolution of quality control. The 
total quality concept emphasises the need for defect 
prevention as apposed to an emphasis on defect detec-
tion, such as that which is inherent in the current 
regulatory control system. Moreover, the total 
quality concept emphasises the organisationwide scope 
of quality management, whereas current good pharma-
ceutical manufacturing practice principles in 
particular are technically oriented and relate 
primarily to the production function only (see Section 
5.6) 
The leadership role of management. The evolution of 
quality control in the pharmaceutical industry may be 
said to have been largely "disaster-driven" (see 
Section 5.6). The commitment to quality by top manage-
ment under these circumstances may consequently be 
expected to be dominated by considerations related to 
compliance with regulatory requirements, rather than a 
market orientation or the need for optimum resource 
utilisation. In terms of the total quality approach, 
on the other hand, it is considered necessary for top 
management to take the lead in the active creation of 
a new organisational culture of "doing the job right 
the first time (see Section 5.10.3). 
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Moreover, in terms of the total quality concept, 
management must actively control quality just as it 
controls any other function of the enterprise. This 
would involve the delegation of quality responsi-
bilities and authorities throughout the enterprise 
while retaining the means of assuring that the results 
achieved match the standards required (see Section 
5.4). This viewpoint contrasts with that found in the 
technical literature; namely that control consists of 
individual (not necessarily interrelated) technical 
functions. 
(v) Formulation of quality policy. The current regulatory 
(vi) 
control system provides an incomplete framework for 
quality policy formulation in certain critical areas; 
it places emphasis only on the identification of tech-
nical quality-related problems and their physical 
analysis. current GMP principles emphasise the docu-
-
mentation of quality policy insofar as the use of 
policies, procedures and instructions are concerned; 
however, these working documents relate mainly to 
tactical decision making and not to strategic quality 
decision making (see Section 5.9). 
Organising for quality. The current regulatory 
control system does not specifically address the 
formal identification of key quality responsibilities 
and authorities; it only provides certain basic 
(vii) 
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guidelines in this regard. Use of a relationship 
chart together with the relevant MBR 1 product 
registration dossier and the process flow diagram of 
the manufacturing plant, may be a useful technique in 
this regard (see Section ·s.10). 
Integration of the quality control system into produc-
tion control systems. The total quality concept forms 
an integral part of modern production control systems 
such as just in time (JIT), material requirements 
planning (MRP), or Synchro-MRP (see Section 5.7). 
Current good manufacturing practice (GMP) principles, 
which are considered to be the benchmark against which 
pharmaceutical quality control systems are to be 
measured, are exclusively technically oriented and 
consequently of limited use from a quality management 
perspective (see Chapter 4). 
(viii) Quality cost management. The only criteria applied in 
the current regulatory control system relate to 
product safety, quality and therapeutic efficacy (see 
Section 3.3); the system does not focus on quality 
cost management. Moreover, the inspection and test 
approach to quality control which is inherent in 
current GMP principles typically emphasises 
expenditure on appraisal costs, rather than prevention 
costs, thereby ignoring the effect on the total cost 
of quality. The total quality concept, on the other 
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hand, emphasises the value of expenditure on preven-
tion (rather than appraisal) activities in terms of 
the reduction of the total cost of quality. In terms 
of this approach quality costs are viewed to be an 
investment, rather than an expense (see Section 5.8) 
The relevance of these aspects to the control of 
quality in the pharmaceutical industry were tested by 
means of a survey questionnaire. The results of this 
research are summarised in Chapter 6. 
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CHAPTER SIX: THE RESEARCH METHODOLOGY, RESULTS AND CONCLUSIONS 
6.1 GENERAL 
A review of the literature reveals several quality manage-
ment principles which could find general application 
within the pharmaceutical industry. These principles 
relate to a specific approach to quality and quality 
management; the strategic business value of quality; the 
leadership role of management; the formulation of quality 
policy; organising for quality; the integration of produc-
tion and quality control systems; and quality cost manage-
ment (see Chapter 5). The relevance of these quality 
management principles to the pharmaceutical industry was 
tested by means of structured interviews with individual 
pharmaceutical companies. 
6.2 DEVELOPMENT OF THE QUESTIONNAIRE 
A structured questionnaire was developed for use during 
personal interviews with randomly selected pharmaceutical 
companies in the Cape Province and Transvaal. Both open-
ended and structured questions were used. Where neces-
sary, prompts were included as an aid to clarifying the 
questions asked. The questionnaire (see Annexure 1) 
consists qf the following sections: 
6.2.1 
6.2.2 
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A company profile 
This section is designed to capture information required 
with a view to possible future contact with the company 
concerned. Data relating to ownership, organisational 
structure, size and product mix were captured with a view 
to establishing possible links between these aspects and 
the company's approach to quality. The company's wishes 
regarding the feedback of research results and the main-
tenance of confidentiality due to the possibly sensitive 
nature of data obtained during the interview, were also 
recorded in this section of the questionnaire. 
The company's guality philosophy 
This section contains six questions which are designed to 
test the company's approach to quality and quality manage-
ment, against the background of current regulatory 
requirements in this regard. These questions are struc-
tured as follows: 
(i) "What is the purpose of your company's quality assurance 
system?" This open-ended question is intended to deter-
mine whether the respondent would focus on technical; 
regulatory; and/or strategic business factors. 
(ii) "How would you define product quality?" This open-ended 
question is intended to determine whether the respondent 
would focus on technical and regulatory aspects, or 
aspects relating primarily to the final consumer. 
(iii) 
(iv) 
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"Who takes final responsibility for product quality in 
your company?" This open-ended question is intended to 
test for a ·functional; regulatory; or total quality 
orientation to quality management. 
"Do you apply the same quality assurance system to 
registered and unregistered products?" This structured 
question is aimed specifically at those companies whose 
product mix includes registerable products (i.e. products 
which by law are subject to regulatory controls) and 
unregistered products (such as cosmetics and health foods) 
which are not subject to the same controls. The question 
is intended to test for parallel standards in the quality 
control systems that are applied to registered and 
unregistered products, i.e. a quality commitment dictated 
by regulatory requirements rather than a genuine 
conviction on the part of top management. 
(v) "Does the scope of your quality assurance system differ 
from that of GMP principles?" This structured question 
is intended to determine whether or not the respondent 
supports the viewpoint found in the technical literature 
that good manufacturing practice (GMP) principles 
represent the ultimate framework for a modern pharma-
ceutical quality assurance system, in terms of an 
organisationwide scope 
industrial cycle. 
and in terms of the entire 
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(vi) ''Do you see the quality improvement process as being 
separate from the quality control activity?" 
6.2.3 
This structured question is intended to test the 
respondent's support for the business economic viewpoint 
that quality should be actively managed just as any other 
function of the enterprise (i.e. quality improvement 
efforts should be integrated with other organisational 
improvement activities), and that the quality improvement 
process should not be driven only by defects detected by 
inspection and test activities. 
The company's quality policy 
This section of the questionnaire contains seven questions 
which are designed to test the respondent's approach to 
quality policy formulation, communication, and revision. 
These questions are structured as follows: 
( i) "Does your company have a quality pol icy?" This 
structured question is intended to distinguish between 
those companies who have a formal quality policy and those 
who do not. 
(ii) Is the company's quality policy statement available in 
writing?" This open-ended question is intended to 
determine the availability and format of the company's 
quality policy statement. 
(iii) 
-276-
"Who finally approves the company's quality policy?" 
This open-ended question is intended to determine the 
managerial level at which the company's quality policy is 
initiated. 
(iv) "How is your company's quality policy communicated?" 
This open-ended question is intended to determine the 
nature of the internal and external communication routes 
used by management to communicate company quality policy. 
(v) "When formulating or revising your quality policy, do you 
identify quality-related decisions at each step of the 
industrial cycle?" This open-ended question is intended 
to determine whether or not the company adopts a multi-
functional, organisationwide approach to quality policy 
formulation and revision in which specific functional 
areas of application are identified and quality 
responsibilities assigned. 
(vi) "When formulating or revising your quality policy, do you 
identify and analyse quality-related problems that may be 
or have been experienced during the entire industrial 
cycle?" This open-ended question is intended to test for 
a multi-functional approach which incorporates the entire 
industrial cycle and which includes a structured approach 
to the possible need to adapt quality policy guidelines. 
(vii) 
6.2.4 
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"How frequently do you revise your quality policy?" 
This structured question is intended to give an indication 
of the company's commitment to the quality improvement 
process. 
Organising for quality 
This section of the questionnaire contains three questions 
that are designed to test the respondent's approach to 
creating the organisational structure needed to implement 
the company's quality policy. These questions are 
structured as follows: 
(i) "How do you identify the key organisationwide quality 
responsiblities and authorities in your company?" This 
question is designed to test for the use of regulatory 
guidelines, the process flow diagram, the company 
organogram, or any other aspect that could possibly be 
used in a relationship chart to identify key organisation-
wide quality responsibilities and authorities within a 
pharmaceutical company. 
(ii) "How are your personnel, marketing and finance depart-
ments involved in your quality assurance system?" This 
question is designed to test the extent of the organi-
sationwide integration of the quality effort. 
(iii) 
6.2.5 
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"What key responsibilities have been formally delegated 
to the quality control function in your organisation?" 
This open-ended question is designed to determine the 
extent to which technical responsibilities; systems 
responsibility; and/or ·a business responsibility has been 
formally delegated to the quality control (or quality 
assurance) function of the enterprise. 
Production control 
This section of the questionnaire contains four questions 
that are designed to determine the suitability of just-in-
time (JIT) and materials requirements planning (MRP) 
production control systems to pharmaceutical production, 
with specific reference to the contribution made to the 
assurance of product quality. These questions are 
structured as follows: 
-(i) "Does your company apply JIT principles of production 
control?" This structured question is designed to 
determine the compatibility of JIT principles with 
pharmaceutical production. 
(ii) ''Do you see a connection between JIT principles and your 
quality assurance system?" This open-ended question is 
intended to determine whether or not JIT is seen as more 
than just an inventory management system. 
(iii) 
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''Does your company use an MRP system of production 
planning and control?" This structured question is 
intended to determine the compatibility of the MRPI,II or 
III systems with pharmaceutical production. 
(iv) "Does the MRP system complement your quality assurance 
system in any way?" This open-ended question is designed 
to determine whether or not the MRP system is seen as a 
production planning and control tool only; and in 
particular wether or not a degree of synergy is seen to 
exist between MRP and JIT by those companies who make use 
of both systems, with specific reference to the quality 
assurance effort. 
6.2.6 Quality costs 
This section of the questionnaire contains five questions 
that are designed to determine the nature and extent of 
quality cost management in the pharmaceutical industry. 
These questions are structured as follows: 
(i) ''Do you measure and report quality costs?" This 
structured question is intended to test for the presence 
of a formal quality cost measurement and reporting system. 
(ii) "What cost categories or cost elements have you defined?" 
This open-ended question is designed to determine the 
nature of the quality cost categories used to collect 
(iii) 
(iv) 
(v) 
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quality cost data, and in particular to determine the 
level of sophistication in distinguishing between quality 
costs and production costs. 
"Who receives the quality cost reports?" This open-
ended question is intended to determine the managerial 
level of involvement and organisationwide scope of the 
quality cost management system. 
"Who decides to take action on quality costs when this 
becomes necessary?" This open-ended question is intended 
to determine the managerial level of involvement in the 
quality cost management system. 
"What percentage of total sales is attributable to total 
quality costs in your company?" This structured question 
is intended to gather empirical data concerning individual 
companies for possible comparison on an industry-wide 
basis. 
6.3 THE RESEARCH METHODOLOGY 
The Register of Pharmacies prepared by the South African 
Pharmacy council (1993) was used to identify the names and 
addresses of 
South Africa. 
pharmaceutical manufacturing facilities in 
For logistical reasons, only companies 
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situated in the Cape Province and Transvaal were 
considered for the purposes of the survey. With the help 
of the Directorate 
the Department of 
selected list was 
Medicines Control and Registration of 
Health (van Heerden, 1994) a randomly 
made of companies who own their own 
manufacturing facilities, and who design, manufacture and 
distribute their own products. 
A mailing list of 29 companies was thus compiled; nine of 
these companies are situated in the Cape Province and 
twenty companies in the Transvaal. A letter requesting an 
hour-long interview was addressed to the quality assurance 
manager of each of these companies, together with a reply-
paid form for indicating the willingness of the company to 
participate in the research as well as a date and time for 
the proposed interview. 
Twenty-two replies were received, nineteen of which were 
positive, two negative, and one which was positive but 
which arrived too late to be included in the sample. 
Seven companies did not respond to the request .for an 
interview. Of the nineteen companies who indicated their 
willingness to participate in the research, four were 
situated in the Eastern Cape, four in the Western Cape, 
and eleven in the Transvaal. All appointments were 
confirmed telephonically. 
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Each interview was conducted according to the structured 
questionnaire described in Section 6.2. The prompts 
included in the questionnaire (see Annexure 1) were used 
where necessary to clarify the relevant question or to 
elicit a response on an aspect not covered in the repon-
dent' s reply. The entire interview was recorded on audio 
tape. 
Each audio tape was transcribed by summarising the respon-
dent's replies. Where prompts were used, this was 
indicated when noting the respondent's reply. In view of 
the fact that every company interviewed pref erred the data 
gathered during the interview to be treated as 
confidential, the participating companies were coded 
alphabetically ( i. e Company "A" to "S") and the different 
fields under each section of the questionnaire were coded 
numerically. Information not readily obtainable during 
the interview, or the release of which had first to be 
cleared with top management, was forwarded by post and 
included in the summary of results upon receipt {e.g. 
extracts from quality manuals). 
6.4 THE RESEARCH RESULTS AND THEIR ANALYSIS 
The following is a summary of the results obtained with 
the use of the survey questionnaire described in Section 
6.2: 
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6.4.1 The company's approach to quality 
The following aspects were researched: 
6.4.1.1 The purpose of the company's quality assurance system 
The majority of respondents (nine) consider the purpose of 
their quality assurance systems to be the assurance that 
the finished product will conform to specifications, or 
will comply with regulatory or ethical requirements. How-
ever, a significant number of respondents (eight) consider 
the purpose of their quality assurance systems to be 
consumer-oriented. Terms such as consumer safety, 
consumer needs and fitness for use criteria were 
considered important in this regard. More- over, four of 
the latter companies see a direct link between their 
quality assurance systems and strategic factors such as 
profitability and risk management (lia- bility exposure) 
in particular. 
6.4.1.2 The definition of product quality 
The majority of respondents (fourteen) defined quality in 
terms of a consumer-orientation. Aspects such as assuring 
consumer satisfaction, satisfying consumer needs, assuring 
consumer safety and fitness for use or conformance to 
specifications as judged by the consumer, were highlighted 
in this regard. Five of the companies who defined the 
purpose of their quality assurance system in technical 
terms (see Section 6.4.1.1), defined product quality in 
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terms of a consumer-orientation. Only four of the respon-
dents defined quality in terms of a technical of 
regulatory orientation (e.g. conformance to specifi-
cations, as determined by the MBRl product registration 
dossier). 
6.4.1.3 Responsibility for product quality 
One respondent stated that responsibility for product 
quality is vested exclusively in the company's board of 
directors. Nine respondents nominated specific members of 
their company's board of directors as being ultimately 
responsible for product quality; four of these nominated 
the chief executive officer as being the responsible 
person; four respondents named the managing director; and 
one respondent named the company medical director. Eight 
respondents stated that the quality assurance manager 
assumes responsibility for product quality, although three 
of these respondents saw this as being a delegated respon-
sibility with ultimate responsibility being vested in the 
company board of directors, and another three respondents 
saw this as being the situation in practice, whereas the 
managing director assumes legal responsibility for product 
quality in terms of current legislation. One respondent 
vests responsibility for product quality with a "quality 
surveillance 
the managing 
the head of 
committee" consisting of the divisional head, 
director, the quality assurance manager and 
the medical division; this committee reports 
directly to corporate headquarters (overseas). 
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6.4.1.4 The application of parallel systems of quality assurance 
All but five of the companies interviewed manufacture both 
registered products (i.e. products subject to the pharma-
ceutical regulatory control system), and unregistered 
(i.e. products not subject to those regulatory products 
controls). Unregistered products thus manufactured 
cosmetics (nine companies); health foods and 
(six companies); veterinary products (four 
companies); medicated animal feeds (one company); and 
include 
vitamins 
toiletries, pulp products, adhesives and woven products 
(one company) . 
Each of the companies who manufactures both registered and 
unregistered products, applies exactly the same quality 
assurance system to both types of product. In most cases 
specifications are, however, not as extensive as is the 
case with registered pharmaceutical products. Some of the 
reasons given for not applying parallel systems of quality 
control to registered and unregistered products include 
the need to "keep employees focussed" on a specific 
system; to prevent possible confusion between differing 
quality assurance procedures; to prevent "corruption of 
the standard set"; and to give the "same level of 
confidence" in all products produced. 
6.4.1.5 The scope of the quality assurance system 
Only six respondents were of the opinion that the scope of 
their quality assurance (QA) systems differed from that of 
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pharmaceutical good manufacturing practice principles 
(GMP). Thirteen respondents stated that there was no 
difference in the scope of their QA systems and GMP 
principles; one of these respondents stated that a QA 
system reinforces GMP .but does not broaden its scope; 
others 
other 
stated that the one 
and that they differed 
is "part and parcel" of the 
from one another only in 
respect of a few minor (technical) details. 
Of the six respondents who did see a difference in scope 
between the concepts of QA and GMP, all agreed that a QA 
system was broader in scope both in terms of its organi-
sationwide purview and its application to the entire 
industrial cycle. Eleven of the thirteen respondents who 
initially equated the scope of their QA systems to GMP 
principles conceded that their QA systems were in fact 
broader in scope, once prompted. Two of these thirteen 
respondents would, however, not agree with the suggestion 
that- GMP principles were limited in scope to mainly the 
production function only. 
6.4.1.6 Management of the quality improvement process 
Twelve respondents were of the opinion that the quality 
improvement process is 
control activity; five 
indeed separate from the quality 
respondents stated that this was 
not the 
regard. 
case; and two respondents had no opinion in this 
Of the above-mentioned twelve respondents who 
6.4.2 
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conduct a separate quality improvement programme, four 
stated that top management had no involvement in the 
programme which was being driven at a middle management 
multidisciplinary (technical) level (three respondents) or 
at a supervisory/department head level (one respondent). 
Eight of the respondents who conduct a separate quality 
improvement programme stated that top management was 
directly involved in this. This involvement came either 
directly from the chief executive officer or board of 
directors. A number of these companies gave specific 
names to their quality improvement programmes, such as 
"(Company) Team Excellence," "Green Areas," "The (Company) 
Way," and the "Simply Better" programme. Many of these 
programmes had been established with the help of outside 
consultants or with the help of corporate headquarters. 
Multinational companies, however, do not always receive 
such support from corporate headquarters; one 
(multinational) respondent stated that top (corporate) 
management did not always give the same status to quality 
as they did to other functions of the enterprise. This 
problem had been recognised in this particular company and 
is being addressed at present. 
The company's quality policy 
The following aspects were researched: 
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6.4.2.1 The existence of a quality policy 
All the respondents interviewed stated that their company 
does have a quality policy. 
6.4.2.2 The existence of a written quality policy 
Thirteen of the nineteen respondents interviewed indicated 
that their company quality policies are available in 
writing. However, a number of the documents examined 
could better be described as mission statements, with no 
direct link to quality policies and procedures. 
Six of the nineteen respondents interviewed indicated that 
their quality policies were not immediately available in 
writing; for the purpose of this research, these documents 
were considered 
of reference. 
to be unavailable as an immediate source 
Two of these six respondents referred to 
policy as being based on an informal their quality 
understanding amongst management. 
6.4.2.3 Final approval of the company's quality policy 
Sixteen 
company 
chief 
of the 
of the 
quality 
nineteen respondents stated that their 
policy had been finally approved by their 
executive officer and/or board of directors. Four 
multinational companies interviewed, stated that 
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their chief executive officer was located overseas at the 
corporate headquarters. One of the nineteen respondents 
stated that the managing director approved company quality 
policy without the board of directors being involved. Two 
of the nineteen respon.dents interviewed have no formal 
quality policy (see section 6.4.2.2); for the purposes of 
this research this question was considered not to be 
applicable to these companies. 
6.4.2.4 Communication of the company's quality policy 
Seven of the nineteen respondents interviewed either do 
not communicate company quality policy externally or did 
not ref er to such external communication in their response 
to the question (see Section 6.2.3.4). Three of the 
nineteen respondents stated that no deliberate attempt was 
being made to incorporate a quality message into advertise-
ments and/or public relations communications. Nine of the 
nineteen respondents interviewed stated that they did 
actively communicate quality policy outside of the company 
through advertising and/or public relations communica-
tions; follow-up on customer surveys; guided tours of the 
plant; and formal vendor contact programmes. 
Seventeen of the nineteen respondents interviewed stated 
that they do communicate their quality policy internally; 
most respondents mentioned verbal and written internal 
communications (mainly standard operating procedures), and 
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training programmes, as being the methods used. Formal 
internal communications programmes, that promote teamwork 
and a collective approach to quality authorities and 
responsibilities, were also mentioned as being methods 
employed in this regard. One respondent saw internal 
auditing programmes to be an important medium for 
communicating quality policy within the company, whereas 
two respondents ref erred to the display of mission 
statements on company noticeboards as being important in 
this regard. 
6.4.2.5 Identifying quality-related decisions 
The majority of respondents (eleven) indicated that a 
multifunctional approach is used to identify quality-
related decisions at each step of the industrial cycle 
during the formulation or revision of quality policy. In 
one of the companies interviewed, this process would for 
instance involve a formal review by a technical committee 
composed of managers from the quality assurance; produc-
tion; product development; engineering; information 
systems; distribution; and safety and security depart-
ments. In another company, all aspects relating to the 
product's industrial cycle are summarised in a "product 
fact file", which is then circularised to every functional 
department for comment and formal approval or change to 
the existing quality policy. 
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In contrast to this mainly technical approach to quality 
policy formulation or revision, one company stated that 
its entire board of directors is involved in this 
process. The quality assurance manager of this company is 
also a member of the board. The board's first step would 
be to determine wether or not quality objectives have 
changed or need to be changed; whether the organisational 
structure and the assignment of responsiblities have 
changed; verification of the resources available; the 
assesment of internal quality audit results; and 
ammendments introduced or requested by the regulatory 
control authorities. Moreover, the review will include 
the quality system in general and control procedures; 
third party contract reviews; a product design review; 
document reviews; document (change) modification; environ-
mental controls; and equipment qualification. All 
(sterile) manufacturing processes are validated twice a 
year; any changes to be made are submitted to the board 
for formal approval. 
6.4.2.6 Identifying and analysing quality-related problems 
The respondents interviewed appeared to be better attuned 
to formally responding to quality-related problems than to 
the formal identification of quality-related decisions 
during the entire industrial cycle. Fifteen of the nine-
teen respondents stated that quality-related problems were 
reviewed by means of a structured multifunctional system, 
whereas eleven respondents indicated that such an approach 
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was used to identify quality-related decisions (see 
Section 6.4.2.5). Two companies stated that they have no 
formal guidelines for analysing quality-related problems, 
but relied instead on personal experience and regulatory 
guidelines in this regard .. 
The multifunctional approaches encountered varied from a 
mainly technical (production) emphasis to more broadly-
based (organisationwide) committees. In some companies 
the relevant failure costs are calculated and reported 
(see Section 6.4.5.1). One company mentioned that it 
relied 
history 
heavily on a very comprehensive system of product 
documentation when analysing quality-related 
such product history files consist of a record 
prototype work, including laboratory and pilot-
problems; 
of the 
scale production; the process validation protocol; equip-
ment qualification protocols; product stability trials; 
transportation and packaging trials, product complaints, 
and -all other relevant data. These data are documented 
per product, and are used when analysing problems or 
designing new products of a similar design. 
6.4.2.7 Quality policy revision intervals 
Four respondents stated that their company quality policy 
is revised at least once a year. 
dents (eleven) stated that they 
The majority of respon-
revise their quality 
policies on an ongoing basis; two of these companies 
6.4.3 
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stated that this would be done at least once in three 
years, while another one of these companies set the limit 
for revision at two years. One respondent stated that the 
policy review process would be triggered by regulatory 
requirements (e.g. upda.ting of the MBRl dossier} or by 
problems being experienced. 
The company's organisational approach to quality 
The following aspects were researched: 
6.4.3.1 Identification of quality responsibilities and authorities 
Four respondents 
ticular the MBRl 
mentioned regulatory guidelines (in par-
registration dossier} as playing an 
the identification of organisationwide 
and responsibilities. One of these 
the MBRl dossier (see section 3.6} as 
important role in 
quality authorities 
respondents 
being the 
uses the 
views 
starting 
guidelines 
point. This particular company then 
provided by the ISO 9000 system to 
identify and analyse key organisationwide areas of quality 
responsibilities and authorities throughout the entire 
industrial cycle, by making use of aids such as a compre-
hensive organogram (including detailed job descriptions} 
and process flow charts. 
Three respondents use the company organogram as the 
primary source for identifying organisationwide quality 
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responsibilities and authorities. Two respondents view 
the process flow chart as being a primary aid in this 
regard, in combination with the company organogram. One 
respondent views the "professionalism" of the pharmacist 
who is in direct control of all critical areas relating to 
quality, as being the single most important aspect in this 
regard. 
When prompted, most respondents agreed that a product MBRl 
dossier and process flow chart, together with the company 
organogram, could be used to identify the relevant organi-
sationwide quality authorities and responsibilities. One 
respondent made the interesting remark that instead of 
targeting specific key areas in this regard, his company 
prefers to adopt an approach which is based on a shared 
(organisationwide) responsibility for quality. 
Most of the respondents view the MBR1 dossier as being a 
valuable guideline regarding (the technical aspects of) 
quality assurance. Two respondents, however, pointed out 
that changes sometimes have to be made to the specif i-
cations contained in the MBRl dossier as part of the 
quality improvement process, and that the regulatory 
control system is often too slow and cumbersome to allow 
those changes to be implemented timeously thereby limiting 
the value of the MBRl dossier as a quality management 
tool. Certain changes to the MBRl dossier may only be 
made with the prior approval of the Medicines Control 
Council (MCC, 1988, Circular to applicants ref. 13/88). 
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These repondents felt that "professional decisions" should 
be given more freedom and authority in this regard. 
6.4.3.2 Multifunctional 
system 
involvement in the quality assurance 
(i) 
(ii) 
Nine of 
personnel; 
the nineteen respondents stated that their 
marketing; and finance functions were not 
formally involved in the formulation of quality policy. 
In those companies where multifunctional participation in 
problem solving and decision making does occur, it was 
found that such involvement was in most cases triggered by 
specific quality problems on an ad hoc basis. 
Three of the nineteen respondents interviewed stated that 
the organisationwide integration of their company's 
quality effort occurs at board level. Six other 
respondents ref erred to an organisationwide, multi-
disciplinary approach to quality problem solving, decision 
making and policy formulation. Many different approaches 
were encountered in this regard, including the following: 
The use of a multidisciplinary "project team" 
Formal, scheduled management meetings to discuss the 
results of internal quality audits and customer com-
plaints for instance, and to recommend quality policy 
changes where necessary. 
(iii) 
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Emphasis on multifunctional teamwork and multiskilled 
training as part of creating a new quality "culture" 
within the company aimed at achieving "world class 
supplier" status. 
(iv) A quality policy which refers to specific quality 
objectives for every individual functional department and 
all levels of management, as well as documented routines 
for the inter-functional co-ordination of activities which 
influence quality. 
(v) In terms of the management responsibilities identified 
with the aid of the ISO 9000 system, key responsibilities 
and detailed job descriptions are detailed in an 
organogram which depicts the formal integration of 
organisationwide quality responsibilities and authorities. 
6.4.3.3 The key responsibilities of the quality control function 
All of the respondents interviewed referred to the 
technical (inspection and test) responsibilities of their 
quality control function. With reference to a systems 
responsibility, the quality control function is seen by 
most respondents to play an important role in personnel 
training and internal auditing programmes. External 
audits involving vendors; the reciprocal auditing of 
different plants within the same organisation; and process 
validation programmes are also seen as being part of the 
routine systems responsibility of the quality control 
(i) 
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function by most respondents. One quality assurance 
manager stated that he has no boundaries in terms of his 
involvement with quality issues within the organisation, 
and that he routinely participates as a member of a multi-
functional team in this r.egard. 
Most respondents 
of the quality 
prompted in that 
referred to the business responsibility 
control function only after having been 
regard. Many respondents stated that 
this is an implied or informally delegated responsibility. 
Five respondents referred to management control systems 
that are used to directly or indirectly evaluate the per-
formance of the quality control function in this regard; 
these include: 
Asset management performance measurement (return on 
investment). 
(ii) Reduction in wastage due to quality-related problems. 
(iii) Achieving throughput targets (in terms of approved product 
output). 
(iv) A monthly productivity report. 
(v) Achieving targeted operating quality costs. 
(vi) Cost deviation reports. 
6.4.4 
Only one respondent referred to quality as a method of 
achieving a competitive advantage. 
The integration of quality control and production control 
systems 
The following aspects were researched: 
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6.4.4.1 The application of JIT principles of production control 
Fourteen of the nineteen respondents stated that they do 
apply just-in-time (JIT) principles; however, most of 
these respondents stateq that these principles are applied 
"selectively" in 
times associated 
order to cope with the variable lead 
with the importation of a large percen-
tage (70 per cent in one case) of starting materials from 
overseas. Another problem mentioned was that of the 
unpredictable ordering patterns of stock by large 
consumers such as government departments, which 
necessitates keeping buffer stocks of (sometimes 
strategic) finished products or raw materials. The very 
large minimum order quantities imposed by certain local 
vendors also presents a problem to some respondents, 
whereas one respondent stated that their company has been 
particularly successful in implementing a JIT programme in 
partnership with local vendors. 
The 
pl es 
majority of those respondents who do apply JIT princi-
of production control, do so in all manufacturing 
departments. These respondents manufacture a wide range 
of products, including sterile liquids and semi-solids; 
all non-sterile dosage forms; products containing poten-
tially toxic or hazardous materials such as hormones, 
penicillins and cephalosporins; and products which are un-
registered and therefore not subject to the medicines 
regulatory control system. 
None of 
duct ion 
variable 
Problems 
and the 
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the five respondents who do not apply JIT pro-
control 
master 
principles 
schedule as 
cited problems with a highly 
being the reason for this. 
with variable lead times of imported materials, 
unreliability, . as well as the very large minimum 
order quantities of certain local suppliers, were cited as 
being the main reasons for them not applying JIT prin-
ciples. Of those respondents who do apply JIT principles, 
the majority considered their variable master schedule not 
to be a problem. 
One respondent mentioned that the first five days of that 
company's production schedule is "set in concrete"; the 
next five days are however negotiable and it is during 
this period that unforseen changes will be accommodated. 
Another respondent stated that the design of highly 
flexible production lines, which allows items of equipment 
to be removed from the line and replaced as complete 
units, enables that company (a manufacturer of small 
volume parenteral products) to react to a change in master 
production schedule within 24 hours. 
6.4.4.2 The benefits of JIT production control 
Seven of the nineteen respondents either do not apply JIT 
principles or do not see a connection between JIT and 
their quality assurance system. Four of these respon-
dents stated that the main purpose of JIT is to reduce 
inventory levels. 
Twelve of 
contributing 
respondents 
JIT to the 
continuous 
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the nineteen respondents do see JIT as 
to their quality assurance systems. Most 
(seven) referred to the contribution made by 
creation of a "right first time" culture of 
improvement . within the organisation. One 
respondent stated that his company measures the success of 
their JIT system in terms of work order delivery rate (i.e 
the time elapsed between commencement of production and 
delivery of the finished product). At the time of the 
interview this company was operating at above 98 per cent 
of the forecasted work order delivery rate. 
The contribution 
vendor relations 
four respondents. 
higher levels of 
made by the JIT system towards improving 
and vendor contact was referred to by 
The motivation of vendors to aspire to 
quality, and the shifting of inspection 
and test activities from the purchaser to the supplier, 
are aspects that were highlighted in this regard. 
The rapid feedback and response to quality problems facili-
tated by a JIT system were mentioned by three respondents. 
The fact that a JIT system regulates production at a 
predetermined workrate which in turn takes the pressure 
off the inspection and test functions of the quality 
assurance system, was referred to by three respondents. 
All those respondents who were prompted, agreed that JIT 
principles contribute to improved production capacity and 
production reliability as well as all the aspects 
mentioned above. 
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6.4.4.3 The use of MRP systems for production planning and control 
Seventeen of the nineteen respondents interviewed stated 
that they employ MRPII systems for production planning and 
control, or 
back loop 
schedule). 
an annual 
a system. 
equivalent .systems (which provide for a feed-
between orders and the master production 
The two smallest companies interviewed (with 
turnover below R20 million) do not operate such 
6.4.4.4 The benefits of MRP production planning and control 
Most respondents (eight) referred to the discipline 
imposed by their MRP system as being its main contribution 
to the quality assurance system. It is felt, in particu-
lar, that the system ensures that quality is not compro-
mised due to a rushed production schedule. 
One ·respondent highlighted the fact that this discipline 
results from the fact that the system demands (right first 
time) compliance, and that it does not allow anybody to 
work outside that system. It should be noted that this 
particular company operates its MRP system on a "realtime" 
basis, and does not follow the practice of "backflushing" 
or batch processing of data, thereby enhancing the disci-
pline inherent in the system. 
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The role of an MRP system in the tracking of materials and 
yields were referred to by two respondents. One respon-
dent also saw it as an aid to the rapid identification of 
quality problems. All but one of the respondent's, when 
prompted, were of the. opinion that there is a synergy 
between their MRP and JIT systems. 
Three respondents viewed their MRP system as being 
primarily a production planning tool which has no direct 
influence on their quality assurance system; when promp-
ted, one of these respondents did however refer to the 
fact that MRP does assist the company's quality assurance 
discipline. 
When prompted about the criticism that the MRP system 
tolerates a degree of waste (contrary to the objectives of 
a quality assurance system), two respondents made the 
interesting remark that this depended on the standards 
designed into the system by the user himself. Taking 
production yield as an example, a zero-based standard 
would require a 100% yield. The system does however allow 
the user to set a budgeted yield of, say 85%, to allow for 
the unavoidable loss of product as a result of the 
flushing of transfer lines for instance, thus enabling the 
attainment of a 100% theoretical yield while in practice 
allowing for a 15% "wastage". 
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6.4.5 Quality cost management 
The following aspects were researched: 
6. 4. 5 .1 The measurement and repor.ting of guali ty costs 
Thirteen of 
that they 
the nineteen respondents interviewed stated 
do measure quality costs. One of these 
companies, which has an annual turnover of approximately 
R27 million, stated that this reporting system had been 
installed only very recently. Most companies report on 
quality costs on a monthly basis; some generate a 
quarterly trend analysis or a weekly deviation report, in 
addition to the monthly report. 
Six 
they 
of the nineteen respondents interviewed stated that 
either do not measure and report quality costs, or do 
an informal basis only. Those companies using an 
system would do so as part of the monthly 
so on 
informal 
production report or as part of the routine accounting 
system. 
6.4.5.2 Defining guality cost categories 
A wide variety of quality cost categories was encountered 
during the research. Most respondents (twelve) measure 
the cost of waste, which includes both internal and 
external failure costs (one company measures internal 
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failure costs only). Examples given include scrap, the 
cost of rework and unplanned line stoppages or machine 
downtime. 
Nine respondents cons~der the cost of product yield 
variation (i.e. the difference between actual and budgeted 
or theoretical product yield) to be part of their quality 
costs. One respondent defines a quality cost as being the 
cost of anything which does not meet the relevant standard 
set by the company i.e. the cost of non-conformance; this 
company has found the "classical" method of quality cost 
classification as suggested by Feigenbaum (1986, pp. 110-
112), to be "cumbersome" and to offer no advantage in 
terms of the information provided to management. Three 
respondents to however apply the "classical" system of 
quality cost measurement (see Section 6.4.5.5). 
One company expresses quality costs as being the differ-
ence- between the budgeted and actual costs for each cost 
category, calculated per production department. The 
"saving" 
calculated 
budgeted 
"saving" 
on internal failure costs is for instance 
as being the difference between actual and 
costs, based on historical data. Similarly, the 
on quality assurance department overheads (which 
is considered to be a quality cost) is expressed as being 
the difference between actual and budgeted expenditure. 
-305-
A considerable divergence of opinion was also encountered 
regarding the distinction between quality costs and 
production costs. One company for instance considers the 
cost of both rework and internal scrap to be production 
costs. Another company is of the opinion that all 
(quality) costs should be considered to be production 
costs. A surprisingly large number of respondents 
(eleven) view the overhead expenses of their quality 
assurance departments as being a quality cost. 
6.4.5.3 The recipients of quality cost reports 
The majority of respondents stated that company quality 
cost reports are submitted to the board of directors or 
top management (usually the chief executive officer). Some 
companies "filter" the quality cost report through tech-
nical/functional management first; in one company, for 
instance, departmental heads report to the quality 
assurance manager who then submits the report to the chief 
executive officer. In another company, the quality cost 
report (which in this case focusses on issues such as 
internal/external failures, yield variation and the 
operating costs of the quality assurance function) is 
discussed during a weekly meeting between the chief 
executive officer, the plant manager, the quality 
assurance manager, and the purchasing manager. In yet 
another company, quality cost data are discussed at a 
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technical committee meeting and also at a factory manage-
ment meeting. The financial director, who prepares the 
formal report which is submitted to top management, is a 
member of the latter committee. 
The technical director (or operations manager) also 
features prominently in the reporting structures of some 
companies. One company for instance measures "quality 
costs", but reports only "excessive" yield variation data 
to the technical director. 
6.4.5.4 Taking action regarding quality costs 
Most of the respondents stated that the company's board of 
directors or chief executive officer would decide wether 
or not to take action on quality costs. Technical 
personnel, however, feature strongly in this decision 
making process; one company for instance stated that 
either the technical manager or the chief executive 
officer would make the decision, depending on the 
seriousness of the problem at hand. Another company 
stated that the decision would be made by the managing 
director, the factory manager, and the quality assurance 
manager without the board of directors itself being 
involved. 
6.4.5.5 Quality costs as a percentage of sales 
Five of the nineteen respondents interviewed had no 
quality cost data at their disposal; another four re-
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spondents had only estimated figures available; and one 
respondent would not disclose these data for reasons of 
confidentiality. 
Due to the widely divergent cost categories and methods of 
measurement used by those respondents who do measure 
quality costs, it is not possible to make direct compari-
sons between the results obtained by each company. 
However, it may be deduced from the results obtained that 
some companies have better control over their quality 
costs than others. One company for instance calculates 
its current (total) operating quality costs to be 0,25 per 
cent of 'sales, and has set itself the objective of 
reducing this figure to 0,1 per cent (calculated as the 
total cost of non-conformance). 
Another company reports "internal failure" costs of 0,25 
per .cent and 
but -these cost 
that "external 
"external failure" costs of 0,04 per cent, 
categories are again vaguely defined in 
failure" costs are for instance calculated 
to include only goods returned to the plant due to damage 
in transit or despatch errors. This company also includes 
product yield variation in its figure of 0,25 per cent 
"internal failure" costs, whereas a number of companies 
estimate loss on yield alone to be as high as 15 to 20 per 
cent of 
overhead 
figure 
sales. Moreover, this company includes the total 
costs of its quality assurance function in the 
for "internal failure" costs, whereas another 
company puts this figure alone at 17,3 per cent of sales. 
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The above-mentioned figures of 0,25 per cent and 0,04 per 
cent therefore appear to be abnormally low, especially in 
view of the fact that the comparative figures were 
supplied by companies engaged in the manufacture of a 
similar range of products. It is therefore not possible 
to make an empirically-based conclusion in this regard, 
other than to state that some companies are either more 
accurate in the measurement of quality costs, or more 
successful in their management of quality costs, than 
others. 
Three companies (company "I", company "M", and company 
"S") were found to have employed the "classical" system of 
quality cost determination i.e. the determination of the 
cost of control and the cost of failure to control. 
However, in the case of company "I" these data had been 
collected for a period of four months only, the system 
having been introduced by the company that recently. In 
the -case of company "M", the figures quoted had been based 
on a once-off survey based on historical data. The 
figures relating to company "S" are considered to be the 
most accurate of these three companies. These figures are 
as follows: 
Company II I II "M" "S II 
Failure costs; internal: 2,5% } 3,6% } 1,7% 
Failure costs; external: 1,0% } } 
Prevention costs: 2% 1,7% 0,2% 
Appraisal costs: 6% 2,8% 3,2% 
Total as a percentage 
of sales 11,5 §.d_ iL.L 
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With reference to the composition of company "S's" (total) 
operating quality costs, it is noted that internal/exter-
nal failure costs comprise 33,3 per cent of the total; 
appraisal costs 63,3 per cent; and prevention costs 3,4 
per cent. 
6.5 THE HYPOTHESES REVIEWED 
6.5.1 
6.5.2 
6.5.3 
6.5.4 
The following hypotheses were developed from the litera-
ture, and from personal observation. 
The existing system of regulatory control will be enhanced 
by a quality management approach to the problem of 
assuring the quality of pharmaceutical products. 
The establishment of a total quality system will result in 
an operations management system superior to that provided 
by the good manufacturing practice principles currently in 
use. -
Quality management principles may be used to develop a 
structured approach to the problem of delegating quality 
authorities and responsibilities within the pharma9eutical 
industry. 
There is a need for more accurate quality cost data in the 
pharmaceutical industry. 
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6.6 THE FINDINGS REVIEWED 
6.6.1 
The survey questionnaire which is described in Section 6.2 
was used to test the practical value of a total quality 
system in the context of. the pharmaceutical industry, with 
reference to the following aspects in particular. 
The quality philosophy and its strategic implications 
The traditional quality culture in the pharmaceutical 
industry is driven by the regulatory process of product 
registration or marketing authorisation (see Chapter 3), 
and the so-called Good Manufacturing Practice (GMP) 
principles on which regulatory manufacturing authorisation 
is based (see Chapter 4). In terms of this traditional 
approach, quality is defined with reference to products 
that meet registration and compendial specifications and 
are produced according to currently accepted GMP 
principles (Kieffer & Nally, 1991, p.131). 
The traditional approach to quality and quality management 
may therefore 
the production 
design. This 
be expected to emphasise issues relating to 
function, and also the quality of product 
is confirmed by the narrow scope of GMP 
principles which by definition focus on the production 
function (see Section 4.2.2), and the emphasis placed on 
issues such as product safety and therapeutic efficacy by 
the product registration process. Pharmaceutical product 
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quality may consequently be expected to be viewed from a 
mainly technical perspective. Moreover, the industry's 
approach to quality management may be expected to be 
determined by regulatory guidelines, particularly in view 
of the legal or quasi-legal status of those guidelines 
(see Section 4.5). 
The finding 
consider the 
that the majority of respondents interviewed 
purpose of their quality assurance system to 
be the assurance that the finished product will conform to 
specifications (see Section 6.4.1.1), is consistent with 
this traditional approach to quality in the pharmaceutical 
industry. Similarly, the fi~ding that the majority of 
respondents interviewed saw no difference between the 
scope of their quality assurance systems and GMP 
principles (see Section 6.4.1.5) is consistent with this 
traditional approach. The finding that strategies for the 
external communication of quality policy are relatively 
underdeveloped (see Section 6.4.2.4) may also be related 
to a lack of appreciation of the strategic business value 
of quality, in accordance with the traditional (techni-
cally-oriented) approach to quality. 
It is, however, now being recognised even in the technical 
literature that good pharmaceutical manufacturing practice 
is attained only when technical expertise is combined with 
the necessary management skills (see Begg, 1984, pp. 
31-32). Moreover, the strategic business value of quality 
is now also being recognised in the technical literature. 
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Kieffer & Nally (loc. cit., p. 131) for instance highlight 
the pharmaceutical industry's current environment of 
global competition, rising health care costs, customer 
demand for better products and services, and the changing 
expectations of employees. They then point to the 
benefits of adopting a total quality philosophy in terms 
of enhanced customer satisfaction, better products and 
services, improved productivity, increased profits, and 
the achievement of a competitive advantage. 
This fundamental shift away from the traditional, purely 
technical, approach to quality is reflected in some of the 
results obtained during this research. For instance, a 
significant number of respondents interviewed consider the 
purpose of their quality assurance systems to be consumer-
oriented, and some of these respondents see a direct link 
between their quality assurance systems and strategic 
business factors such as profitability and risk management 
in ·particular (see Section 6.4.1.1). Moreover, the 
majority of respondents defined quality in terms of a 
customer-orientation, while only four out of nineteen 
respondents defined quality purely in terms of a technical 
or regulatory orientation (see Section 6.4.1.2). The 
majority of respondents were also of the opinion that the 
quality improvement process is separate from the quality 
control activity, and a number of companies were found to 
have implemented high profile in-house programmes in this 
regard (see Section 6.4.1.6). All those companies who 
manufacture both registered and unregistered products were 
6.6.2 
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found to apply the same quality assurance system to all 
products 
latory 
as that which is required in terms of the regu-
controls pertaining to (registered) pharmaceutical 
products (see Section 6.4.1.4). This is seen as another 
example of the current philosophical shift away from the 
traditional approach to quality and quality management in 
the pharmaceutical industry. 
Quality policy and the leadership role of management 
The majority of respondents stated that their company 
quality policies were available in writing and are revised 
on an ongoing basis. In some cases it was however 
difficult to establish a direct link between the policy 
document and quality objectives and procedures; 
particularly in cases where the policy document took the 
form of a so-called "mission statement" (see Sections 
6.4.2.1, 6.4.2.2 and 6.4.2.7). In these companies, and 
also- in those companies who do not have a written quality 
policy, no clear delineation of quality objectives exists. 
The leadership role of top management is thus only vaguely 
defined. 
Many companies were found to rely on written standard 
operating procedures and job descriptions to communicate 
quality policy internally. In cases where this communi-
cations system is based on pharmaceutical good manufactu-
ring practice (GMP) principles, the effective feedforward 
and feedback of quality information may be a problem. 
This 
which 
mainly 
than 
5.9). 
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is related to the fact that the working documents 
are created in terms of GMP requirements, relate 
to tactical (i.e day-to-day) decision making rather 
to strategic quality decision making (see Section 
This may for instance explain why many of the 
quality assurance managers interviewed cited technical, 
rather than strategic, aspects as being the rationale for 
their company's quality assurance system (see Section 
6.4.1.1.). The strategic business elements of a company's 
quality policy may thus be overshadowed by technical 
considerations related to GMP compliance. 
Reference is made in Section 6.4.1.6 to a number of 
quality improvement programmes encountered amongst the 
companies researched. This would serve to indicate an 
awareness within the pharmaceutical industry of the need 
for top management to initiate such programmes. Moreover, 
these programmes are characterised by a high degree of 
employee involvement; the "Green Areas" programme of one 
company for instance involves daily discussions by a 
worktearn of issues relating to quality, safety, equipment 
and housekeeping. Suggestions for improvements in any of 
these areas are formally recorded and followed up with the 
active involvement of senior and top management. careful 
planning of employee education in areas such as the 
dynamics of the modern enterprise, and the development of 
inter-personal communications skills, preceded the intro-
duction of the "Green Areas" programme in this company. 
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This company's programme is however at present applied in 
selected functional areas only; namely the shop floor, 
purchasing department, planning department, and 
distribution department. 
One of 
mentioned 
interviewed during the research the companies 
that their attempt at introducing the "Green 
met with a great deal of resistance 
floor personnel. These employees saw 
Areas" 
from 
the 
concept had 
certain shop 
scheme as being an imposition by management, rather 
than an attempt at obtaining their constructive involve-
ment. This experience would seem to suggest that careful 
planning and appropriate training is required before 
introducing the "Green Areas" concept, and that it should 
certainly not be seen by management to be a "quick-fix" 
method of achieving a commitment to continuous quality 
improvement. The development of interpersonal communica-
tion skills, and an appreciation for the strategic 
business value of quality are seen to be important 
prerequisites in this regard; but the key to the sucess of 
such a programme appears to lie in effective planning, a 
sustained involvement, and a genuine commitment on the 
part of top management. 
Another company 
its quality 
principles: (i) 
which participated in the research bases 
organisational structure on five broad 
Leadership; which is defined with refer-
ence to management's responsibility for giving direction 
and providing employees with the necessary information, 
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training, resources and authority, and for employees 
themselves to demonstrate leadership by finding better 
ways to do their work. (ii) Total involvement; which 
refers to the organisationwide involvement of everybody in 
quality improvement activities and a shared responsi-
bility for quality. (iii) Customer focus; which refers to 
the goal of meeting or exceeding customer requirements, 
including those of internal customers. (iv) Measurement; 
which refers to the need for monitoring quality perfor-
mance as compared to stated quality goals. (v) Continuous 
improvement; with specific reference to prevention and 
innovation activities. Top management sees this programme 
as providing a "values-based" approach to each task 
performed in that the entire programme is based on the 
core values of people (customer/employee), integrity, and 
excellence. Top management also actively communicates the 
programme as providing the "tools and processes" needed to 
support the company's business strategies; in other words, 
the -strategic business value of the programme is accen-
tuated. 
Deming, 
slogans 
He notes 
quoted by Greenwood (1988, pp. 36-37), warns that 
management 
help of 
tion of 
and exhortations serve only to frustrate workers. 
that most problems originate from within the 
system itself and that management requires the 
the workers to improve this system. The elimina-
empty slogans, and the frustration which it 
is consequently considered to be one of top causes, 
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management's "system obligations". One of the companies 
interviewed during this research feels so strongly about 
this particular aspect that it cites this as being the 
reason for the company not having a written quality policy 
at all. Not having a clearly delineated quality policy to 
guide decision making at all levels within the 
organisation may however result in precisely those 
frustrations and inefficiencies which this company is 
attempting to avoid. 
Of the nineteen companies who participated in this 
research, one stands out as having the most clearly 
articulated quality policy and quality management system. 
This company's quality policy consists of a short three-
paragraph written statement by the chief executive officer 
in which he formally commits the company to a policy of 
total quality management; formally delegates responsi-
bility for its implementation (to a particular plant 
manager on this case); and states the quality policy 
objective to be the assurance that all goods and services 
supplied by the company will meet the critical performance 
criteria set out in the company's "mission", "values" and 
"objectives". 
This company's "mission" is stated as striving to be a 
leading south African pharmaceutical company in terms of 
both volume and value growth; and to market, produce and 
distribute quality products to the health care profes-
sions. The mission statement furthermore declares that 
these objectives will be achieved firstly by producing 
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high quality cost effective medicines which shall be made 
available to the entire population of south Africa; and 
secondly, by virtue of the efforts of competent employees 
who are encouraged to continually improve their work know-
ledge, skills and performance through "free and open 
communication, training, self discipline and being 
completely committed to living the company's values and 
achieving the company's quality objectives". 
This company furthermore formally relates its competitive 
strategy to the following core values: 
(i) A customer orientation; i.e. striving to provide products 
and services of superior quality and value in order to 
meet the expectations of internal and external customers. 
(ii) A commitment to innovation; i.e. encouraging employees to 
continually strive to be creative and innovative in order 
to produce new and better quality ideas for improved 
organisationwide performance. 
(iii) 
(iv) 
The ·maintenance of personal and corporate integrity; i.e. 
conduct based on openness and honesty in order to engender 
trust and be able to pass the test of public and internal 
scrutiny at all times. 
Teamwork; i.e. the value of teamwork and open communi-
cation in enabling employees to work together as partners 
in pursuit of the company's "mission", "values" and 
business strategy. 
(v) A performance orientation; i.e. a focus on results 
achieved, and continuous improvement in organisationwide 
activities. Top management has also introduced a formal 
programme of continuous improvement which is based on 
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these core values. This "Simply Better" programme of 
continuous improvement includes guidelines for putting 
into practice the above-mentioned values, and for setting 
an example for others to follow. 
The "objectives" referred to in this company's quality 
policy are summarised as follows: 
(i) To provide high quality products and services to satisfy 
all internal and external customers. 
(ii) 
(iii) 
To encourage and maintain a high level of quality 
awareness amongst all employees. 
To continually improve and monitor operating competency. 
These broadly-stated objectives are supplemented by 
specific quality objectives for a particular twelve-month 
period. For example, the quality objectives for 1994 
include the reduction of total failure costs by a 
specified percentage as compared to the average monthly 
total failure costs for 1993. Similar objectives have 
been set for the current year in the areas of quality 
awareness and improved operating competency. 
A predominantly technical approach to the identification 
of quality-related 
amongst some of the 
decisions was however encountered 
companies who participated in the 
research (see 
companies were 
identification 
Section 6.4.2.5). 
found to be 
and analysis of 
Moreover, most of these 
better attuned to the 
quality-related problems 
than they were regarding quality-related decisions (see 
6.6.3 
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Section 6.4.2.6). 
technically-orientated 
rather than as part 
policy formulation. 
Organising for quality 
This is seen to be the result of 
regulatory demands in this regard, 
of a structured approach to quality 
It was found that the relevant MBRl registration dossier; 
the company organogram and job descriptions; and the rele-
vant process flow-chart are used to a greater or lesser 
extent by most companies as a management tool for the 
identification of organisationwide quality authorities and 
responsibilities. The MBRl dossier was highlighted by 
some respondents as being a valuable guideline regarding 
the technical aspects of quality assurance in particular. 
The opinion was expressed that delays caused by the 
regulatory requirement of first having to obtain the 
formal approval of the Medicines Control Council to make 
certain changes to the MBRl dossier, limits the practical 
value of the MBRl dossier in this regard (see section 
6.4.3.1). This criticism is accepted with some reser-
vation. Annexure 16 of the MBR1 dossier requires a 
summary of experimental data from which final product 
specifications, analytical methods, manufacturing 
procedures, the product stability profile, and pharma-
ceutical and bioavailability characteristics are derived 
(see section 3.6.2.5). The requirement is therefore for a 
thoroughly structured series of new design control 
activities which, if performed properly, should yield a 
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product and manufacturing processes that are unlikely to 
require major adjustment at a later stage. This approach 
by the regulatory authorities in fact underscores the 
total quality principle that the assurance of customer 
quality satisfaction mQst begin during new product design 
and development (see Feigenbaum, loc. cit., p. 617). 
Moreover, a thorough approach to machine qualification and 
process validation to determine the process variables and 
acceptable limits for those variables, is now accepted 
even in the technical literature as being fundamental to 
pharmaceutical manufacture (see Nally & Kieffer, 1993, pp. 
25-30). Provided the pharmaceutical development of the 
product (as summarised under Annexure 16 of the MBRl 
dossier) 
mentioned 
considered 
is conducted 
principles, 
to be a 
in accordance with the above-
the MBRl dossier could therefore be 
valuable aid in identifying the 
technical aspects of organisationwide quality responsi-
bilities and authorities. 
Quality problems transcend individual functional organi-
sational boundaries within companies (Feigenbaum,loc. 
cit., p. 150). Multifunctional participation in quality 
problem solving and decision 
fundamental requirement for 
integration of the quality effort. 
making is therefore a 
the organisationwide 
Many of the companies 
interviewed during the research either have no formal 
multifunctional involvement in their quality assurance 
system, or adopt an ad hoc approach to such involvement 
(see Section 6.4.3.2). Feigenbaum (ibid., pp. 150-152) 
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draws attention to the fact than more than 80 per cent of 
fundamental quality problems requiring improvement today 
are outside the scope of traditional quality control 
departments. It may therefore be predicted that many of 
the abovementioned companies might have difficulty in 
effectively responding to quality problems and in achieving 
sustained improvement in quality. 
It was found that most respondents view the key responsi-
bilities of the quality control function in terms of 
technical and systems responsibilities (see Section 
6.4.3.3). This is consistent with the traditional quality 
culture in the pharmaceutical industry. Reference is 
however made in Section 6.6.1 to the finding that many 
respondents adopt a consumer-orientation to quality; 
recognise the need to actively manage the quality improve-
ment process; apply a unitary system of quality assurance 
to all products, wether they be subject to regulatory 
control or not; and display an understanding the relation-
ship between product quality and strategic business factors 
such as profitability and risk management .. It may there-
fore be concluded that a business responsibility has in 
fact been delegated by top management to the quality 
assurance functions 
this responsibility 
informally. 
of the companies researched, but that 
has in many cases been delegated 
Details relating to the organisational structure of four-
teen pharmaceutical manufacturing companies were obtained 
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during the research. In all of the companies researched 
the quality assurance manager either reports directly to a 
member of the board, or is himself a member of the board of 
directors. This organisational structure would suggest 
that quality is managed in the same way as major functions 
such as finance, marketing, human resources, public 
relations and production. A more detailed examination of 
these organisational structures however shows that this is 
not necessarily the case. 
The quality assurance manager is often placed at the same 
managerial level as the managers of the production 
planning, engineering, logistics, technical training, 
distribution and loss control departments for instance. 
These functionaries would typically report to a technical 
or operations director, who is a board member. It is also 
quite common for the quality assurance manager to have a 
"dotted line" link with the chief executive officer of the 
company which enables him to communicate directly with top 
management on matters regarding product quality. In some 
of the multinational companies, this structure extends up 
to corporate headquarters (overseas), thereby providing the 
quality assurance manager with a direct link with top 
management in the event of a possible internal dispute over 
a quality issue. 
Reference is made in Chapter 4 of the functions that have 
to be performed by a quality assurance manager in terms of 
current pharmaceutical GMP principles (see section 4.6.2). 
6.6.4 
-324-
One of the basic tenets in this regard is that the quality 
assurance manager should function independently from the 
production manager. Moreover, in terms of the provisions 
of section 22 read with section 29 of the Pharmacy Act 
(South Africa, 1974) a pharmacist, who is the managing 
director of the company, shall assume legal responsibility 
for product quality. With reference to the organisational 
structure of most of the companies included in this 
research, it was found that a significant number of 
companies conduct quality problem solving, decision making 
and quality policy formulation activities at a technical 
level (see Section 6.4.3.2). It would appear that the 
position of the quality assurance manager in the 
organisational hierarchy may be determined by current 
regulatory requirements rather than a conviction that 
quality is a strategic business function within the modern 
enterprise. 
Quality and production control systems 
Most of the respondents who do apply JIT principles of 
production control stated that they do so on a "selective" 
basis, due to problems experienced with the variable lead 
times of materials sourced from overseas suppliers and the 
unpredictable ordering patterns of certain large (public 
sector) consumers in particular (see Section 6.4.4.1). 
This may be interpreted to mean that these respondents view 
JIT as being synonymous with zero inventories and pull 
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production, rather than being a philosophy based on the 
principles of continuous improvement and the elimination of 
any activity which does not add value to the product (see 
Ray, 1990, pp. 179-180). Most of the respondents see JIT 
as contributing positively to their quality assurance 
systems and in particular to the creation of a "right first 
time" culture within the organisation (see Section 
6.4.4.2). The results obtained during the research however 
point to a predisposition within the pharmaceutical 
industry towards viewing JIT more as an inventory manage-
ment tool than as the core component of manufacturing 
excellence (see Ray, ibid., p. 180). 
This viewpoint may change under the increasing pressures of 
cost constraints brought to bear on the industry through 
the introduction of generic substitution and other macro-
environmental factors (see Section 2.2.2). The reference 
that was made by four respondents to the role played by JIT 
in ·improving 
considered to 
(see Section 
vendor relations and vendor contact is 
be particularly significant in this regard 
6.4.4.2). Ray (ibid., pp. 187-188) refers 
to the extension of the concepts of manufacturing 
excellence to vendors and their own vendors, and states 
that in the ideal JIT environment vendors deliver directly 
to the production line. From the research results 
obtained, it appears that there is already a movement 
towards this goal in the pharmaceutical industry; this 
would herald the need for a fundamental change in the 
approach to incoming material control by the regulatory 
authorities. 
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The research showed that JIT principles are currently being 
applied in the manufacture of a wide range of pharma-
ceutical and related products (see Section 6.4.4.1). It 
may therefore be concluded that JIT production control 
principles are universally compatible with pharmaceutical 
production. Most of the respondents interviewed either did 
not refer to problems with the highly variable master 
production schedules normally associated with pharma-
ceutical production, or did not state this to be the 
rationale for them not using JIT principles of production 
control (see Section 6.4.4.1). 
The MRP II system of production planning and control, which 
plans and controls inventories and production capacities 
via a feedback loop between orders and the production 
master schedule, was found to be used by most of the 
companies who participated in the research. Only two 
companies, with an annual turnover of less than R20 
million, were found not to operate this sytem (see Section 
6.4.4.3). 
The ability of the MRP system to ensure a planned workload 
on the quality assurance laboratory in particular was 
mentioned by most respondents as being the most important 
contribution to their quality assurance systems (see 
Section 
incoming 
finished 
6.4.4.4). This would for instance result in 
material controls, in-process controls and 
product release controls being conducted time-
ously and without the integrity of the system being com-
promised due to a rushed production schedule. 
6.6.5 
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The 
with 
that 
majority of respondents prompted in this regard agree 
the viewpoint of Boccard (1990, pp. 39-40); namely 
MRP may be viewed as the planning half, and JIT as the 
execution half, of a production control system which incor-
porates both MRP and JIT principles. Moreover, when asked 
about the criticism put forward by Schroeder (1985, p. 485) 
concerning the ability of the MRP system to tolerate a 
degree of waste (and hence bad quality), two respondents 
highlighted the fact that this depended on the standards 
designed into the system by the user himself (see Section 
6.4.4.4). Based on these responses it is concluded that a 
Synchro-MRP system, as described by Esparragio (1988, pp. 
9-10) may be adapted for use in the pharmaceutical 
industry. 
Quality cost management 
Most of 
quality 
indicate 
industry 
variety 
the companies surveyed do measure and report 
costs (see Section 6.4.5.1). This would appear to 
a general acceptance within the pharmaceutical 
of the value of quality cost management. The wide 
of quality cost categories. encountered during the 
research, and the divergence of opinion that was found to 
exist regarding the distinction between quality costs and 
production costs, does however bring into question the 
level of sophistication of quality cost management in the 
industry (see Section 6.4.5.2). The majority of respon-
dents stated that quality cost reports are submitted to top 
management (see Section 6.4.5.3) who then also decide upon 
what action to take when necessary (see Section 6.4.5.4). 
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The individual cost categories and combination of cost 
categories used by most of the companies surveyed is 
however of such a nature that the value to management of 
the resultant quality cost data is extremely limited. 
The majority of companies surveyed measure internal and 
external failure costs only. The difficulties encountered 
with the "classical" prevention-appraisal-failure categori-
sation of quality costs in the pharmaceutical industry 
appear to confirm the limitations of this approach, as 
highlighted by Plunkett & Dale (1990, pp. 165-168). They 
are of the opinion that the need to identify and measure 
quality costs across a wider spectrum of company activities 
has exposed the following limitations in this approach: 
(i) These quality cost categories do not match well with 
the cost information most commonly available from accoun-
ting systems. (ii) Many grey areas exist regarding quality-
related activities, making cost categories difficult. (iii) 
It often happens in practice that cost categorisation takes 
place after data collection in accordance with the 
"received wisdom" on the topic. (iv) This categorisation 
seems to be of interest only to quality department 
personnel. 
the most 
(v) It is not an appropriate categorisation for 
common uses of quality cost information; hence 
companies tend to devise their own elements to suit their 
own situation or industry. According to Plunkett & Dale 
(ibid., p. 167), the use of a broader categorisation 
which measures only the cost of conformance and the cost of 
non- conformance is gaining favour as an alternative 
approach to quality cost measurement. 
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Based on the results obtained during this research, the 
alternative approach referred to by Plunkett & Dale 
(supra) is accepted with reservation. Firstly, this 
approach is essentially based on the same broad cate-
gorisation of principal operating costs as that which is 
used by Feigenbaum (loc. cit., pp. 110-112) to develop 
the "classical" prevention-appraisal-failure method of 
categorisation, namely the cost of control (i.e. cost of 
conformance) and the cost of failure of control (i.e. cost 
of non-conformance). A major problem identified during 
this research is the inability of companies to disting-
uish between that which is a quality cost and that which is 
a production cost (see section 6.4.5.2). Plunkett & Dale 
(loc. cit., p. 167) state that the alternative approach 
in practice requires departments within the company to 
"identify key-result processes" against which to measure 
their performance and costs. This approach is not seen as 
providing a solution to the above-mentioned problem of cost 
categorisation encountered within the pharmaceutical 
industry. 
Another important criticism of the alternative approach to 
cost categorisation relates exactly to that which is seen 
by Plunkett & Dale (ibid., p. 166) as being a weakness of 
the "classical" method of cost categorisation, namely that 
it adds nothing to the data's potential for provoking 
action by management. It is considered fundamental to the 
quality cost management process that management should be 
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able to distinguish between the appraisal cost and preven-
tion cost components of the cost of control (cost of 
conformance) for instance. The reason for this relates to 
the fact that, without this information, management could 
be tempted to solve the.problem of high failure costs (cost 
of non-conformance) simply by increasing appraisal costs. 
In terms of the total quality concept, on the other hand, 
increased expenditure on prevention costs will reduce 
failure costs as well as appraisal costs. This results in 
a reduction in the (total) cost of quality while at the 
same time increasing the level of quality, productivity and 
profitability (see Feigenbaum, loc. cit., pp. 112-114). 
One of the companies surveyed reported their current 
operating quality costs to be 0,25 per cent of sales, calcu-
lated as the total cost of non-conformance (see Section 
6.4.5.5). This figure is in itself most impressive. How-
ever, without knowing what that company's cost of appraisal 
is, - it would be impossible to determine wether or not net 
profit performance may be improved through more efficient 
quality management. Moreover, without knowing the ratio of 
appraisal costs to prevention costs, it would not be 
possible to devise an effective strategy in this regard. 
Only three 
"classical" 
these three 
companies 
system of 
companies 
were found to have employed the 
quality cost categorisation, and of 
only the figures supplied by one 
company 
6.4.5.5). 
are considered to be reliable (see Section 
It is noted that this company's (internal and 
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external) failure costs comprise 33,3 per cent of total 
operating quality costs; appraisal costs 63,3 per cent; 
and prevention costs 3,4 per cent. Based on these figures, 
it may for instance be recommended that future strategies 
to reduce total operating quality costs in this company be 
aimed at increasing expenditure on prevention activities 
while at the same time reducing expenditure on appraisal. 
6.7 THE CONCLUSIONS 
6.7.1 
An interpretation of the results obtained from the research 
is given in the sections which follow. 
Conclusions regarding the hypotheses 
A comparison between the current regulatory control system 
which is used to assure the quality of pharmaceutical 
products in South Africa, and the total quality concept, 
highlights the following aspects in particular: 
6.7.1.1 The field of reference 
Current regulatory requirements relating to the granting of 
marketing authorisation (product registration) incorporate 
many (but not all) of the new design control; incoming 
material control; product control; and post-marketing 
surveillance activities that would routinely be performed 
in terms of a total quality system (see Chapter 3). 
-332-
It should be noted however that the components of the South 
African regulatory control system are exclusively techni-
cally-orientated, with no managerial focus. This charac-
teristic in fact underlies the irispection and test approach 
to quality which is ·inherent in the current regulatory 
control system. 
The regulatory requirements relating to manufacturing 
authorisation, and which are embodied in current good manu-
facturing practice principles, are by definitlon related 
only to the production phase of the industrial cycle (see 
Chapter 4). The· total quality concept, on the other hand, 
forms the foundation for the organisationwide integration 
of all those activities which have to be performed in order 
to consistently achieve the quality objectives of the 
enterprise (see Section 5.5). The organisationwide scope 
of the total quality concept, and its application to the 
entire industrial cycle, are seen as its primary disting-
uishing features when compared to the current regulatory 
control system. 
6.7.1.2 The strategic business value of quality 
The possible existence of oligopolistic and even mono-
polistic therapeutic submarkets in the South African 
pharmaceutical market, is referred to Section 1.2. The 
unique features of the South African market for pre-
scription medicines that have thusfar contributed to a low 
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elasticity of demand, and those macroenvironmental issues 
which are now challanging the traditional status quo, are 
referred to in Section 2.2.2. Both this research and the 
technical literature reveals that a fundamental shift away 
from a purely technical approach to quality is beginning to 
take place within the pharmaceutical industry. A customer-
orientation to quality; the association that is made 
between quality and profitability; and the high profile 
which is given to quality improvement programmes based on 
employee involvement, is evident amongst some of the 
companies who particpated in the research (see Section 
6.6.1). The technical literature now also recognises the 
strategic business value of quality in terms of such 
aspects as improved productivity, increased profitability, 
and the achievement of a competitive advantage (see Kieffer 
& Nally, loc. cit., pp. 131-138). 
This philosophical shift away from a purely technical 
approach to quality is seen as being influenced by the 
modern competitive environment of the pharmaceutical 
industry. This may be due to a realisation that quality is 
an essential part of the marketing mix; that it enables 
companies to effectively differentiate their products from 
those of their competitors, whilst the elimination of waste 
through improved quality results in the most efficient 
utilisation of company resources and hence the maximisation 
of productivity, profitability and competitive advantage. 
This is in contrast to the traditional approach to quality 
and quality management, which is related mainly to the need 
for regulatory compliance. 
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6.7.1.3 Quality policy formulation 
The current regulatory control system does not provide any 
formal guidelines to quality policy formulation. Section 
1(3) of the Medicines . Control Act (South Africa, 1965) 
determines that criteria related to safety, quality and 
therapeutic efficacy must be met before marketing authori-
sation may be granted in respect of a pharmaceutical 
product (see Section 3.3). Besides this broadly stated 
objective, only the guidelines contained in good manu-
facturing practice principles, which by definition apply 
mainly to the production phase of the industrial cycle, 
serve to guide industry in this regard (see Section 4.3). 
It is also important to note that the quality objectives 
described by the regulatory control system are of a 
technical nature only. This must of necessity result in 
the strategic business elements of company quality policy 
being overshadowed by technical considerations related to 
regulatory compliance. 
A formal policy statement, in which a company's quality 
objectives are clearly defined, is a fundamental component 
of a total quality system. Similarly, a structured 
approach to the identification and analysis of quality-
related decisions and problems is an integral part of such 
a system. The current regulatory control system lacks both 
these elements. 
A quality policy 
limits within 
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is established to formally stipulate the 
which all quality-related management 
decisions are to be taken in order to meet stated quality 
objectives. The quality policy may thus be looked upon as 
being the first level . of communication which is used by 
management to communicate specific quality objectives. 
Such communication is specifically aimed at functionaries 
throughout the organisation (see Section 5.9). In terms of 
the total quality approach, the nature of such communica-
tion will moreover have a strong strategic business content 
rather than an exclusively technical orientation. 
It is felt that the weakly-developed quality policy and 
communications structures encountered in some companies 
during this research (see Section 6.6.2) can be improved by 
means of a total quality approach. Such an approach is 
also seen as fundamental to the success of many of the 
quality improvement programmes encountered during the 
research (see Section 6.4.1.6). Without the firm basis 
which is provided by a clearly defined quality policy, such 
programmes may flounder as a result of a lack of co-
ordination and organisationwide impact; and a (perceived) 
lack of involvement by top management. 
6.7.1.4 The quality organisational structure 
Reference is made in Section 6.6.1 to the fact that the 
traditional quality culture in the pharmaceutical industry 
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is influenced by the dual regulatory processes of market-
ing authorisation and manufacturing authorisation. These 
two processes may occur independently from one another (see 
Sections 3.5 and 4.1). It is also possible for marketing 
authorisation and manufacturing authorisation to be granted 
in respect of the same product to different parties acting 
independently from one another; for instance in the case of 
the holder of a marketing authorisation contracting an 
authorised third party manufacturer to manufacture a 
particular product. This may lead to a fragmented or unco-
ordinated approach to quality control during the industrial 
cycle of a particular product. 
The South African regulatory control system apportions 
final responsibility for product quality to the managing 
director of a pharmaceutical company. In terms of the 
provisions of section 22 of the Pharmacy Act (South Africa, 
1974) the managing director must be a pharmacist who is 
required to "manage the business" of the company. No 
guidelines are given in this regard other than by section 
29 of that Act, which stipulates that the manufacture of a 
medicine must be supervised by a pharmacist (see Section 
4.6.2). The functions of a company managing director are 
furthermore not defined by South African company law. The 
duties and powers of a managing director are determined 
instead by that which is assigned to him by the company•s 
board of directors (Pretorius, et al, 1991, pp. 459 - 462). 
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This combination of factors has resulted in the somewhat 
paradoxical situation of the managing director sometimes 
being a mere figurehead who is appointed only to satisfy 
regulatory requirements in that regard. At best this 
creates two internal lines of communication within a large 
organisation; one dealing with regulatory issues and the 
other with the management of the actual day-to-day affairs 
of the company. This is seen as being a potential 
hindrance to the co-ordination of the quality effort in a 
pharmaceutical company. 
specifically delegated 
terms of current GMP 
An examination of the functions 
to the quality assurance manager in 
principles (see Table 4.1), reveals 
that these relate mainly to technical responsibilities and 
some systems responsibilities. The results obtained from 
the research (see Section 6.4.3.3) appears to confirm that 
this is indeed the situation in practice. The research did 
however reflect a realisation amongst respondents of the 
key role played by the quality assurance function in terms 
of strategic business factors. The fact that this business 
responsibility has in many cases been delegated to the 
quality assurance function in an informal manner only, 
would appear to indicate that top management may however 
still not be entirely convinced of the business strategic 
value of quality; or that considerations related to 
regulatory demands predominate in this regard. 
From the 
regulatory 
above it 
control 
may be concluded that the current 
system has had a profound effect on the 
quality organisational structures within the South African 
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pharmaceutical industry. This has resulted in a sometimes 
unco-ordinated approach to quality control during the 
various stages of a product's industrial cycle; a lack of 
internal 
technical 
organisationwide co-ordination; and an essentially 
approach to .quality, with the emphasis being on 
regulatory compliance. 
It is felt that a total quality approach can be used to 
complement the current regulatory control system in this 
regard. The structured approach inherent in the total 
quality concept with reference to the identification of key 
organisationwide quality authorities and responsibilities; 
the identification of the technical, systems, and business 
authorities and responsibilities of the quality control 
function itself; and the leadership role of management is 
seen as offering particularly appropriate solutions to the 
problems identified (see Section 5.10). 
The -total quality approach is seen as being complementary 
to the current regulatory control system not only in the 
sense that it gives a new dimension to the ~anagement of 
quality, but also due to the fact that certain elements of 
the regulatory control system will be more fully devel-
oped. The relevant MBRl dossier and process flow-chart, 
together with the company organogram and job descriptions, 
may for instance be used to construct a relationship chart 
with which to identify organisationwide quality authorities 
and responsibilities. Most of the relevant management 
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information already exists within the current regulatory 
control system; a total quality approach provides the basis 
for co-ordinating and applying this information to maximum 
effect (see Section 6.6.3). 
6.7.1.5 Enhanced operations management 
In Section 5.7 the interdependence that exists between the 
total quality concept and operations management systems 
such as just-in-time (JIT) and materials requirements 
planning (MRP), is contrasted with current GMP principles. 
It may be concluded that, due to the technical orientation 
of GMP guidelines, those guidelines are of limited use from 
an operations management perspective. 
The 
MRP 
ible 
From 
with 
research revealed that the application of both JIT and 
principles of production control are entirely compat-
wi th pharmaceutical manufacture (see Section 6.6.4). 
the literature, it appears that a mayor difficulty 
the application of JIT production control techniques 
to pharmaceutical manufacture would relate to the unstable 
master production schedule that is normally associated with 
pharmaceutical manufacture. The research however revealed 
this not to be the case (see Section 6.4.4.1). The 
research also revealed the widespread use of the MRPII 
system of production planning and control amongst the 
companies surveyed (see Section 6.4.4.3); and that the 
criticism relating to the tolerance of waste by the MRP 
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system is valid only insofar as the standards designed into 
the system by the user himself allows for wastage (see 
Section 6.4.4.4). 
Most respondents felt .that JIT and MRP systems make some 
positive contribution to their quality assurance pro-
grammes; and the majority of respondents interviewed also 
felt that these two systems complement one another (see 
Sections 6.4.4.2 and 6.4.4.4). This would serve to confirm 
the opinion in the literature that these systems are not 
only compatible but also enhance the benefits derived from 
eachother; in particular if MRP is viewed as the planning 
half and JIT as the execution half of such an integrated 
system (see Section 5.7). The critical part played by 
quality issues in the successful application of JIT 
principles in particular, are furthermore considered to be 
of paramount importance to this research (see Ray, 1990, 
pp. 179-190). This is due to the fact that the fundamental 
role- played by quality in the application of JIT/MRP 
integrated systems will enable the pharmaceutical industry 
to co-ordinate its quality control and production control 
systems more effectively than would be the case were it to 
rely on GMP principles only. The purely technical 
orientation of GMP principles does not provide a basis for 
such integration of quality control systems with effective 
production planning and control systems. 
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6.7.1.6 Management's control over quality costs 
A fundamental component of the control function of 
management relates to monitoring conformance with set 
standards. Whereas the technical literature often views 
control as consisting of various individual (technical) 
functions that are not necessarily interrelated, the 
business economic viewpoint holds that control consists of 
the setting of standards; appraisal of conformance; taking 
corrective action when necessary; and planning for improve-
ments to be made (see Section 5.4). This would serve to 
emphasise the fact that effective control cannot take place 
without the effective feedback of relevant information to 
management. The GMP principles which currently form part 
of the regulatory control system (see Chapter 4) do not 
provide for such a structured feedback of information to 
management. 
Managerial decision making cannot be based on technical 
information only. Quality cost data are an essential 
component of the quality management process; one of the 
companies researched applies the dictum: "You cannot manage 
what you do not measure" in this regard. The surprisingly 
unsophisticated systems of quality cost management 
generally encountered amongst the companies surveyed, 
however points to a possible need within the industry for 
guidance in this regard. 
6.7.2 
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The total quality concept incorporates the identification 
and measurement of various quality cost categories. It 
also assists management in understanding the important 
interrelationship between these cost categories. In 
particular it enables .management to direct the quality 
improvement effort into areas that will maximise its 
contribution to company profitability (see Section 6.6.5). 
Conclusions regarding the implications 
The implications of the research relate to the need for a 
fundamental change in the philosophical approach to quality 
and quality management in the pharmaceutical industry. The 
total quality philosophy embodies characteristics related 
to the establishment, maintenance, and improvement of 
quality control systems which have important implications 
to both the pharmaceutical industry and the regulatory 
authorities regarding the following aspects in particular: 
(i) The need to move away from a purely technical (inspection 
and test) approach to quality, towards a recognition of the 
pivotal role played by management skills in the attainment 
of the quality objective. It is concluded from the discus-
sion in Section 4.5 that both the pharmaceutical industry 
and regulatory authorities internationally consider good 
manufacturing practice (GMP) principles to be the bench-
mark against which any quality assurance system must be 
measured. This viewpoint ignores the limitations inherent 
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in GMP principles, which are related to their narrow, 
production-orientated, focus. Moreover, GMP principles 
have a purely technical basis (see Chapter 4), whereas the 
total quality concept is based on the precept that quality 
is the result of good .management; quality control is seen 
as being a management tool which enables top management to 
fulfil a leadership role with regard to product quality 
(see Section 5.5). 
The technical (rather than managerial) orientation of the 
South African regulatory control system, and similar 
systems elsewhere, is seen as being the inevitable 
consequence of the fact that this regulatory control system 
is itself based upon (natural) scientific principles only. 
The planning, co-ordination and control of those activities 
necessary to consistently deliver a product of the required 
quality to the final consumer is thus linked to inspection 
and test activities based on technical principles only. 
The business economic viewpoint, on the other hand, is that 
quality is in essence a way of managing the enterprise and 
that managerial control over quality is achieved in exactly 
the same manner as control over the financial, marketing 
and other functions of the enterprise. The total quality 
concept provides the basis for a structured approach to the 
establishment of a dynamic company-wide managerial 
structure aimed at consistently achieving a stated quality 
goal. An understanding of the total quality concept is 
thus seen as being important to the pharmaceutical industry 
as well as regulatory quality auditors in particular. 
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(ii) A recognition of the strategic business value of quality in 
the modern competitive environment; and in particular the 
positive contribution to company net profits that can be 
made by the effective management of quality. Reference is 
currently being made in the technical literature to the 
strategic nature of quality in the current environment of 
global competition in which the pharmaceutical industry 
operates (see Kieffer & Nally, loc. cit., p. 131). It is 
furthermore considered significant that the majority of 
respondents who participated in this research, defined 
quality in terms of a customer-orientation, and that some 
of these respondents see a direct link between their 
quality assurance systems and strategic business factors 
such as profitability and risk management (see Section 
6.6.1). The traditional quality culture in the pharma-
ceutical industry, which has its roots in requirements 
relating to the need to comply with (mainly technical) 
regulatory demands concerning product quality, is however 
in need of a fundamental re-orientation to the strategic 
business value of quality. The total quality concept 
provides the mechanism whereby this may be achieved, with 
specific reference to aspects such as the improvement of 
the company's competitive position, increased productivity, 
and increased profitability. 
The aim, 
industry 
serve the 
with respect to product quality, of both the 
as well as the regulatory authorities, is to best 
interest of final consumers of medicines. Any 
(iii) 
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system of quality assurance that not only achieves this 
objective but at the same time enhances the achievement of 
business strategic goals, 
wholehearted supported 
must of necessity receive the 
of industry at large. This 
incentive would serve to increase the commitment to quality 
within the pharmaceutical industry beyond that which may 
currently be based largely on regulatory demands only. 
A broadening 
beyond issues 
of the scope of the quality control function 
that relate mainly to product design and 
production, towards an integrated approach that is focussed 
on the entire industrial cycle. Reference is made in 
Section 6.6.1 to the fact that the traditional quality 
culture in the pharmaceutical industry is influenced by a 
regulatory control system which is based on a process of 
marketing authorisation (see Chaper 3) and a process of 
manufacturing authorisation (see Chapter 4). In practice, 
these two processes may take place entirely independently 
from· one another, both in terms of timing as well as in 
terms of the individual companies involved. It is for 
instance possible for one company to obtain marketing 
authorisation, and for another company to obtain manufac-
turing authorisation, in respect of the same product. The 
regulatory control process by its very nature therefore 
allows a fragmented appraoch to be adopted to quality 
control during the industrial cycle. This is done for 
practical reasons which cannot be avoided. 
(iv) 
This fragmented 
exacerbated by 
GMP guidelines 
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approach to quality control is however 
the narrow, production-orientated focus of 
which form the basis for regulatory 
manufacturing authorisation. The total quality approach, 
which highlights the fact that quality is affected at every 
stage of the industrial cycle, is seen as having the 
potential for making an important contribution in this 
regard. From a regulatory point of view in particular, it 
is important that companies are able to view the 
interrelationship between the various stages of a product's 
industrial cycle in the correct perspective. 
The formulation of quality policy. The total quality 
concept 
policy 
quality 
emphasises 
statement in 
objectives. 
the need for a clearly-defined quality 
which top management sets out company 
such a policy statement is required to 
relate to integrated policies and procedures which are 
aimed at ensuring the active involvement and continued 
commitment of all employees, and of top management, to the 
quality effort. The current regulatory control system 
provides an incomplete framework for quality policy 
formulation. In particular, it places emphasis only on the 
identification of technical quality-related problems and 
their (physical) analysis (see Section 5.9). Moreover, the 
system of documentary control which is an integral part of 
GMP guidelines (see Section 4.6.3) relates mainly to 
day-to-day technical decision making without specifically 
contributing to strategic quality decision making. The 
finding that it was difficult to establish a direct link 
(v) 
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between the policy documents and the quality objectives 
and procedures of some of the companies who participated in 
this research (see Section 6.6.2), is seen to be directly 
related to the above-mentioned characteristics of the 
current regulatory control system. 
The formal 
effort. No 
co-ordination of the organisationwide quality 
generally applied approach to the identif i-
cation of key organisationwide quality responsibilities and 
authorities in a pharmaceutical company was revealed by the 
research (see Section 6.4.3.1). The systems responsi-
bility, and in particular the business responsibility of 
the quality control function of most of the companies 
researched were found to be relatively weakly-developed 
(see Section 6.4.3.3). A review of the evolution of 
quality control in the pharmaceutical industry moreover 
suggests that the commitment to quality by top management 
may be related primarily to regulatory requirements in that 
regard (see Section 5.6). Evidence was, however, found of 
a significant awareness within the industry of the need to 
continually improve quality; particularly in the areas of 
defect prevention and the need for innovation (see Section 
6.6.2). The total quality concept is seen as providing a 
structured approach to the task of organising for quality 
in the absence of regulatory guidelines in that regard. 
The use of a relationship chart which is based on the 
relevant company organogram; process flow chart; and the 
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MBRl product 
(1989, p.24), 
registration dossier, as suggested by Mader 
is seen as an example of the approach to 
co-ordination inherent in the total organisationwide 
quality concept. 
(vi) The active involvement of all employees in the quality 
establishment; maintenance; and improvement process. The 
importance of the activities of people in the assurance of 
pharmaceutical product quality is well-recognised even in 
the technical literature. The current regulatory process 
in general and GMP guidelines in particular, are largely 
procedure-driven. The danger is that human nature will 
tend to circumvent standard operating procedures if not 
convinced about their relevance or value. Moreover, 
without the active involvement of employees in the quality 
effort, management will be deprived of the feedback of 
quality-related information so vital to the decision-
making process. The active involvement of all employees is 
a fundamental component of the total quality concept. 
Evidence was found of the fact that a number of the 
companies researched recognise the importance of employee 
participation in the quality improvement process for 
instance (see Section 6.4.1.6). such programmes cannot 
however be conducted in isolation from the quality 
establishment-maintenance-improvement process. 
effectiveness and sustainability will be assured 
Their 
only 
through a formal and structured integration into the 
quality system, as part of a total quality system. 
(vii) 
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The importance, and correct use of quality cost data. In 
terms of the current regulatory control system the only 
criteria that are applied during the marketing and 
manufacturing authorisation processes, are those which 
relate to product safety-, quality, and therapeutic efficacy 
(see Section 3.3). Moreover, the inspection and test 
approach to quality control which is inherent in current 
GMP principles would result in a possible overemphasis of 
expenditure on appraisal costs, rather than prevention 
costs, thereby ignoring the effect on the total cost of 
quality. The wide variety and selective use of quality 
cost categories which were encountered during the research, 
and the divergence of opinions regarding the distinction 
between quality costs and production costs amongst those 
companies surveyed, points to a relatively unsophisticated 
level of quality cost management in the pharmaceutical 
industry (see Section 6.6.5) .. Control is one of the basic 
functions of management, and involves the setting of 
standards; appraising conformance; acting when necessary; 
and planning for improvements (see Section 5.4). Capturing 
accurate quality cost data is considered to be an essential 
component of the management function relating to product 
quality and of the total quality concept. 
The above-mentioned aspects would serve to emphasise that 
better quality cannot be achieved merely by tightening up 
regulatory requirements or by moving technical goalposts; 
nor can it be achieved without a genuine commitment and the 
6.7.3 
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active involvement of company top management. There is 
nevertheless a great deal of compatibility between total 
quality methods and philosophies, and the current regu-
latory control system. This is primarily related to the 
fact that consumer interest is the focal point of the 
quality control efforts of both the pharmaceutical industry 
and the regulatory authorities. The total quality concept 
is consequently seen as being the next logical step in the 
evolutionary process of quality control in the pharma-
ceutical industry. 
Conclusions regarding further research 
The relatively unsophisticated quality cost systems 
encountered in the pharmaceutical industry during the 
research, serves to indicate a need for development in that 
regard. In particular, the establishment of guidelines 
that will distinguish between quality costs and production 
-
costs in the pharmaceutical industry is considered to be an 
essential component of such further research. It is 
envisaged that broad principles of quality cost deter-
mination may be established and developed to a level of 
sophistication that will also enable their use by regu-
latory control auditors as an aid to the identification of 
specific quality problem areas within a plant, as well as 
their causes. Potential quality problems may for instance 
be identified by an upward trend in internal failure costs, 
and possible causes for this trend may be indicated by 
increasing 
declining 
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appraisal costs together with static or 
prevention costs. such research will however 
have to be based upon a larger sample size than that which 
was used for the present research. 
No reference is made in this research to statistical 
control methods, despite the fact that these methods 
constitute an integral part of the total quality concept. 
This was purposely done in order to focus on the role of 
the management function in the assurance of pharmaceutical 
product quality, particularly in the light of the purely 
technical approach of the current regulatory control system 
in this regard. Process validation and machine qualifi-
cation issues are however increasingly regarded as being of 
crucial importance by South African regulatory authorities 
(Schlebusch, 1994). It is consequently felt that further 
research regarding the total quality approach to the use of 
statistical control methods will be both valuable and 
opportune. In particular, the effect on quality costs (and 
net profits) of a pharmaceutical process validation 
programme is seen as being an important area for further 
research. 
The majority of respondents who participated in this 
research stated that they do apply just-in-time (JIT) 
principles of production control (see Section 6.4.4.1). 
However, reference is made in Section 6.6.4 to the possi-
bility that these respondents in general may view JIT as 
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being synonymous with zero inventories and pull production, 
rather than a philosophy which is based on the principles 
of continuous improvement and the elimination of waste. 
Further research is required in this regard to determine 
the validity of this deduction, and its application to the 
pharmaceutical industry in general. 
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ANNEXURE ONE: SURVEY QUESTIONNAIRE 
This annexure contains details relating to the structured 
questionnaire which is referred to under Section 6.2. 
The questionnaire consists of a section for gathering data 
required to compile a profile of the company concerned, and 
sections relating to the company's quality philosophy; the 
company's quality policy; the company's quality organisational 
structure; the production control systems being used; and quality 
cost management. Where necessary, prompts were included in the 
questionnaire (see boxed areas) as an aid to clarifying the 
questions being asked. Each interview was recorded on audio 
tape. 
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COMPANY PROFILE 
NAME OF COMPANY: 
POSTAL ADDRESS: .................................................... 
TEL. (CODE) : . . . . . . . • . . (NUMBER) : FAX: •••••••••••••••• 
CONTACT PERSON: ..................................................... 
MULTINATIONAL D 
ORGANOGRAM (ATTACHED) 
ANNUAL TURNOVER: 
PRODUCT MIX: 
STERILE LIQUIDS 
SEMI-SOLIDS 
SOLIDS 
TOXIC/HAZARDOUS PRODUCTS: 
PENICILLINS 
CEPHALOSPORINS 
HORMONES 
CYTOSTATICS 
OTHERS (SPECIFY) 
SOUTH AFRICAN D 
NON-STERILE LIQUIDS 
SEMI-SOLIDS 
SOLIDS 
UNREGISTERED PRODUCTS: 
HEALTH FOODS/VITAMINS 
VETERINARY MEDICINES 
COSMETICS 
OTHERS (SPECIFY) 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
FEEDBACK REQUIRED? 
CONFIDENTIALITY REQUIRED? 
DYES 
DYES 
D NO 
D NO 
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QUESTIONNAIRE 
1. COMPANY'S QUALITY PHILOSOPHY 
1.1 What is the purpose of your company's quality assurance system? 
Technical factors : inspection and test, production oriented 
Regulatory requirements : what is legally required 
Strategic factors : competitive advantage, productivity, 
profitability 
1.2 How would you define product quality? 
Technical orientation conformance to specified standards 
regulatory compliance 
Customer orientation safety 
therapeutic efficacy 
affordable product 
judged by consumer's experience 
1.3 Who takes final responsibility for product quality in your 
company? 
top management Total quality orientation 
Regulatory orientation 
Functional orientation 
managing director (pharmacist) 
QA function 
production function 
line supervisors/inspectors 
1.4 Do you apply the same quality assurance system to registered and 
unregistered products? 
Medicines registered i.t.o. Act 101 } parallel standards -
Cosmetics/unregistered products } quality commitment 
related to regulatory 
requirements 
1.5 Does the scope of your quality assurance system differ from that 
of GMP principles? 
Entire industrial cycle 
Organisation wide scope 
new design control 
incoming material control 
product control 
post marketing surveillance 
not restricted to manufacturing 
only. 
I . ... 
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1.6 Do you see the quality improvement process as being separate 
from the quality control activity? 
Multidisciplinary quality improvement steering committee. 
Chaired by die c.E.O. 
Quality improvement integrated with other organisational 
improvement activities. 
2. COMPANY'S QUALITY POLICY 
2.1 Does your company have a quality policy? 
2.2 Is the company's quality policy statement available in writing? 
Copy available? 
Broad statement. Specific functional areas of application. 
Procedures (who, how, when). Instructions (step-by-step 
performance of tasks). 
2.3 Who finallly approves the company's quality policy? 
Chief Executive Officer 
Managing Director 
Quality Manager 
. . . . . . . . . . . . . . . . . . . . . . . . . . . 
2.4 How is your company's quality policy communicated? 
Verbally } 
During personnel training } internal communication 
Via a quality manual } 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Advertising } external 
Public relations } communication 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
2.5 When formulating or revising your quality policy, do you 
identify quality-related decisions at each step of the 
industrial cycle? 
Multifunctional approach 
Plan actions, responsibilities, time scales 
Set operational standards : eg. no errors, no defects 
Target specific functional areas of application. 
I . ... 
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2.6 When formulating or revising your quality policy, do you 
identify and analyse quality-related problems that may be or 
have been experienced during the entire industrial cycle? 
Multifunctional approach 
Formal procedure includes formulation problems 
production problems 
marketing problems 
Structured approach 
product performance problems 
how could problem have been prevented? 
do policy guidelines need to be 
changed? 
2.7 How frequently do you revise your quality policy? 
3. ORGANISING FOR QUALITY 
3.1 How do you identify the key organisationwide quality responsi-
bilities and authorities in your company? 
Pharmacy Act 
GMP Guidelines 
MBRl dossier 
Relationship chart 
} Regulatory requirements used as 
} the primary guideline. 
} Based on process flow-chart, 
} organogram. 
3.2 How is your personnel; marketing; and finance departments 
involved in your quality assurance system? 
Quality policy formulation 
Involvement in decision making, problem solving and feedback 
of quality information. 
Organisationwide integration of the quality effort. 
I 
3.3 What key responsibilities have been formally delegated to the 
quality control function in your organisation? 
Business responsibility: QA programme must foster sound 
business growth, profitability, competitive advantage. 
System responsilibity:(i) Primary leadership i.c.w. quality 
objectives, training, employee involvement in the quality 
establishment/maintenance/improvement process, and system 
design. (ii) Structuring of quality system : Co-ordinate 
people, machines, information. Define quality information 
flow, processing and control. (iii) Administrative control 
of the QA system : Continuous f eedforward/f eedback of per-
formance data (including quality costs). Periodic internal 
and external audit of the system. 
I . ... 
I . ... 
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Technical responsibility: (i) Incoming material control 
(Annexure 6). (ii) Final product release (Annexure 9A). 
(iii) Container release (Annexure 9B). (iv) In-process 
controls (Annexure 11). (v) Product complaints (technical/ 
adverse drug reactions - Reg. 12). 
4. PRODUCTION CONTROL 
4.1 Does your company apply JIT principles of production control? 
Downstream work centre starved if upstream work centre does 
not deliver on time? 
Highly variable master schedule a problem? 
Applied in particular department only? 
4.2 Do you see a connection between JIT principles and your 
quality assurance system? 
Improved production capacity 
Improved production reliability 
Eliminate the causes of inventory 
Immediate feedback/response to quality problems 
Reduced equipment set-up time 
Vendor approval system 
"Right first time" philosophy 
4.3 Does your company use an MRP system of production planning 
and control? 
MRP I inventory control system generates manufacturing and 
purchase orders to achieve master production schedule out-
put. -
MRP II plans and controls inventories and production capa-
cities; feedback loop between orders and master schedule 
allows for adjustments according to available capacity. 
MRP III plans and controls all manufacturing resources 
including inventory; cash; personnel; facilities and capital 
equipment. 
4.4 Does the MRP system complement your quality assurance system 
in any way? 
Production planning and control tool only? 
Linked to quality via efficient resource utilisation? 
Does tolerate a degree of waste? 
Only if used in combination with a JIT system (MRP for 
planning; JIT for execution)? 
I . ... 
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5. QUALITY COSTS 
5.1 Do you measure and report quality costs? 
5.2 What cost categories or cost elements have your defined? 
Quality costs = expenses of the QA function? 
Quality costs = those costs that are amenable to change 
by quality management. 
Cost of control = prevention costs + appraisal costs 
Cost of failure to control = internal + external failure 
costs 
5.3 Who receives the quality cost reports? 
Shopfloor supervisors : e.g. weekly reports of costs of 
scrap and rework. 
Departmental managers : e.g. monthly reports of total 
costs highlighting current problems or progress with quality 
improvement projects. 
Top management : e.g. quality costs included in companyts 
cost reporting system, highlighting total costs and costs to 
be acted upon. 
5.4 Who decides to take action on quality costs when this becomes 
necessary? 
Top management 
Financial management 
Quality assurance manager 
Multifunctional committee 
5.5 What percentage of total sales is attributable to total quality 
costs in your company? 
5 - 10 - 15 - 20 - 25 per cent 
actual figure 
estimated figure 
no idea 
